PROTOCADHERIN, THEIR AUTIBODIES AND USES

Abstract: Polynucleotide sequences encoding novel cadherin-like polypeptides, designated protocadherins, and variants thereof are provided by the invention as well as methods and materials for the recombinant production of the same. Antibody substances specific for protocadherins are also disclosed as useful for modulating the natural binding and/or regulatory activities of the protocadherins.

Description: PROTOCADHERINS , THEIR ANTIBODIES AND USES This application in a continuation-in-part of U.S. Patent Application Serial No. 07/998,003 which was filed on December 29, 1992. FIELD OF THE INVENTION The present invention relates, in general, to materials and methods relevant to cell-cell adhesion. More particularly, the invention relates to novel adhesion proteins, designated protocadherins, and to polynucleotide sequences encoding the protocadherins. The invention also relates to methods for inhibiting binding of the protocadherins to their natural ligands/antiligands. BACKGROUND In vivo, intercellular adhesion plays an important role in a wide range of events including morphogenesis and organ formation, leukocyte extravasion, tumor metastasis and invasion, and the formation of cell junctions. Additionally, cell-cell adhesion is crucial for the maintenance of tissue integrity. Intercellular adhesion is mediated by specific cell surface adhesion molecules. Cell adhesion molecules have been classified into at least four families including the immunoglobulin superfamily, the integrin superfamily, the selectin family and the cadherin superfamily. All cell types that form solid tissues express some members of the cadherin superfamily suggesting that cadherins are involved in selective adhesion of most cell types. Cadherins have been generally described as glycosylated integral membrane proteins that have an N-terminal extracellular domain (the N-terminal 113 amino acids of the domain appear to be directly involved in binding) consisting of five subdomains characterized by sequences unique to cadherins, a hydrophobic membrane-spanning domain and a C-terminal cytoplasmic domain that interacts with the cytoskeleton through catenins and other cytoskeleton- associated proteins. Some cadherins lack a cytoplasmic domain, however, and appear to function in cell-cell adhesion by a different mechanism than cadherins having a cytoplasmic domain. The cytoplasmic domain is required for the adhesive function of the extracellular domain in cadherins that do have an cytoplasmic domain. Binding between members of the cadherin family expressed on different cells is homophilic (i.e. , a member of the cadherin family binds to cadherins of its own or a closely related subclass) and Ca 2+ -dependent. For recent reviews on cadherins, see Takeichi, Annu. Rev. Biochem. , 59: 237-252 (1990) and Takeichi, Science, 251: 1451-1455 (1991). The first cadherins to be described (E-cadherin in mouse epithelial cells, L-CAM in avian liver, uvomorulin in the mouse blastocyst, and CAM 120/80 in human epithelial cells) were identified by their involvement in Ca 2+ - dependent cell adhesion and their unique immunological characteristics and tissue localization. With the later immunological identification of N-cadherin, which was found to have a different tissue distribution than E-cadherin, it became apparent that a new family of Ca 2+ -dependent cell-cell adhesion molecules had been discovered. The molecular cloning of the genes encoding E-cadherin [see Nagafuchi et al. , Nature, 329: 341-343 (1987)], N-cadherin [Hatta et al. , J. Cell. Biol , 106: 873-881 (1988)], and P-cadherin [Nose et al. , EMBO J. , 6: 3655-3661 (1987)] provided structural evidence that the cadherins comprised a family of cell adhesion molecules. Cloning of L-CAM [Gallin et al. , Proc. Natl. Acad. Sci. USA, 84: 2808-2812 (1987)] and uvomorulin [Ringwald et al , EMBO J. , 6: 3647-3653 (1986)] revealed that they were identical to E-cadherin. Comparisons of the amino acid sequences of E-, N-, and P-cadherins showed a level of amino acid similarity of about 45%-58% among the three subclasses. Liaw et a , EMBO J., 9: 2701-2708 (1990) describes the use of PCR with degenerate oligonucleotides based on conserved regions of the E-, N- and P-cadherins to amplify N- and P-cadherin from a bovine microvascular endothelial cell cDNA. The isolation by PCR of eight additional cadherins was reported in Suzuki et al, Cell Regulation, 2: 261-270 (1991). Subsequently, several other cadherins were described including R-cadherin [Inuzuka et al. , Neuron, 7: 69-79 (1991)], M-cadherin [Donalies, Proc. Natl. Acad. Sci. USA, 88: 8024-8028 (1991)], B-cadherin [Napolitano, J. Cell. BioL, 113: 893-905 (1991)] and T- cadherin [Ranscht, Neuron, 7: 391-402 (1991)]. Additionally, proteins distantly related to cadherins such as desmoglein [Goodwin et al. , Biochem. Biophys. Res. Commun. , 173: 1224-1230 (1990) and Koch et al. , Eur. J. Cell BioL, 53: 1-12 (1990)] and the desmocollins [Holton et al , J. Cell Science, 97: 239-246 (1990)] have been described. The extracellular domains of these molecules are structurally related to the extracellular domains of typical cadherins, but each has a unique cytoplasmic domain. Mahoney et al. , Cell, 67: 853-868 (1991) describes a tumor suppressor gene of Drosophila, called fat, that also encodes a cadherin-related protein. The fat tumor suppressor comprises 34 cadherin-like subdomains followed by four EGF-like repeats, a transmembrane domain, and a novel cytoplasmic domain. The identification of these cadherin-related proteins is evidence that a large superfamily characterized by a cadherin extracellular domain motif exists. Studies of the tissue expression of the various cadherin-related proteins reveal that each subclass of molecule has a unique tissue distribution pattern. For example, E-cadherin is found in epithelial cells while N-cadherin is found in neural and muscle cells. Expression of cadherin-related proteins also appears to be spatially and temporally regulated during development because individual proteins appear to be expressed by specific cells and tissues at specific developmental stages [for review see Takeichi (1991), supra]. Both the ectopic expression of cadherin-related proteins and the inhibition of native expression of cadherin-related proteins hinders the formation of normal tissue structure [Derrick et al , Neuron, 4: 493-506 (1990); Fujimori et al , Development, 110: 97-104 (1990); Kintner, Cell, 69: 225-236 (1992)]. The unique temporal and tissue expression pattern of the different cadherins and cadherin-related proteins is particularly significant when the role each subclass of proteins may play in vivo in normal events (e.g., the maintenance of the intestinal epithelial barrier) and in abnormal events (e.g., tumor metastasis or inflammation) is considered. Different subclasses or combinations of subclasses of cadherin-related proteins are likely to be responsible for different cell-cell adhesion events in which therapeutic detection and/or intervention may be desirable. For example, auto-antibodies from patients with pemphigus vulgaris, an autoimmune skin disease characterized by blister formation caused by loss of cell adhesion, react with a cadherin-related protein offering direct support for adhesion function of cadherins in vivo [Amagai et al. , Cell, 67: 869- 877 (1991)]. Studies have also suggested that cadherins and cadherin-related proteins may have regulatory functions in addition to adhesive activity. Matsunaga et al. , Nature, 334: 62-64 (1988) reports that N-cadherin has neurite outgrowth promoting activity. The Drosophila fat tumor supressor gene appears to regulate cell growth and supress tumor invasion as does mammalian E-cadherin [see Mahoney et al , supra; Frixen et al , J. Cell. Biol, 775: 173-185 (1991); Chen et al , J. Cell, Biol , 114:319-327 (1991); and Vleminckx et al , Cell, 65: 107-119 (1991)]. Thus, therapeutic intervention in the regulatory activities of cadherin-related proteins expressed in specific tissues may be desirable. There thus continues to exist a need in the art for the identification and characterization of additional cadherin-related proteins which participate in cell-cell adhesion and/or regulatory events. Moreover, to the extent that cadherin- related proteins might form the basis for the development of therapeutic and diagnostic agents, it is essential that the genes encoding the proteins be cloned. Information about the DNA sequences and amino acid sequences encoding the cadherin-related proteins would provide for the large scale production of the proteins by recombinant techniques and for the identification of the tissues/cells naturally producing the proteins. Such sequence information would also permit the preparation of antibody substances or other novel binding molecules specifically reactive with the cadherin-related proteins that may be useful in modulating the natural ligand/antiligand binding reactions in which the proteins are involved. SUMMARY OF THE INVENTION The present invention provides cadherin-related materials and methods that are relevant to cell-cell adhesion. In one of its aspects, the present invention provides purified and isolated polynucleotides (e.g. , DNA and RNA, both sense and antisense strands) encoding the novel cell adhesion molecules designated herein as protocadherins, including protocadherin-42 and protocadherin-43. Preferred polynucleotide sequences of the invention include genomic and cDNA sequences as well as wholly or partially synthesized DNA sequences, and biological replicas thereof (i.e. , copies of the sequences made in vitro). Biologically active vectors comprising the polynucleotide sequences are also contemplated. Specifically illustrating protocadherin polynucleotide sequences of the present invention are the inserts in the plasmids pRC/RSV-pc42 and pRC/RSV-pc43 which were deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852 on December 16, 1992 and were assigned ATCC Accession Nos. 69162 and 69163, respectively. The scientific value of the information contributed through the disclosures of the DNA and amino acid sequences of the present invention is manifest. For example, knowledge of the sequence of a partial or complete DNA encoding a protocadherin makes possible the isolation by standard DNA/DNA hybridization or PCR techniques of full length cDNA or genomic DNA sequences that encode the protein and, in the case of genomic DNA sequences, that specify protocadherin-specific regulatory sequences such as promoters, enhancers and the like. Alternatively, DNA sequences of the present invention may be chemically synthesized by conventional techniques. Hybridization and PCR techiques also allow the isolation of DNAs encoding heterologous species proteins homologous to the protocadherins specifically illustrated herein. According to another aspect of the invention, host cells, especially eucaryotic and procaryotic cells, are stably transformed or transfected with the polynucleotide sequences of the invention in a manner allowing the expression of protocadherin polypeptides in the cells. Host cells expressing protocadherin polypeptide products, when grown in a suitable culture medium, are particularly useful for the large scale production of protocadherin polypeptides, fragments and variants thereby enabling the isolation of the desired polypeptide products from the cells or from the medium in which the cells are grown. The novel protocadherin protein products of the invention may be obtained as isolates from natural tissue sources, but are preferably produced by recombinant procedures involving the host cells of the invention. The products may be obtained in fully or partially glycosylated, partially or wholly de- glycosylated, or non-glycosylate forms depending on the host cell selected or recombinant production and/or post-isolation processing. Protocadherin variants according to the invention may comprise polypeptide analogs wherein oneior more of the specified amino acids is deleted or replaced or wherein one or more non-naturally encoded amino acids are added: (1) without loss, and preferably with enhancement, of one or more of the biological activities or immunological characteristics specific for a protocadherin; or (2) with specific disablement of a particular ligand/antiligand binding function. Also contemplated by the present invention are antibody substances (e.g., monoclonal and polyclonal antibodies, chimeric and humanized antibodies, antibody domains including Fab, Fab', F(ab') 2 , Fv or single variable domains, and single chain antibodies) which are specific for the protocadherins of the invention. Antibody substances can be developed using isolated natural, recombinant or synthetic protocadherin polypeptide products or host cells expressing such products on their surfaces. The antibody substances may be utilized for purifying protocadherin polypeptides of the invention, for determining tissue expression of polypeptides and as antagonists of the ligand/antiligand binding activities of the protocadherins. Specifically illustrating monoclonal antibodies of the present invention are the protocadherin-43 specific monoclonal antibodies produced by the hybridoma cell line designated 38I2C which was deposited with the ATCC on December 2, 1992 and was assigned ATCC Accession No. HB 11207. Numerous other aspects and advantages of the present invention will be apparent upon consideration of the following detailed description, reference being made to the drawing wherein FIGURE 1A-C is an alignment of protocadherin amino acid sequences of the invention with the amino acid sequences of N-cadherin and of the Drosophila fat tumor suppressor. DETAILED DESCRIPTION The present invention is illustrated by the following examples wherein Examples 1, 2 and 3 describe the isolation by PCR of protocadherin polynucleotide sequences. Example 3 also describes the chromosome localization of several protocadherin genes of the invention. Example 4 presents the construction of expression plasmids including polynucleotides encoding protocadherin-42 or protocadherin-43 and the transfection of L cells with the plasmids. The generation of antibodies to protocadherin-42 and protocadherin-43 is described in Example 5. Example 6 presents the results of immunoassays of transfected L cells for the expression of protocadherin-42 or protocadherin-43. Example 7 describes the cell aggregation properties of L cells transfected with protocadherin-42, protocadherin-43 or a chimeric protocadherin-43/E-cadherin molecule. The calcium-binding properties of pc43 are described in Example 8. The results of assays of various tissues and cell lines for the expression of protocadherin-42 and protocadherin-43 by Northern blot, Western blot and in situ hybridization are respectively presented in Examples 9, 10 and 11. Example 12 describes immunoprecipitation experiments identifying a 120 kDa protein that coprecipitates with protocadherin-43. Example 1 The polymerase chain reaction (PCR) was used to isolate novel rat cDNA fragments encoding cadherin-related polypeptides. Design of PCR Primers Two regions of conserved amino acid sequence, one from the middle of the third cadherin extracellular subdomain (EC-3) and the other from the C-terminus of the fourth extracellular subdomain (EC-4), were identified by comparison of the published amino acid sequences for L-CAM (Gallin et al. , supra), E-cadherin (Nagafuchi et al , supra), mouse P-cadherin (Nose et al , supra), uvomorulin (Ringwald et al , supra), chicken N-cadherin (Hatta et al , supra), mouse N-cadherin [Miyatani et al , Science, 245:631-635 (1989)] and human P-cadherin [Shimoyama et al. , J. Cell. Biol. , 109: 1787-1794 (1989)], and the corresponding degenerate oligonucleotides respectively set out below in IUPAC-IUB Biochemical nomenclature were designed for use as PCR primers. Primer 1 (SEQ ID NO: 1) 5' AARSSNNTNGAYTRYGA 3' Primer 2 (SEQ ID NO: 2) 3' TTRCTRTTRCGNGGNNN 5' The degenerate oligonucleotides were synthesized using an Applied Biosystems model 380B DNA synthesizer (Foster City, California). Cloning of cDNA Sequences by PCR PCR was carried out in a manner similar to that described in Suzuki et al , Cell Regulation, 2: 261-270 (1991) on a rat brain cDNA preparation. Total RNA was prepared from rat brain by the guanidium isothiocyanate/cesium chloride method described in Maniatis et al , pp. 196 in Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory (1982). Brain poly(A) + RNAs were then isolated using a FastTrack ® kit (Invitrogen, San Diego, California) and cDNA was prepared using a cDNA synthesis kit (Boehringer Mannheim Biochemicals, Indianapolis, Indiana). The PCR reaction was initiated by adding 2.5 units of Taq DNA polymerase (Boehringer Mannheim Biochemicals) to 100 ng template cDNA and 10 μg of each primer, after which 35 reaction cycles of denaturation at 94 "C for 1.5 minutes, annealing at 45 °C for 2 minutes, and polymerization at 72 β C for 3 minutes were carried out. Two major bands of about 450 base pairs (bp) and 130 bp in size were found when the products of the PCR reaction were subjected to agarose gel electrophoresis. The 450 bp band corresponded to the expected length between the two primer sites corresponding to the middle of the third cadherin extracellular subdomain (EC-3) and the carboxyl terminus of the fourth cadherin extracellular subdomain (EC-4), but the 130 bp band could not be predicted from any of the previously identified cadherin sequences. The 450 bp and 130 bp bands were extracted by a freezing and thawing method. The resulting fragments were phosphorylated at the 5' end with T4 polynucleotide kinase and subcloned by a blunt-end ligation into the Sma I site of M13mpl8 (Boehringer Mannheim Biochemicals) in a blunt end ligation for sequence analysis. Sequencing of the fragments was carried out by the dideoxynucleotide chain termination method using a Sequenase kit (United States Biochemicals, Cleveland, Ohio). DNA and amino acid sequence were analyzed using the Beckman Microgenie program (Fullerton, California). Analysis of cDNA Sequences Nineteen novel partial cDNA clones were isolated. The DNA and deduced amino acid sequences of the clones (including sequences corresponding to the PCR primers) are set out as follows: RAT-123 (SEQ ID NOs: 3 and 4, respectively), RAT-212 (SEQ ID NOs: 5 and 6), RAT-214 (SEQ ID NOs: 7 and 8), RAT-216 (SEQ ID NOs: 9 and 10), RAT-218 (SEQ ID NOs: 11 and 12), RAT-224 (SEQ ID NOs: 13 and 14), RAT-312 (SEQ ID NOs: 15 and 16), RAT- 313 (SEQ ID NOs: 17 and 18), RAT-314 (SEQ ID NOs: 19 and 20), RAT-315 (SEQ ID NOs: 21 and 22), RAT-316 (SEQ ID NOs: 23 and 24), RAT-317 (SEQ ID NOs: 25 and 26), RAT-321 (SEQ ID NOs: 27 and 28), RAT-323 (SEQ ID NOs: 29 and 30), RAT-336 (SEQ ID NOs: 31 and 32), RAT-352 (SEQ ID NOs: 33 and 34), RAT-411 (SEQ ID NOs: 35 and 36), RAT-413 (SEQ ID NOs: 37 and 38), and RAT-551 (SEQ ID NOs: 39 and 40). The deduced amino acid sequences of the cDNA clones are homologous to, but distinct from the known cadherins. The cadherins described thus far have highly conserved, short amino acid sequences in the third extracellular subdomain (EC-3) including the consensus sequence D- Y-E or D-F-E located at the middle region of the subdomain and the consensus sequence D-X-N-E-X-P-X-F (SEQ ID NO: 41) or D-X-D-E-X-P-X-F (SEQ ID NO: 42) at its end (Hatta et al., supra), while the corresponding sequences of other subdomains, except for the fifth extracellular subdomain (EC -5), are D-R-E and D-X-N-D-N-X-P-X-F (SEQ ID NO: 43), respectively. In contrast, the deduced amino acid sequences of the new clones that correspond to cadherin extracellular subdomains include the sequence D-Y-E or D-F-E at one end, but have the sequence D-X-N-D-N-X-P-X-F instead of D-X-N-E-X-P-X-F or D-X-D-E-X-P-X-F, at the other end. The polypeptides encoded by the partial clones are homologous to previously identified cadherins but did not show significant homology to any other sequences in Genbank. Therefore, the partial cDNAs appear to comprise a new subclass of cadherin-related molecules. Example 2 Various cDNA fragments structurally similar to the rat cDNAs described in Example 1 were isolated from human, mouse, and Xenopus brain cDNA preparations and from Drosophila and C. elegans whole body cDNA preparations by PCR using Primers 1 and 2 as described in Example 1. The DNA and deduced amino acid sequences of the resulting PCR fragments (including sequences corresponding to the PCR primers) are set out as follows: MOUSE-321 (SEQ ID NOs: 44 and 45), MOUSE-322 (SEQ ID NOs: 46 and 47), MOUSE-324 (SEQ ID NOs: 48 and 49), MOUSE-326 (SEQ ID NOs: 50 and 51), HUMAN-11 (SEQ ID NOs: 52 and 53), HUMAN-13 (SEQ ID NOs: 54 and 55), HUMAN-21 (SEQ ID NOs: 56 and 57), HUMAN-24 (SEQ ID NOs: 58 and 59), HUMAN-32 (SEQ ID NOs: 60 and 61), HUMAN-42 (SEQ ID NOs: 62 and 63), HUMAN-43 (SEQ ID NOs: 64 and 65), HUMAN-212 (SEQ ID NOs: 66 and 67), HUMAN-213 (SEQ ID NOs: 68 and 69), HUMAN-215 (SEQ ID NOs: 70 and 71), HUMAN-223 (SEQ ID NOs: 72 and 73), HUMAN-410 (SEQ ID NOs: 74 and 75), HUMAN-443 (SEQ ID NOs: 76 and 77), XENOPUS-21 (SEQ ID NOs: 78 and 79), XENOPUS-23 (SEQ ID NOs: 80 and 81), XENOPUS-25 (SEQ ID NOs: 82 and 83), XENOPUS-31 (SEQ ID NOs: 84 and 85), DROSOPHILA- 12 (SEQ ID NOs: 86 and 87), DROSOPHILA-13 (SEQ ID NOs: 88 and 89), DROSOPHILA-14 (SEQ ID NOs: 90 and 91) and C.ELEGANS-41 (SEQ ID NOs: 92 and 93). Comparison of the deduced amino acid sequences indicates significant similarity between sets of these clones. In particular, there are three sets of clones that appear to be cross-species homologues: RAT-218, MOUSE-322 and HUMAN-43; RAT-314, MOUSE-321 and HUMAN-11; and MOUSE-326 and HUMAN-42. Example 3 To ascertain the complete structure of the new proteins defined by the PCR products, two full length human cDNAs corresponding to the partial cDNAs HUMAN-42 and HUMAN-43 were isolated. Isolation of Full-length Human cDNAs A human fetal brain cDNA library (Stratagene, La Jolla, California) in the λZapII vector was screened by the plaque hybridization method [described in Ausubel et al , Eds., Current Protocols in Molecular Biology, Sections 6.1.1 to 6.1.4 and 6.2.1 to 6.2.3, John Wiley & Sons, New York (1987)] with 32 P-labelled HUMAN-42 and HUMAN-43 DNA fragments. The positive clones were plaque-purified and, using a helper virus, the inserts were cut out by an in vivo excision method in the form of a Bluescript SK(+) plasmid. The insert sequences were then subcloned into the Ml 3 vector (Boehringer Mannheim, Biochemicals) for sequencing. Several overlapping cDNA clones were isolated with each probe including two cDNAs which contained the putative entire coding sequences of two novel proteins designated protocadherin-42 (pc42) and protocadherin-43 (pc43). The DNA and deduced amino acid sequences of pc42 are set out in SEQ ID NOs: 94 and 95, respectively, while the DNA and deduced amino acid sequences of pc43 are set out in SEQ ID NOs: 96 and 97, respectively. A description of the cloning of protocadherin sequences of the invention was published in Sano et al, The EMBO Journal, 12(6): 2249-2256 (1993) after filing of the priority application hereto. The deduced amino acid sequence of pc43 was previously presented at the December 9, 1991 meeting of the American Society for Cell Biology. An abstract of the presentation is published as Suzuki et al , J. Cell. Biol , 115: 72a (Abstract 416) (December 9, 1991). Analysis of Full-length Human Clones Comparison of the full length cDNA sequences of pc42 and pc43 to the sequences of the various DNA fragments originally obtained by PCR reveals that MOUSE-326 and HUMAN-42 correspond to a portion of the fourth extracellular subdomain (EC-4) of pc42, and RAT-314, MOUSE-321, and HUMAN- 11 correspond to a portion of the third extracellular subdomain (EC-3) of pc43 and RAT-218, MOUSE-322 and HUMAN-43 correspond to a portion of the fifth extracellular domain (EC-5) of pc43. The overall structures of pc42 and pc43 are similar to that of typical cadherins but the new molecules also have distinct features. Both protocadherin cDNA sequences contain putative translation initiation sites and translated amino acid sequences start with typical signal sequences, but the clones lack the prosequences that are present in all known cadherin precursors. The cDNAs encode proteins having a large N-terminal extracellular domain and a relatively short C-terminal cytoplasmic domain connected by a transmembrane sequence. The extracellular domains of pc42 and pc43 are different in length and pc42 contains seven subdomains that closely resemble the typical cadherin extracellular subdomain while pc43 has six such subdomains. The sizes of the protocadherin cytoplasmic domains are similar to those of typical cadherins, but the sequences do not show any significant homology with those of known cadherins or cadherin-related proteins. Amino acid identity determinations between extracellular subdomains of human pc42 and pc43, and of mouse N-cadherin (SEQ ID NO: 98) (presented as an example of a "typical" cadherin) and the eighteenth extracellular subdomain of Drosophila fat tumor suppressor (EC- 18, SEQ ID NO: 99) (the eighteenth extracellular subdomain of fat is a prototypical fat subdomain) are presented in Table 1 below, wherein, for example, "N-EC-1 x pc42" indicates that the first extracellular subdomain of N-cadherin was compared to the extracellular subdomain of pc42 indicated on the horizonal axis. Table 1 - - - - - - - The amino acid identity values between the extracellular subdomains of pc42 and pc43, and N-cadherin EC-1 through EC-5 and Drosophilafat EC- 18 are mostly less than 40% . These identity values are comparable to the values between the subdomains of other cadherin subclasses. However, higher identity values indicate that pc42 and pc43 are more closely related to fat than to N-cadherin. Amino acid identity determinations between extracellular subdomains of human pc42 and pc43 are presented in Table 2 below. The identity values between respective EC-1, EC-2, EC-3, EC-4, EC-5 subdomains and the last subdomains of pc42 and pc43 are generally higher values than values obtained for comparisons of the protocadherins to N-cadherin. These results suggest that pc42 and pc43 are more closely related to one another than they are to classic cadherins. FIGURE 1A-C presents an alignment of the deduced amino acid sequences of the extracellular subdomains of pc42 (EC-1 through EC-7), pc43 (EC-1 through EC-6), mouse N-cadherin (EC-1 through EC-5) and Drosophilafat EC-18. A sequence on a line in FIGURE IA continues on the same line in FIGURES IB and IC. Gaps were introduced to maximize homology. The amino acid residues described by capital letters in the "motif line are present in more than half of the subdomains of N-cadherin, pc42, pc43 and Drosophilafat. The amino acid residues described by small letters in the motif line are less well conserved in human pc42, pc43, and Drosophilafat. FIGURE 1A-C shows that many amino acids characteristic of other cadherin extracellular domain repeats are conserved in the pc42 and pc43 sequences, including the cadherin sequence motifs DXD, DRE and DXNDNXPXF (SEQ ID NO: 43), two glycine residues, and one glutamic acid residue. Additionally, pc42 and pc43 share unique features in comparison to N-cadherin. More amino acids at specific sites are conserved between pc42 and pc43, such as the DXDXGXN (SEQ ID NO: 100) protocadherin sequence motif near the amino terminus of the pc42 and pc43 subdomains and the AXDXGXP (SEQ ID NO: 101) sequence motif near the carboxyl terminus of the subdomains. Additionally, both protocadherins share regions that do not show significant homology with the typical cadherin motif (of N-cadherin) near the carboxyl terminus of EC-1, in the middle of EC-2 and EC-4, and at the carboxyl terminus of the last repeat. A cysteine residue is located at a similar position in the middle of EC-4 of pc42 and pc43. In general, the extracellular subdomains of pc42 and pc43 are more similar to EC- 18 of fat than the extracellular subdomains of N-cadherin. Possible Alternative Splicing Sequence analysis of various overlapping protocadherin cDNA clones revealed that some clones contained unique sequences at the 3' end, although the 5' end sequences were identical to other clones. The sequences forming the boundaries of the 3' end regions are consistent with the consensus sequence of mRNA splicing, suggesting that these clones may correspond to alternatively spliced mRNAs. The DNA and deduced amino acid sequences of one possible product of alternative splicing of pc42 mRNA are set out in SEQ ID NOs: 102 and 103. The DNA and deduced amino acid sequences of two possible products of alternative splicing of pc43 mRNA are respectively presented in SEQ ID NO: 104 and 105, and SEQ ID NOs: 106 and 107. Chromosome Localization The chromosomal location of the protocadherin 413 gene (SEQ ID NO: 37) and of the pc42 and pc43 genes was determined by conventional methods. Briefly, C3H/HeJ-g/-2 and Mus spretus (Spain) mice and [(C3aWHe -gld x Mus spretus) F. x C3H/HeJ-g/ti] interspecies backcross mice were bred and maintained as previously described in Seldin, et αl, J. Exp. Med. , 167: 688-693 (1988). Mus spretus was chosen as the second parent in the cross because of the relative ease of detection of informative restriction fragment length variants (RFLVs) in comparison with crosses using conventional inbred laboratory strains. Gene linkage was determined by segregation analysis. Genomic DNA isolated from mouse organs by standard techniques was digested with restriction endonucleases and 10μg samples were electrophoresed in 0.9% agarose gels. DNA was transferred to Nytran membranes (Schleicher & Schull, Inc., Keene, NH), hybridized with the appropriate probe at 65 * C and washed under stringent conditions, all as previously described in Maniatis et αl, supra). To localize the pc42 gene, a mouse sequence probe corresponding to nucleotides 1419 to 1906 of SEQ ID NO: 94 was used and for pc43 a rat sequence probe corresponding to nucleotides 1060 to 1811 of SEQ ID NO: 96 was used. To localize the procadherin 413 gene, a probe including the sequence set out in SEQ ID NO: 37 was used. Other clones used as probes in the current study and RFLVs used to detect anonymous DNA loci were all previously described [Chromosome 7, DNA segment, Washington 12 (D7Wasl2); the parathyroid hormone (Pth); calcitonin (Calc); hemoglobin, β chain ( bb); metallothionein-I (Mt-1); adenine phosphoribosyltransferase (Aprt); growth hormone receptor (Ghr); prostaglandin E receptor EP2 subtype (Ptgerep2); dihydrofolate reductase-2 (Dhfr2); fibroblast growth factor a (Fgfa); and glucocorticoid receptor- 1 (Gr/-7)]. Comparison of the haplotype distribution of protocadherin genes with those determined for loci throughout the mouse genome allowed each to be mapped to specific regions of mouse chromosomes. The probability for linkage was > 99 % and indicated assignment of both the pc42 gene and the pc43 gene was chromosome 18. The assignment of the protocadherin 413 gene was chromosome 7. The region of chromosome 18 to which the pc42 and pc43 genes were mapped corresponds to the ataxia (ax) loci [Burt, Anat. Rec, 196: 61-69 (1980) and Lyon, J. Hered. , 46: 77-80 (1955)] and twirler (Tw) loci [Lyon, J. Embryol. Exp. MorphoL , 6: 105-116 (1958)], while the region of chromosome 7 to which the protocadherin 413 gene was mapped corresponds to the shaker (sh- 1) locus [Kikuchi et al , Ada Oto-Laryngol , 60: 287-303 (1965) and Lord et al. , Am. Nat. , 63: 453-442 (1929)]. These loci have been implicated as involved in hereditary neural disease in the mouse. This result is consistent with in situ hybridization results (see Example 11) showing that pc42 and pc43 are strongly expressed in the brain and particularly in the cerebellum. Example 4 The full length human cDNAs encoding pc42 and pc43 were expressed in L cells (ATCC CCL 1) using the pRC/RSV expression vector (Invitrogen, San Diego, California). The cDNAs were isolated from the Bluescript SK(+) clones described in Example 2 by digestion with Sspl followed by blunt-ending with DNA polymerase and digestion with Xbal (for pc42), or by double digestion with Spel and EcoRV (for pc43). The pRC/RSV expression vector was digested with Hindlll, followed by blunt-ending and re-digestion with Xbal for insertion of pc42 sequences, or by digested with Xbal followed by blunt-ending and re-digestion with Spel for insertion of pc43 sequences. The isolated protocadherin DNAs were ligated into the linearized pRC/RSV vector. The resulting pc42 expression plasmid designated pRC/RSV-pc42 (ATCC 69162) and pc43 expression plasmid designated pRC/RSV-pc43 (ATCC 69163) were purified by CsCl gradient centrifugation and transfected into L cells by a Ca- phosphate method. The pc42 and pc43 transfectants were morphologically similar to the parental cells. Northern blot analysis of L cells transfected with pc42 or pc43 DNA sequences showed that the transfected cells expressed mRNAs of a size expected to encode the particular protocadherin. Example 5 Rabbit polyclonal antibodies specific for pc42 and pc43 were generated as well as a mouse monoclonal antibody specific for pc43. Preparation of Polyclonal Antibodies Specific for pc42 and pc43 DNA sequences encoding portions of the extracellular domain of pc42 and pc43 were each fused to a maltose binding protein-encoding sequence and expressed in bacteria. Specifically, DNAs corresponding to EC-4 through EC-7 of pc42 and EC-3 through EC-5 of pc43 were prepared by PCR and subcloned in the correct reading frame into the multicloning site of the pMAL expression vector (New England Biolabs, Beverly, Massachusetts) which contains sequences encoding maltose binding protein immediately upstream of the multicloning site. The resulting plasmids were then introduced into E. coli NM522 cells (Invitrogen, San Diego, California) by a single step transformation method. Expression of the fusion proteins was induced by the addition of IPTG and the fusion proteins were purified from cell extracts by amylose resin affinity chromatography (New England Biolabs) as described by the manufacturer. The fusion proteins were used for the immunization of rabbits without further purification. Polyclonal antibodies were prepared in rabbits by immunization at four subcutaneous sites with 500μg of purified fusion protein in Freund's complete adjuvant. Subsequent immunizations with lOOμg of the fusion protein were in Freund's incomplete adjuvant. Immune sera was passed through sepharose coupled to maltose binding protein (New England Biolabs) and polyclonal antibodies were purified from immune sera using Sepharose affinity columns prepared by reaction of the purified fusion protein with CNBr Sepharose (Pharmacia). Reactivity of the polyclonal sera with purified pc42 fusion protein and pc42 transfected cell extracts (described in Example 4) was confirmed. Preparation of Monoclonal Antibodies Specific for pc43 The pc43 fusion protein (containing the EC-3 through EC-5 subdomains of pc43) was used to generate monoclonal antibodies in mice according to the method of Kennett, Methods in EnzymoL, 58:345-359 (1978). Briefly, mice were immunized with the pc43 fusion protein (lOOμg) at two subcutaneous sites. The spleen from the highest titer mouse was fused to the NS 1 myeloma cell line. The resulting hybridoma supernatants were screened in a ELISA assay for reactivity with the pc43 fusion protein and with maltose binding protein. The fusion wells with the highest reactivity to the pc43 extracellular domains were subcloned. The hybridoma cell line designated 38I2C (ATCC HB 11207) produced a IgG, subtype monoclonal antibody specific for pc43. Reactivity of the monoclonal antibody produced by hybridoma cell line 38I2C to pc43 was confirmed by immunoblotting the pc43 L cell transfectants described in Example 4. The 38I2C monoclonal antibody is specific for human pc43. Example 6 L cells transfected with DNA sequences encoding pc42 and pc43 as prepared in Example 4 were assayed for expression of the protocadherins by immunoblot and by immunofluorescence microscopy. Immunoblot Analysis Cell extracts of pc42 and pc43 transfectants were subjected to SDS-PAGE and then blotted electrophoretically onto a PVDF membrane (Millipore, Bedford, Massachusetts). The membranes were incubated with 5% skim milk in Tris-buffered saline (TBS) for two hours and then respectively with either pc42 polyclonal sera or pc43 monoclonal antibody for one hour. The membranes were washed three times (for 5 minutes each wash) with TBS containing 0.05% Tween 20 and respectively incubated with alkaline phosphatase-conjugated anti-rabbit IgG antibody or anti-mouse IgG antibody (Promega, Madison, Wisconsin) in the same buffer for one hour. After washing the membranes with TBS containing 0.05% Tween 20, reactive bands were visualized by using Western Blue solution (Promega). Anti-pc42 polyclonal antibodies stained a band of about 170 kDa molecular weight in pc42 transfected cells, but not parental L cells. The pc43- specific monoclonal antibody (38I2C) and polyclonal antibodies stained two adjacent bands of about 150 kDa molecular weight in pc43 transfected cells. The pc43 antibodies did not stain bands in parental L-cells. The molecular weights indicated by the staining of bands by the pc42 and pc43 antibodies are significantly larger than the molecular weights predicted from the deduced amino acid sequences. This discrepancy in molecular weight is common among various cadherin-related proteins and may be attributable to the glycosylation and/or cadherin specific structural properties. The pc42 antibody also stained smaller bands, which may be proteolytic degradation products. When transfected cells were trypsinized and cell extracts were prepared, run on SDS/PAGE and immunoblotted with the appropriate antibody, the pc42 and pc43 polypeptides expressed by the transfected cells were found to be highly sensitive to proteolysis and were easily digested by 0.01 % trypsin treatment. In contrast to the classic cadherins, however, these proteins were not protected from the digestion in the presence of 1-5 mM Ca 2+ . Immunofluorescence Microscopy Transfected cells were grown on a cover slip precoated with fibronectin and were fixed with 4% paraformaldehyde for 5 minutes at room temperature or with cold methanol on ice for 10 minutes followed by 4% paraformaldehyde fixation. After washing with TBS, the cells were incubated with TBS containing 1 % BSA for 30 minutes and then with anti-pc42 polyclonal antibody or anti-pc43 monoclonal antibody in TBS containing 1 % BSA for 1 hour at room temperature. Cover slips were then washed with TBS containing 0.01 % BSA and respectively incubated with FITC-conjugated anti-rabbit antibody or anti-mouse antibody (Cappel, Durham, North Carolina) for 60 minutes at room temperature. The cells were washed again with TBS containing 0.01 % BSA and subjected to fluorescence microscopy. Both pc42-specific and pc43-specific polyclonal antibodies stained the cell periphery of transfected cells expressing the protocadherin proteins, mainly at the cell-cell contact sites. The antibodies did not stain the parent L cells, nor did rabbit preimmune sera stain the pc42 and pc43 transfectants. Example 7 The cell aggregation properties of the transfected L cells expressing protocadherin proteins were examined. Transfected L cells were cultured in Dulbecco's Modified Eagles Medium (DMEM) (Gibco, Grand Island, New York) supplemented with 10% fetal bovine serum at 37°C in 5% CO 2 . Cells grown near confluence were treated with 0.01 % trypsin in the presence of 1 mM EGTA for 25 minutes on a rotary shaker at 37 °C and collected by centrifugation. The cells were washed three times with Ca 2+ free HEPES-buffered saline (HBS) after adding soybean trypsin inhibitor, and were resuspended in HBS containing 1 % BSA. The cell aggregation assay [Urushihara et al , Dev. Biol, 70: 206-216 (1979)] was performed by incubating the resuspended cells in a 1:1 mixture of DMEM and HBS containing 1 % BSA, 2 mM CaCl 2 and 20 μg/ml of deoxyribonucelease on a rotary shaker at 37 °C for 30 minutes to 6 hours. The pc42 and pc43 transfectants did not show any significant cell aggregation activity during periods of incubation less than 1 hour. This is in contrast to the cell aggregation that occurs with classic cadherins in similar experiments (Nagafuchi et al , supra, and Hatta et al , supra). However, prolonged incubation of transfected cells (more than 1-2 hours) resulted in gradual re-aggregation of the cells into small aggregates. Similar results were obtained when single cell suspensions of transfected cells were prepared by trypsin treatment in the presence of Ca 2+ . No re-aggregation was observed under the same conditions when untransfected L cells or L cells transfected with pRC/RSV vector alone were tested. When pc43 transfectants labelled with DiO (Molecular Probes, Eugene, OR) were incubated with unlabelled pc42 transfectants in the cell aggregation assay, aggregation of labelled and unlabelled cells was almost mutually exclusive indicating that protocadherin binding is homophilic. In view of the fact that the protocadherin cytoplasmic domains exhibit no apparent homology to cadherin domains, experiments were performed to determine if the difference in cytoplasmic domains could account for the difference in cell aggregation activity observed in cadherin and protocadherin transfectants. The cytoplasmic domain of pc43 was replaced with the cytoplasmic domain of E-cadherin and aggregation of cells transfected with the chimeric construct was analyzed. The Bluescript SK(+) clone described in Example 2 which contained the entire coding sequence for pc43 was digested with EcoRV and then partially digested with Xbal to remove the sequence corresponding to the cytoplasmic domain, and the plasmid DNA was purified by agarose gel electrophoresis. The cDNA corresponding to the cytoplasmic domain of mouse E-cadherin was synthesized by PCR using mouse cDNA made from mouse lung mRNA as a template and specific primers corresponding to a region near the N- terminus of the cytoplasmic domain sequence or the region containing the stop codon of mouse E-cadherin (Nagafuchi et al, supra). A Xbal sequence was included to the 5' end of the upstream primer. The E-cadherin cytoplasmic domain cDNA was then subcloned into the linearized pc43 Bluescript clone. The DNA containing the entire resulting chimeric sequence was cut out with Spel and EcoRV and was subcloned into the Spel-blunted Xbal site of the expression vector pRc/RSV vector. Finally, L cells were transfected with the resultant construct by a calcium phosphate method. After screening with G418 for about 10 days, the transfectants were stained with FITC-labeled 38I2C anti-pc43 antibody and subjected to FACS analysis. A portion of highly labeled cells were isolated and cloned. Transfectants showed a morphology similar to that of parental L cells and the expressed protein was localized at the cell periphery using pc43 antibody for immunofluorescence microscopy. Cell aggregation activity of the chimeric transfectants was analyzed as follows. The chimeric pc43 transfectants were labeled with DiO for 20 minutes at room temperature. The resultant cells were trypsinized in the presence of ImM EGTA and single cell suspension was made. Then, the cells were mixed with unlabeled other type of transfectants and incubated on a rotary shaker for two hours. The results were examined with a fluorescence and a phase contrast microscope apparatus. Antibody inhibition of cell aggregation was examined by incubation of the transfectants in the presence of polyclonal anti-pc43 antibody (100 ng/ml) in the standard assay medium. In the cell aggregation assay, the chimeric pc43 transfectants showed clear Ca 2+ -dependent cell aggregation within forty minutes of incubation. Cell aggregation was inhibited by the addition of pc43-specific polyclonal antibody. Example 8 The procedures of Maruyama et al , J. Biochem., 95: 511-519 (1984) were used to determine the calcium binding properties of pc43 by Western blot analysis in the presence or absence of calcium-45. The pc43 fusion protein described in Example 5 containing pc43 subdomains EC-3 through EC-5 was compared to the calcium binding protein calmodulin. Samples of purified pc43 fusion protein were run on SDS/PAGE and electrophoretically transferred to PVDF membrane. Binding of the 45 Ca 2+ to the pc43 fusion protein was detected by autoradiography and was determined to be nearly as efficient as binding of 5 Ca 2+ to calmodulin. In contrast, there was no binding of calcium to purified maltose binding protein lacking the pc43 extracellular domain. The pc43 subdomains EC-3 through EC-5 contain sequences highly homologous to the putative Ca 2± binding motifs found in E-cadherin. [See, Ringwald et al. , EMBO J., 6: 3647-3653 (1987).] Example 9 The expression of mRNA encoding pc42 and pc43 was assayed in various tissues and cell lines by Northern blot. Total RNAs were prepared by the guanidium isothiocyanate method and poly (A) + RNAs were isolated using a FastTrack kit (Invitrogen). RNA preparations were electrophoresed in a 0.8% agarose gel under denaturing conditions and transferred onto a nitrocellulose filter using a capillary method. Northern blot analyses were performed according to the method of Thomas, Proc. Natl. Acad. Sci. USA, 77: 5201-5205 (1980). The final wash was in 0.2X standard saline citrate containing 0.1 % sodium dodecyl sulfate at 65 β C for 10 minutes. Protocadherin mRNA Expression in Adult Rat Tissues Total mRNA preparations of rat tissues including brain, heart, liver, lung, skin, kidney and muscle were se2parated electrophoretically under denaturing conditions (10 μg mRNA/lane) and transferred onto nitrocellulose filters. The filters were hybridized with 32 P-labelled cDNA fragments MOUSE- 326 (which corresponds to EC-4 of human pc42) and RAT-218 (which corresponds to EC-5 of human pc43). The mRNAs of both protocadherins were highly expressed in brain. The pc42 probe detected a major band of 7 kb and a minor band of 4 kb in size, possibly representing the products of alternative splicing. The pc43 probe hybridized to a major band of 5 kb in size and with minor bands of smaller sizes. Developmental Expression of Protocadherin mRNA in Rat Brain To examine the developmental regulation of mRNA expression of the protocadherins, brain mRNA from rats at embryonic days 17 and 20, neonatal days 5 and 11 and from adult rats was prepared and subjected to Northern blot analysis as described above for other rat tissues, β-actin was used as an internal standard. mRNA levels for pc42 and pc43 proteins increased during embryonic development of the brain as compared with β-actin expression. Protocadherin mRNA Expression in Human Cell Lines Several neuronal and glial cell lines (including human SK-N-SH neuroblastoma, human U251 glioma, and mouse Neuro-2a neuroblastoma cell lines) were assayed by Northern blot using 32 P-labelled for expression of pc42 and pc43 mRNA. Human cell lines were probed with HUMAN-42 (which corresponds to EC-4 of human pc42) and HUMAN-43 (which corresponds to EC- 5 of human pc43) cDNA fragments while the mouse cell line was probed with MOUSE-326 (which corresponds to EC-4 of human pc42) and RAT-322 (which corresponds to EC-5 of human pc43) cDNA fragments. SK-N-SH human neuroblastoma cells and U251 human glioma cells were found to express pc43 mRNA and Neuro-2a mouse neuroblastoma cells were found to express pc42 mRNA. Example 10 Expression of pc43 protein in various tissues, extracts and cells was assayed by Western blot and immunofluorescence microscopy. Expression in Rat Cardiac Muscle Extracts A rat heart non-ionic detergent extract was prepared by freezing a heart in liquid nitrogen after removal, powdering in a mortar and pestle, grinding briefly in a polytron in 0.5% Nonidet P40 in [10 mM PIPES (pH 6.8), 50 mM NaCl, 250 mM NH 4 SO 4 , 300 mM sucrose, 3 M MgClJ and microfuging for 15 minutes. Samples were separated by SDS/PAGE and electrophoretically transferred to nitrocellulose (Towbin et al , PNAS 7 :4350-4354, 1979). Two pc43 protein bands with molecular weights of 150 KDa and 140 KDa were detected with rabbit polyclonal antibodies to pc43 by the immunoblot method described in Example 6. Expression in Tissue Sections and Cells To determine the localization of the protocadherins in various tissues, human and rat adult tissues were removed, incubated in 30% sucrose in PBS for 30 minutes at 4°C, embedded in OCT compound (Tissue-Tek, Elkhart, Indiana) in cryomolds and quickly frozen. Six micron sections were cut and placed on glass slides. The slides were washed with PBS and fixed in 3% p- formaldehyde for 5 minutes. To permeablize the tissue sections, the slides were immersed in -20 'C acetone for 10 minutes and air dried. The sections were blocked with 2% goat serum and 1 % BSA in PBS for 30 minutes and then incubated with the rabbit anti-pc43 polyclonal antisera for 1 hour at room temperature. The sections were rinsed 3 times in PBS containing 0.1 % BSA and incubated with a biotinylated anti-rabbit (Vector Laboratories, Burlingame, California) in 1 % BSA in PBS for 30 minutes. After rinsing 3 times, strepavidin- conjugated with FITC (Vector Laboratories) was added for 30 minutes and again washed 3 times. For co-localization studies, an appropriate primary antibody was used with a TRJTC-conjugated secondary antibody. A. Muscle Immunolocalization of pc43 in rat cardiac muscle shows that pc43 is localized in a repeating pattern which is consistent with pc43 being associated with the sarcomeres. Sarcomeres are repetitive contractile units between the fascia adherens in skeletal and cardiac muscle. Co-localization with cytoskeletal proteins shows that pc43 is present at the ends of the sarcomeres in the Z lines which are associated with desmin and the actin-binding protein vinculin, and alpha-actinin. The thin microfilaments of F-actin are associated with the thick myosin filaments between the Z lines. In contrast, N-cadherin is localized at the ends of cardiac myocytes at the fascia adherens junctions at sites of mycocyte:myocyte contact. The localization of pc43 in cardiac muscle suggests that pc43 may play a role in muscle contraction in the anchoring of the contractile apparatus to the plasma membrane. Similar localization for pc43 was observed in rat skeletal muscle. Ultrastructural studies have shown that dystrophin, the gene product lacking in Duchenne muscular dystrophy, is a component of the sarcolemma [Porter et al. , J. Cell Biol, 777:997-1005 (1992)]. The sarcolemma is connected to the contractile apparatus at the M and Z lines where pc43 is localized. B. Brain Reactivity of anti-pc43 polyclonal antibody and monoclonal antibody 38I2C on frozen sections of rat and human cerebellum, respectively, shows that the major sites of pc43 expression are located in Purkinje cells and the granule cell layer which contains numerous small neurons. C. Placenta Strong reactivity of monoclonal antibody 38I2C with human syncytiotrophoblasts was also observed in development of the placenta at an early state (5-7 weeks of gestation). Expression appeared to gradually decrease as the stage progressed indicating that pc43 may be involved in the implantation of fertilized eggs into the placenta. D. Neuroblastoma and Astrocytoma Cells Immunocytochemical localization of pc43 in Sk-N-SH neuroblastoma cells and UW28 astrocytoma cells using anti-pc43 antibodies reveals a punctate cell surface distribution of pc43 and in some cells there is a localization at the tips of extensions of neuronal foot processes. At sites of cell- cell contact of TJW28 astrocytoma cells, pc43 is organized in a series of parallel lines. The lines start at the contact site and extend approximately 5 micron. F- actin microfilaments were identified with rhodamine-phalloidin (Molecular Probes, Eugene, Oregon, as described by the manufacturer) showing that the microfilaments in the cell appear to end in the pc43 linear structures which extend from the edge of the cell at sites of cell contact. Immunoblotting studies with pc43 specific antibodies show that a protein with a molecular weight of 140 kDa is recognized in human Sk-N-SH neuroblastoma cells and in UW28 astrocytoma cells. E. Osteoblasts Immunocytochemical localization of pc43 using monoclonal antibody 38I2C in tow human ostogenic sarcoma cell lines [SaOS (ATCC HTB 85) and MG-63 (ATCC CRL 1427)] and in cultures of normal human trabecular osteoblasts [culture system described in Civitelli et al. , J. Clin. Invest. , 91: 1888- 1896 (1993)] showed that pc43 is expressed in osteoblasts in a pattern similar to that seen in UW28 astrocytoma cells. At sites of cell-cell contact, pc43 is organized in a series of parallel lines that appear to correspond to the actin stress fibers. In addition, in some cells, pc43 appears to localize at the tips of contacting cell processes. Northern blot analysis provides additional evidence that pc43 is expressed in normal human trabecular osteoblasts. A pc43 specific DNA probe hybridized to a major band of 5 kb in samples of poly- A mRNA isolated from normal human trabecular osteoblasts. Example 11 In situ hybridization experiments using protocadherin specific RNA probes were preformed on cryosections of rat tissue. Sense and antisense 35 S-riboprobes were made using the standard procedure described by Promega (Madison, Wisconsin). An approximately 400 bp EcoRI-Xbal fragment of the MOUSE-326 cDNA clone was used as a pc42 specific probe. This fragment encodes the middle of EC-3 to the end of EC-4 of pc42. An approximately 700 bp Smal fragment of the RAT-218 cDNA clone was used as a pc43 specific probe. The fragment encodes the end of EC-3 to the end of EC-5 of pc43. Rat adult tissues were harvested and immediately embedded with OCT Compound (Tissue-Tek) in cryomolds and quickly frozen in a bath of 95 % ethanol/dry ice. The frozen blocks were stored at -80 °C until cut. Six micron tissue sections were cut using a cryostat (Reichert-Jung, Model #2800 Frigocut N, Leica, Inc., Gilroy, California). Cut tissue sections were stored at -80°C. The in situ protocol used was a variation of that described by Angerer et al. , Methods in Enzymology, 152: 649-660, (1987). All solutions were treated with diethylpyrocarbonate (DEPC, Sigma, St. Louis, Missouri) to remove RNase contamination. The tissue sections were first fixed in 4% paraformaldehyde at 4°C for 20 minutes. To remove excess paraformaldehyde and stop the tissue fixation, the slides were washed in PBS (phosphate buffered saline), denatured in a graded series of alcohols (70, 95, 100%) and then dried. To prevent the tissue from detaching from the glass slide during the in situ procedure, the tissue sections were treated in a poly-L-lysine solution (Sigma) at room temperature for 10 minutes. To denature all RNA in the tissue, the sections were placed in a solution of 70% formamide/2x SSC (0.15 M NaCl/0.3 M Na citrate, pH 7.0) at 70 * C for 2 minutes after which they were rinsed in chilled 2x SSC, dehydrated in a graded series of alcohols and then dried. Once dried, the sections were prehybridized in hybridization buffer [50% formamide/50 mM DTT (dithiothrietol)/0.3M NaCl/20 mM Tris, pH 8.0/5 mM EDTA/1X Denhardt's (0.02% Ficoll Type 400/0.02% polyvinylpyrrolidone/0.02% BSA)/10% Dextran Sulfate] at the final hybridization temperature for approximately 4 hours. After prehybridization, approximately 1 X 10 6 cpm of the appropriate riboprobe was added to each section. The sections were generally hybridized at 45 °C overnight (12-16 hours). To insure that the hybridization seen was specific, in some experiments the hybridization stringency was increased by raising the hybridization temperature to 50 ° C. As both the 45 * C and 50 ° C experiments gave comparable results, the standard hybridization temperature used was 45 °C. To remove excess, nonhybridized probe, the sections were put through a series of washes. The sections were first rinsed in 4X SSC to remove the bulk of the hybridization solution and probe. Next a 15 minute wash in 4X SSC/50 mM DTT was carried out at room temperature. Washes at increased stringencies were also utilized. A 40 minute wash in 50% formam.de/2X SSC/50 mM DTT was performed at 60 'C. Four final room temperature washes were carried out for 10 minutes each: two in 2X SSC and two in 0.1X SSC. The washed slides were dehydrated in a graded series of alcohols and dried. To visualize the hybridized probe, the slides were dipped in Kodak NTB2 nuclear emulsion (International Biotechnology, New Haven, Connecticut) which had been diluted 1:1 in dH 2 O. Once dry, the slides were stored at 4° C in light-tight boxes for the appropriate exposure time. The in situ slides were independently viewed by two persons and scored positive or negative for hybridization signal. All in situ hybridization studies were performed on rat tissue. Because results from Northern blot experiments (see Example 9) indicated that both pc42 and pc43 are expressed in adult brain, in situ hybridization studies were carried out to localize the expression of these molecules to specific brain cell types. Hybridization seen in the normal adult rat brian was specific (no background hybridization was seen with the sense probes) and was localized to specific regions in the brain. The overall pattern of expression seen for pc42 and pc43 was very similar, with the major difference being in the level of expression. pc43 appears to be expressed at a lower level than pc42. Both molecules are expressed in the germinal and pyramidal cells of the hippocampus, Purkinje cells of the cerebellum and neurons in grey matter. In addition, pc42 is expressed in glial cells in the white matter but, in contrast to the expression of pc43 in glioma cell lines (as described in Example 9), expression of pc43 in normal glial cells was not observed. In the spinal chord, both protocadherins are expressed in the motor neurons in the gray matter and pc42 is expressed in the glial cells in the white matter. When expression of both protocadherin molecules was analyzed in brains and spinal chords from rats having EAE (experimental allergic encephalomyelitis) [Vandenbark et al , Cell. Immunol , 12: 85-93 (1974)], the same structures as described above were found to be positive. In addition, expression of pc42 was observed in the leukocytic infiltrates in the EAE tissues. Expression of pc42 in leukocytes was confirmed by in situ hybridization analysis of two leukocytic cell lines, RBL-1 and y3. Expression of both protocadherin-42 and -43 was observed in the developing brain of rat embryos at all embryological days tested (E15-E19). In addition protocadherin-43 was observed in the developing rat heart at all embryological days tested (E13-E19). This finding is consistent with the immunohistochemistry results showing protocadherin-43 expression in adult heart. Example 12 Conventional immunoprecipitations using pc43-specifιc polyclonal antibodies and monoclonal antibody 38I2C were performed to identify proteins that interacted with pc43 in L cell transfectants. The pc43 and chimeric pc43 transfectants were metabolically labeled by incubating the cells in Dulbecco's modified Eagle's medium containing [ 35 S] methionine (50 uCi/ml) overnight. After washing, the transfectants were lysed with PBS containing Triton X 100 and incubated with anti-pc43 antibody. The immunocomplexes were then collected using protein A-Sepharose beads. The resulting beads were washed five times with a washing buffer (50mM Tris-HCl, pH 8.0, containing 0.5M NaCl, 0.1 % ovalbumin, 0.5% NP-40, 0.5% Triton X 100 and ImM EDTA) at room temperature. Protein was separated by SDS-PAGE and subjected to autoradiography. The chimeric pc43 co-precipitated with 105 kDa and a 95 kDa bands that are likely to correspond to - and /3-catenins, respectively, because anti-α-catenin and anti-jS-catenin antibodies stained comparable bands. Pc43, on the other hand, co-precipitated with a 120 kDa band. While the present invention has been described in terms of specific methods and compositions, it is understood that variations and modifications will occur to those skilled in the art. Therefore, only such limitations as appear in the claims should be placed on the invention. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Suzuki, Shintaro (ii) TITLE OF INVENTION: Protocadherin Materials and Methods (iii) NUMBER OF SEQUENCES: 107 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Marshall, O'Toole, Gerstein, Murray, ~ Borun (B) STREET: 6300 Sears Tower, 233 S. Wacker Drive (C) CITY: Chicago (D) STATE: Illinois (E) COUNTRY: USA (F) ZIP: 60606 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA (A) APPLICATION NUMBER: US 07/998,003 (B) FILING DATE: 29 DEC 1992 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Noland, Greta E. (B) REGISTRATION NUMBER: 35,302 (C) REFERENCE/DOCKET NUMBER: 31811 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 312/474-6300 (B) TELEFAX: 312/474-0448 (C) TELEX: 25-3856 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID Nθ:l: AARSSNNTNG AYTRYGA 17 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: TTRCTRTTRC GNGGNNN 17 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: AAGGGAGTGG ACTTTGAGGA GCAGCCTGAG CTTAGTCTCA TCCTCACGGC TTTGGATGGA 60 GGGACTCCAT CCAGGTCTGG GACTGCATTG GTTCAAGTGG AAGTCATAGA TGCCAATGAC 120 AACGCACCGT A 131 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: : Lys Gly Val Asp Phe Glu Glu Gin Pro Glu Leu Ser Leu lie Leu Thr 1 5 10 15 Ala Leu Asp Gly Gly Thr Pro Ser Arg Ser Gly Thr Ala Leu Val Gin 20 25 30 Val Glu Val lie Asp Ala Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: AAACGCATGG ATTTCGAGGA GTCTTCCTCC TACCAGATCT ATGTGCAAGC TACTGACCGG 60 GGACCAGTAC CCATGGCGGG TCATTGCAAG GTGTTGGTGG ACATTATAGA TGTGAACGAC 120 AACGCACCTA A 131 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Lys Ala Met Asp Phe Glu Glu Ser Ser Ser Tyr Gin lie Tyr Val Gin 1 5 10 15 Ala Thr Asp Arg Gly Pro Val Pro Met Ala Gly His Cys Lys Val Leu 20 25 30 Val Asp lie lie Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: AAGCGACTGG ACTTTGAGAC CCTGCAGACC TTCGAGTTCA GCGTGGGTGC CACAGACCAT 60 GGCTCCCCCT CGCTCCGCAG TCAGGCTCTG GTGCGCGTGG TGGTGCTGGA CCACAATGAC 120 AATGCCCCCA A 131 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Lys Arg Leu Asp Phe Glu Thr Leu Gin Thr Phe Glu Phe Ser Val Gly 1 5 10 15 Ala Thr Asp His Gly Ser Pro Ser Leu Arg Ser Gin Ala Leu Val Arg 20 25 30 Val Val Val Leu Asp His Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: AAGGGCCTGG ATTACGAGGC ACTGCAGTCC TTCGAGTTCT ACGTGGGCGC TACAGATGGA 60 GGCTCACCCG CGCTCAGCAG CCAGACTCTG GTGCGGATGG TGGTGCTGGA TGACAACGAC 120 AACGCCCCTA A 131 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Lys Gly Leu.Asp Tyr Glu Ala Leu Gin Ser Phe Glu Phe Tyr Val Gly 1 5 10 15 Ala Thr Asp Gly Gly Ser Pro Ala Leu Ser Ser Gin Thr Leu Val Arg 20 25 30 Met Val Val Leu Asp Asp Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: AAGGCGTTTG ATTTTGAGGA TCAGAGAGAG TTCCAGCTAA CCGCTCATAT AAACGACGGA 60 GGTACCCCGG TTTTGGCCAC CAACATCAGC GTGAACATAT TTGTTACTGA CCGCAATGAC 120 AACGCCCCGC A 131 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Lys Ala Phe Asp Phe Glu Asp Gin Arg Glu Phe Gin Leu Thr Ala His 1 5 10 15 lie Asn Asp Gly Gly Thr Pro Val Leu Ala Thr Asn lie Ser Val Asn 20 25 30 lie Phe Val Thr Asp Arg Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: AAGGCGGTGG ATTACGAAAT CACCAAGTCC TATGAGATAG ATGTTCAAGC CCAAGATCTG 60 GGTCCCAATT CTATTCCTGC TCATTGCAAA ATTATAATTA AGGTCGTGGA TGTCAACGAC 120 AACGCTCCCA A 131 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: Lys Ala Val Asp Tyr Glu lie Thr Lys Ser Tyr Glu lie Asp Val Gin 1 5 10 15 Ala Gin Asp Leu Gly Pro Asn Ser lie Pro Ala His Cys Lys lie lie 20 25 30 lie Lys Val Val Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 135 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: TATGACCATG ATTACGAGAC AACCAAAGAA TATACACTGC GGATCCGGGC CCAGGATGGT 60 GGCCGGACTC CACTTTCCAA CGTCTCCGGT CTAGTAACCG TGCAGGTCCT AGACATCAAC 120 GACAATGCCC CCCCA 135 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 44 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Tyr Asp His Asp Tyr Glu Thr Thr Lys Glu Tyr Thr Leu Arg lie Arg 1 5 10 15 Ala Gin Asp Gly Gly Arg Thr Pro Leu Ser Asn Val Ser Gly Leu Val 20 25 30 Thr Val Gin Val Leu Asp lie Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 129 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: GGGGGGTCGA TTACGAGGAG AACGGCATGT TAGAGATCGA CGTGCAGGCC AGAGACCTAG 60 GACCTAACCC AATTCCAGCC CATTGCAAGG TCACAGTCAA GCTCATCGAC CGCAATGATA 120 ACGCCCCCA 129 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Arg Gly Val Asp Tyr Glu Glu Asn Gly Met Leu Glu lie Asp Val Gin 1 5 10 15 Ala Arg Asp Leu Gly Pro Asn Pro lie Pro Ala His Cys Lys Val Thr 20 25 30 Val Lys Leu lie Asp Arg Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: AAGGGGTTGG ACTACGAAGA CACCAAACTC CATGAGATTT ACATCCAGGC CAAAGACAAA 60 GGTGCCAATC CGGAAGGAGC GCATTGCAAA GTACTGGTAG AGGTTGTGGA CGTTAACGAC 120 AATGCCCCTC A 131 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Lys Gly Leu Asp Tyr Glu Asp Thr Lys Leu His Glu lie Tyr lie Gin 1 5 10 15 Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys Lys Val Leu 20 25 30 Val Glu Val Val Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: AAGGGTTTGG ACTTTGAGCA AGTAGATGTC TACAAAATCC GCGTTGACGC GACGGACAAA 60 GGACACCCTC CGATGGCAGG CCATTGCACT GTTTTAGTGA GGGTATTGGA TGAAAACGAC 120 AATGCGCCTC T 131 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: Lys Gly Leu Asp Phe Glu Gin Val Asp Val Tyr Lys lie Arg Val Asp 1 5 10 15 Ala Thr Asp Lys Gly His Pro Pro Met Ala Gly His Cys Thr Val Leu 20 25 30 Val Arg Val Leu Asp Glu Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 134 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: AAGGGTATAG ACTTCGAGCA GATCAAGGAC TTCAGCTTTC AAGTGGAAGC CCGGGACGCC 60 GGCAGTCCCC AGGCGCTGTC CGGCAACTGC ACTGTCAACA TCTTGATAGT GGATCAGAAC 120 GACAACGCCC CTAA 134 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 44 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Lys Gly lie Asp Phe Glu Gin lie Lys Asp Phe Ser Phe Gin Val Glu 1 5 10 15 Ala Arg Asp Ala Gly Ser Pro Gin Ala Leu Ala Gly Asn Thr Thr Val 20 25 30 Asn lie Leu lie Val Asp Gin Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 134 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: AAGCCGTTCG ACTATGAGCA AACCGCCAAC ACGCTGGCAC AGATTGACGC CGTGCTGGAA 60 AAACAGGGCA GCAATAAATC GAGCATTCTG GATGCCACCA TTTTCCTGGC CGATAAAAAC 120 GACAATGCGC CAGA 134 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 44 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Lys Pro Phe Asp Tyr Glu Gin Thr Ala Asn Thr Leu Ala Gin lie Asp 1 5 10 15 Ala Val Leu Glu Lys Gin Gly Ser Asn Lys Ser Ser lie Leu Asp Ala 20 25 30 Thr lie Phe Leu Ala Asp Lys Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: AAGCGGCTGG ATTTCGAACA GTTCCAGCAG CACAAGCTGC TCGTAAGGGC TGTTGATGGA 60 GGAATGCCGC CACTGAGCAG CGATGTGGTC GTCACTGTGG ATGTCACCGA CCTCAACGAT 120 AACGCGCCCT A 131 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Lys Arg Leu Asp Phe Glu Gin Phe Gin Gin His Lys Leu Leu Val Arg 1 5 10 15 Ala Val Asp Gly Gly Met Pro Pro Leu Ser Ser Asp Val Val Val Thr 20 25 30 Val Asp Val Thr Asp Leu Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: AAGGGGATAG ACTTTGAGAG TGAGAATTAC TATGAATTTG ATGTGCGGGC TCGCGATGGG 60 GGTTCTCCAG CCATGGAGCA ACATTGCAGC CTTCGAGTGG ATCTGCTGGA CGTAAATGAC 120 AACGCCCCAC T 131 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: Lys Gly lie Asp Phe Glu Ser Glu Asn Tyr Tyr Glu Phe Asp Val Arg 1 5 10 15 Ala Arg Asp Gly Gly Ser Pro Ala Met Glu Gin His Cys Ser Leu Arg 20 25 30 Val Asp Leu Leu Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: AAGGCATTGG ACTTTGAGGC CCGGCGACTG TATTCGCTGA CAGTTCAGGC CACGGACCGA 60 GGCGTGCCCT CGCTCACCGG GCGTGCCGAA GCGCTTATCC AGCTGCTAGA TGTCAACGAC 120 AACGCACCCA T 131 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: Lys Ala Leu Asp Phe Glu Ala Arg Arg Leu Tyr Ser Leu Thr Val Gin 1 5 10 15 Ala Thr Asp Arg Gly Val Pro Ser Leu Thr Gly Arg Ala Glu Ala Leu 20 25 30 lie Gin Leu Leu Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 125 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: AAGCCAATTG ATTACGAGGC AACTCCATAC TATAACATGG AAATTGTAGC CACAGACAGC 60 GGAGGTCTTT CGGGAAAATG CACTGTGTCT ATACAGGTGG TGGATGTGAA CGACAACGCC 120 CCCAA 125 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 41 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: Lys Pro lie Asp Tyr Glu Ala Thr Pro Tyr Tyr Asn Met Glu lie Val 1 5 10 15 Ala Thr Asp Ser Gly Gly Leu Ser Gly Lys Cys Thr Val Ser lie Gin 20 25 30 Val Val Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 446 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: AAGCGGGTAG ACTTCGAAAT GTGCAAAAGA TTTTACCTTG TGGTGGAAGC TAAAGACGGA 60 GGCACCCCAG CCCTCAGCAC GGCAGCCACT GTCAGCATCG ACCTCACAGA TGTGAATGAT 120 AACCCTCCTC GGTTCAGCCA AGATGTCTAC AGTGCTGTCA TCAGTGAGGA TGCCTTAGAG 180 GGGGACTCTG TCATTCTGCT GATAGCAGAA GATGTGGATA GCAAGCCTAA TGGACAGATT 240 CGGTTTTCCA TCGTGGGTGG AGATAGGGAC AATGAATTTG CTGTCGATCC AATCTTGGGA 300 CTTGTGAAAG TTAAGAAGAA ACTGGACCGG GAGCGGGTGT CAGGATACTC CCTGCTCATC 360 CAGGCAGTAG ATAGTGGCAT TCCTGCAATG TCCTCAACGA CAACTGTCAA CATTGATATT 420 TCTGATGTGA ACGACAACGC CCCCCT 446 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 148 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: Lys Arg Val Asp Phe Glu Met Cys Lys Arg Phe Tyr Leu Val Val Glu 1 5 10 15 Ala Lys Asp Gly Gly Thr Pro Ala Leu Ser Thr Ala Ala Thr Val Ser 20 25 30 lie Asp Leu Thr Asp Val Asn Asp Asn Pro Pro Arg Phe Ser Gin Asp 35 40 45 Val Tyr Asp Ala Val lie Ser Glu Asp Ala Leu Glu Gly Asp Ser Val 50 55 60 lie Leu Leu lie Ala Glu Asp Val Asp Ser Lys Pro Asn Gly Gin lie 65 70 75 80 Arg Phe Ser lie Val Gly Gly Asp Arg Asp Asn Glu Phe Ala Val Asp 85 90 95 Pro lie Leu Gly Leu Val Lys Val Lys Lys Lys Leu Asp Arg Glu Arg 100 105 110 Val Ser Gly Tyr Ser Leu Leu lie Gin Ala Val Asp Ser Gly lie Pro 115 120 125 Ala Met Ser Ser Thr Thr Thr Val Asn lie Asp lie Ser Asp Val Asn 130 135 140 Asp Asn Ala Pro 145 (2) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 440 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: AAGGGGGTTG ATTATGAGAC AAACCCACGG CTACGACTGG TGCTACAGGC AGAGAGTGGA 60 GGAGCCTTTG CTTTCTCGGT GCTGACCCTG ACCCTTCAAG ATGCCAATGA CAATGCTCCC 120 CGTTTCCTGC AGCCTCACTA CGTGGCTTTC CTGCCAGAGT CCCGACCCTT GGAAGGGCCC 180 CTGCTGCAGG TGGAAGCAGA CGACCTGGAT CAAGGCTCTG GAGGACAGAT CTCCTACAGT 240 CTGGCTGCAT CCCAGCCAGC ACGGGGCTTG TTCCATGTAG ACCCAGCCAC AGGCACTATC 300 ACTACCACAG CCATCCTGGA CCGGGAAATC TGGGCTGAAA CACGGCTGGT ACTGATGGCC 360 ACAGACAGAG GAAGCCCAGC ATTGGTGGGC TCAGCTACCC TGACAGTGAT GGTCATCGAT 420 ACCAACGACA ATGCTCCCCT 440 (2) INFORMATION FOR SEQ ID NO:38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 146 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: Lys Gly Val Asp Tyr Glu Thr Asn Pro Arg Leu Arg Leu Val Leu Gin 1 5 10 15 Ala Glu Ser Gly Gly Ala Phe Ala Phe Ser Val Leu Thr Leu Thr Leu 20 25 30 Gin Asp Ala Asn Asp Asn Ala Pro Arg Phe Leu Gin Pro His Tyr Val 35 40 45 Ala Phe Leu Pro Glu Ser Arg Pro Leu Glu Gly Pro Leu Leu Gin Val 50 55 60 Glu Ala Asn Asp Leu Asp Gin Gly Ser Gly Gly Gin lie Ser Tyr Ser 65 70 75 80 Leu Ala Ala Ser Gin Pro Ala Arg Gly Leu Phe His Val Asp Pro Ala 85 90 95 Thr Gly Thr lie Thr Thr Thr Ala lie Leu Asp Arg Glu He Trp Ala 100 105 110 Glu Thr Arg Leu Val Leu Met Ala Thr Asp Arg Gly Ser Pro Ala Leu 115 120 125 Val Gly Ser Ala Thr Leu Thr Val Met Val He Asp Thr Asn Asp Asn 130 135 140 Ala Pro 145 (2) INFORMATION FOR SEQ ID NO:39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 124 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: AAGGTCTCGA TTATGAGGCA ACTCCATATT ATAACGTGGA AATTGTAGCC ACAGATGGTG 60 GGGGCCTTTC AGGAAAATGC ACTGTGGCTA TAGAAGTGGT GGATGTGAAC GACGGCGCTC 120 CAAT 124 (2) INFORMATION FOR SEQ ID NO:40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 41 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: Lys Gly Leu Asp Tyr Glu Ala Thr Pro Tyr Tyr Asn Val Glu He Val 1 5 10 15 Ala Thr Asp Gly Gly Ala Phe Asp Glu Asn Cys Thr Val Ala He Glu 20 25 30 Val Val Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA ( i) SEQUENCE DESCRIPTION: SEQ ID NO:41: Asp Xaa Asn Glu Xaa Pro Xaa Phe 1 5 (2) INFORMATION FOR SEQ ID NO:42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: Asp Xaa Asp Glu Xaa Pro Xaa Phe 1 5 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: Asp Xaa Asn Asp Asn Xaa Pro Xaa Phe 1 5 (2) INFORMATION FOR SEQ ID NO:44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (P) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: AAGCGGATGG ATTTTGAAGA CACCAAACTC CATGAGATTT ACATCCAGGC CAAAGACAAA 60 GGTGCCAATC CCGAAGGAGC GCATTGCAAA GTACTTGTAG AGGTTGTAGA CGTAAACGAC 120 AACGCCCCAG T 131 (2) INFORMATION FOR SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: Leu Arg Met Asp Phe Glu Asp Thr Lys Leu His Glu He Tyr He Gin 1 5 10 15 Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys Lys Val Leu 20 25 30 Val Glu Val Val Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: AAGGCTTTGG ATTACGAGGA TCAGAGAGAG TTCCAACTAA CAGCTCATAT AAACGACGGA 60 GGTACCCCAG TCTTAGCCAC CAACATCAGC GTGAACGTAT TTGTTACTGA CCGCAATGAT 120 AACGCCCCCT A 131 (2) INFORMATION FOR SEQ ID NO:47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: Lys Ala Leu Asp Tyr Glu Asp Gin Arg Glu Phe Gin Leu Thr Ala His 1 5 10 15 He Asn Asp Gly Gly Thr Pro Val Leu Ala Thr Asn He Ser Val Asn 20 25 30 Val Phe Val Thr Asp Arg Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: AAGCGCTTGG ACTACGAGGA GAGTAACAAT TATGAAATTC ACGTGGATGC TACAGATAAA 60 GGATACCCAC CTATGGTTGC TCACTGCACC GTACTCGTGG GAATCTTGGA TGAAAATGAC 120 AACGCACCCA T 131 (2) INFORMATION FOR SEQ ID NO:49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: Lys Arg Leu Asp Tyr Glu Glu Ser Asn Asn Tyr Glu He His Val Asp 1 5 10 15 Ala Thr Asp Lys Gly Tyr Pro Pro Met Val Ala His Cys Thr Val Leu 20 25 30 Val Gly He Leu Asp Glu Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50: AAACCGGTGG ACTACGAGAA AGTCAAAGAC TATACCATCG AGATCGTGGC TGTGGATTCC 60 GGCAACCCTC CACTCTCTAG CACCAACTCC CTCAAGGTGC AGGTGGTAGA CGTCAACGAT 120 AACGCCCCTC T 131 (2) INFORMATION FOR SEQ ID NO:51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: Lys Pro Val Asp Tyr Glu Lys Val Lys Asp Tyr Thr He Glu He Val 1 5 10 15 Ala Val Asp Ser Gly Asn Pro Pro Leu Ser Ser Thr Asn Ser Leu Lys 20 25 30 Val Gin Val Val Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52: AAGCCTTTTG ATTTCGAGGA CACCAAACTC CATGAGATTT ACATCCAGGC CAAAGACAAG 60 GGCGCCAATC CCGAAGGAGC ACATTGCAAA GTGTTGGTGG AGGTTGTGGA TGTGAACGAC 120 AATGCCCCTC A 131 (2) INFORMATION FOR SEQ ID NO:53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53: Lys Pro Phe Asp Phe Glu Asp Thr Lys Leu His Glu He Tyr He Gin 1 5 10 15 Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys Lys Val Leu 20 25 30 Val Glu Val Val Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 122 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54: AAAGGTGTCG ATTACGAGGT GAGTCCACGG CTGCGACTGG TGCTGCAGGC AGAGAGTCGA 60 GGAGCCTTTG CCTTCACTGT GCTGACCCTG ACCCTGCAAG ATGCCAACGA CAACGCCCCG 120 AG 122 (2) INFORMATION FOR SEQ ID NO:55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 40 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: Lys Gly Val Asp Tyr Glu Val Ser Pro Arg Leu Arg Leu Val Leu Gin 1 5 10 15 Ala Glu Ser Arg Gly Ala Phe Ala Phe Thr Val Leu Thr Leu Thr Leu 20 25 30 Gin Asp Ala Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: AAAGGGATTG ATTACGAGCA GTTGAGAGAC CTACAGCTGT GGGTGACAGC CAGCGACAGC 60 GGGGACCCGC CTCTTAGCAG CAACGTGTCA CTGAGCCTGT TTGTGCTGGA CCAGAACGAC 120 AACGCCCCCC T 131 (2) INFORMATION FOR SEQ ID NO:57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: Lys Gly He Asp Tyr Glu Gin Leu Arg Asp Leu Gin Leu Trp Val Thr 1 5 10 15 Ala Ser Asp Ser Gly Asp Pro Pro Leu Ser Ser Asn Val Ser Leu Ser 20 25 30 Leu Phe Val Leu Asp Gin Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 125 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: AAGGCGGTCG ATTTTGAGCG CACATCCTCT TATCAACTCA TCATTCAGGC CACCAATATG 60 GCAGGAATGG CTTCCAATGC TACAGTCAAT ATTCAGATTG TTGATGAAAA CGACAACGCC 120 CCCCA 125 (2) INFORMATION FOR SEQ ID NO:59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 41 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59: Lys Ala Val Asp Phe Glu Arg Thr Ser Ser Tyr Gin Leu He He Gin 1 5 10 15 Ala Thr Asn Met Ala Gly Met Ala Ser Asn Ala Thr Val Asn He Gin 20 25 30 He Val Asp Glu Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60: AAACGGCTAG ACTTTGAAAA GATACAAAAA TATGTTGTAT GGATAGAGGC CAGAGATGGT 60 GGTTTCCCTC CTTTCTCCTC TTACGAGAAA CTTGATATAA CAGTATTAGA TGTCAACGAT 120 AACGCGCCTA A 131 (2) INFORMATION FOR SEQ ID NO:61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61: Lys Arg Leu Asp Phe Glu Lys He Gin Lys Tyr Val Val Trp He Glu 1 5 10 15 Ala Arg Asp Gly Gly Phe Pro Pro Phe Ser Ser Tyr Glu Lys Leu Asp 20 25 30 He Thr Val Leu Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62: AAGGGGATCG ATTATGAGAA GGTCAAAGAC TACACCATTG AGATTGTGGC TGTGGACTCT 60 GGCAACCCCC CACTCTCCAG CACTAACTCC CTCAAGGTGC AGGTGGTGGA CGTCAATGAC 120 AACGCACCGT G 131 (2) INFORMATION FOR SEQ ID NO:63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63: Lys Gly He Asp Tyr Glu Lys Val Lys Asp Tyr Thr He Glu He Val 1 5 10 15 Ala Val Asp Ser Gly Asn Pro Pro Leu Ser Ser Thr Asn Ser Leu Lys 20 25 30 Val Gin Val Val Asp Val Asn Asp Aβn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64: AAGGGACTCG ACTACGAGGA TCGGCGGGAA TTTGAATTAA CAGCTCATAT CAGCGATGGG 60 GGCACCCCGG TCCTAGCCAC CAACATCAGC GTGAACATAT TTGTCACTGA TCGCAACGAT 120 AATGCCCCCG T 131 (2) INFORMATION FOR SEQ ID NO:65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65: Lys Gly Leu Asp Tyr Glu Asp Arg Arg Glu Phe Glu Leu Thr Ala His 1 5 10 15 He Ser Asp Gly Gly Thr Pro Val Leu Ala Thr Asn He Ser Val Asn 20 25 30 He Phe Val Thr Asp Arg Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 470 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66: AAGGGTTTGG ACTACGAGAC CACACAGGCC TACCAGCTCA CGGTCAACGC CACAGATCAA 60 GACAACACCA GGCCTCTGTC CACCCTGGCC AACTTGGCCA TCATCATCAC AGATGTCCAG 120 GACATGGACC CCATCTTCAT CAACCTGCCT TACAGCACCA ACATCTACGA GCATTCTCCT 180 CCGGGCACGA CGGTGCGCAT CATCACCGCC ATAGACCAGG ATCAAGGACG TCCCCGGGGC 240 ATTGGCTACA CCATCGTTTC AGGGAATACC AACAGCATCT TTGCCCTGGA CTACATCAGC 300 GGAGTGCTGA CCTTGAATGG CCTGCTGGAC CGGGAGAACC CCCTGTACAG CCATGGCTTC 360 ATCCTGACTG TGAAGGGCAC GGAGCTGAAC GATGACCGCA CCCCATCTGA CGCTACAGTC 420 ACCACGACCT TCAATATCCT GGTTATTGAC ATCAACGACA ACGCCCCACT 470 (2) INFORMATION FOR SEQ ID NO:67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 156 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67: Lys Gly Leu Asp Tyr Glu Thr Thr Gin Ala Tyr Gin Leu Thr Val Asn 1 5 10 15 Ala Thr Asp Gin Asp Asn Thr Arg Pro Leu Ser Thr Leu Ala Asn Leu 20 25 30 Ala He He He Thr Asp Val Gin Asp Met Asp Pro He Phe He Asn 35 40 45 Leu Pro Tyr Ser Thr Asn He Tyr Glu His Ser Pro Pro Gly Thr Thr 50 55 60 Val Arg He He Thr Ala He Asp Gin Asp Gin Gly Arg Pro Arg Gly 65 70 75 80 He Gly Tyr Thr He Val Ser Gly Asn Thr Asn Ser He Phe Ala Leu 85 90 95 Asp Tyr He Ser Gly Val Leu Thr Leu Asn Gly Leu Leu Asp Arg Glu 100 105 110 Asn Pro Leu Tyr Ser Gly Gly Phe He Leu Thr Val Lys Gly Thr Glu 115 120 125 Leu Asn Asp Asp Arg Thr Pro Ser Asp Ala Thr Val Thr Thr Thr Phe 130 135 140 Asn He Leu Val He Asp He Asn Asp Asn Ala Pro 145 150 155 (2) INFORMATION FOR SEQ ID NO:68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68: AAGGGGGTCG ATTACGAGGT ACTACAGGCC TTTGAGTTCC ACGTGAGCGC CACAGACCGA 60 GGCTCACCGG GGCTCAGCAG CCAGGCTCTG GTGCGCGTGG TGGTGCTGGA CGACAATGAC 120 AACGCTCCCG T 131 (2) INFORMATION FOR SEQ ID NO:69: ^ (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69: Lys Gly Val Asp Tyr Glu Val Leu Gin Ala Phe Glu Phe His Val Ser 1 5 10 15 Ala Thr Asp Arg Gly Ser Pro Gly Leu Ser Ser Gin Ala Leu Val Arg 20 25 30 Val Val Val Leu Asp Asp Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70: AAGGGGCTGG ATTATGAGCA GTTCCAGACC CTACAACTGG GAGTGACCGC TAGTGACAGT 60 GGAAACCCAC CATTAAGAAG CAATATTTCA CTGACCCTTT TCGTGCTGGA CCAGAATGAT 120 AACGCCCCAA A 131 (2) INFORMATION FOR SEQ ID NO:71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71: Lys Gly Leu Asp Tyr Glu Gin Phe Gin Thr Leu Gin Leu Gly Val Thr 1 5 10 15 Ala Ser Asp Ser Gly Asn Pro Pro Leu Arg Ser Asn He Ser Leu Thr 20 25 30 Leu Phe Val Leu Asp Gin Asn Asp Aβn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72: AAGCGGGTTG ATTACGAGGA TGTCCAGAAA TACTCGCTGA GCATTAAGGC CCAGGATGGG 60 CGGCCCCCGC TCATCAATTC TTCAGGGGTG GTGTCTGTGC AGGTGCTGGA TGTCAACGAC 120 AATGCCCCGG A 131 (2) INFORMATION FOR SEQ ID NO:73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73: Lys Arg Val Asp Tyr Glu Asp Val Gin Lys Tyr Ser Leu Ser He Lys 1 5 10 15 Ala Gin Asp Gly Arg Pro Pro Leu He Asn Ser Ser Gly Val Val Ser 20 25 30 Val Gin Val Leu Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:74: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 125 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74: AAACCGGTAG ACTTTGAGCT ACAGCAGTTC TATGAAGTAG CTGTGGTGGC TTGGAACTCT 60 GAGGGATTTC ATGTCAAAAG GGTCATTAAA GTGCAACTTT TAGATGACAA CGACAATGCC 120 CCGAT 125 (2) INFORMATION FOR SEQ ID NO:75: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 41 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75: Lys Pro Val Asp Phe Glu Leu Gin Gin Phe Tyr Glu Val Ala Val Val 1 5 10 15 Ala Trp Asn Ser Glu Gly Phe His Val Lys Arg Val He Lys Val Gin 20 25 30 Leu Leu Asp Asp Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:76: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 125 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76: AAGGGATTAG ATTTTGAAAC TTTGCCCATT TACACATTGA TAATACAAGG AACTAACATG 60 GCTGGTTTGT CCACTAATAC AACGGTTCTA GTTCACTTGC AGGATGAGAA TGATAACGCC 120 CCAAA 125 (2) INFORMATION FOR SEQ ID NO:77: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 41 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77: Lys Gly Leu Asp Phe Glu Thr Leu Pro He Tyr Thr Leu He He Gin 1 5 10 15 Gly Thr Asn Met Ala Gly Leu Ser Thr Asn Thr Thr Val Leu Val His 20 25 30 Leu Gin Asp Glu Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:78: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 134 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78: AAGCGGGCGG ATTTCGAGGC GATCCGGGAG TACAGTCTGA GGATCAAAGC GCAGGACGGG 60 GGGCGGCCTC CCCTCAGCAA CACCACGGGC ATGGTCACAG TGCAGGTCGT GGACGTCAAT 120 GACAACGCAC " CCCT 134 (2) INFORMATION FOR SEQ ID NO:79: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 44 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79: Lys Arg Ala Asp Phe Glu Ala He Arg Glu Tyr Ser Leu Arg He Lys 1 5 10 15 Ala Gin Asp Gly Gly Arg Pro Pro Leu Ser Asn Thr Thr Gly Met Val 20 25 30 Thr Val Gin Val Val Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:80: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ;ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80: AAGCGGTTGG ATTACGAAAA GGCATCGGAA TATGAAATCT ATGTTCAAGC CGCTGACAAA 60 GGCGCTGTCC CTATGGCTGG CCATTGCAAA GTGTTGCTGG AGATCGTGGA TGTCAACGAC 120 AACGCCCCCT T 131 (2) INFORMATION FOR SEQ ID NO:81: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81: Lys Arg Leu Asp Tyr Glu Lys Ala Ser Glu Tyr Glu He Tyr Val Gin 1 5 10 15 Ala Ala Asp Lys Gly Ala Val Pro Met Ala Gly His Cys Lys Val Leu 20 25 30 Leu Glu He Val Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:82: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82: AAGGGGATCG ATTATGAGGA TCAGGTCTCT TACACATTAG CAGTAACAGC ACATGACTAT 60 GGCATCCCTC AAAAATCAGA CACTACCTAT TTGGAAATCT TAGTAATTGA TGTTAACGAC 120 AACGCGCCCC A 131 (2) INFORMATION FOR SEQ ID NO:83: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83: Lys Gly He Asp Tyr Glu Asp Gin Val Ser Tyr Thr Leu Ala Val Thr 1 5 10 15 Ala His Asp Tyr Gly He Pro Gin Lys Ser Asp Thr Thr Tyr Leu Glu 20 25 30 He Leu Val He Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:84: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84: AAAGGGTTAG ATTTCGAGGG CACTAAAGAT TCAGCGTTTA AAATAGTGGC AGCTGACACA 60 GGGAAGCCCA GCCTCAACCA GACAGCCCTG GTGAGAGTAG AGCTGGAGGA TGAGAACGAC 120 AACGCCCCAA T 131 (2) INFORMATION FOR SEQ ID NO:85: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85: Lys Gly Leu Asp Phe Glu Gly Thr Lys Asp Ser Ala Phe Lys He Val 1 5 10 15 Ala Ala Asp Thr Gly Lys Pro Ser Leu Asn Gin Thr Ala Leu Val Arg 20 25 30 Val Glu Leu Glu Asp Glu Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:86: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 130 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86: AAGGGTGTGG ATTTTGAAAG TGTGCGTAGC TACAGGCTGG TTATTCGTGC TCAAGATGGA 60 GGCAGCCCCT CCAGAAGTAA CACCACCCAG CTCTTGGTCA ACGTCATCGA TCGAATGACA 120 ATGCGCCGCT 130 (2) INFORMATION FOR SEQ ID NO:87: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87: Lys Gly Val Asp Phe Glu Ser Val Arg Ser Tyr Arg Leu Val He Arg 1 5 10 15 Ala Gin Asp Gly Gly Ser Pro Ser Arg Ser Asn Thr Thr Gin Leu Leu 20 25 30 Val Asn Val He Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88: AAGGGTGTGG ACTTCGAGCT GACACATCTG TATGAGATTT GGATTGAGGC TGCCGATGGA 60 GACACGCCAA GTCTGCGTAG TGTAACTCTT ATAACGCTCA ACGTAACGGA TGCCAATGAC 120 AATGCTCCCA A 131 (2) INFORMATION FOR SEQ ID NO:89: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89: Lys Gly Val Asp Phe Glu Leu Thr His Leu Tyr Glu He Trp He Glu 1 5 10 15 Ala Ala Asp Gly Asp Thr Pro Ser Leu Arg Ser Val Thr Leu He Thr 20 25 30 Leu Asn Val Thr Asp Ala Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:90: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 441 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90: CAAGGCGTTT GATTTTGAAG AGACAAGTAG ATATGTGTTG AGTGTGGAAG CTAAGGATGG 60 AGGAGTACAC ACAGCTCACT GTAATGTTCA AATAGAAATT GTTGACGAGA ATGACAATGC 120 CCCAGAGGTG ACATTCATGT CCTTCTCTAA CCAGATTCCA GAGGATTCAG ACCTTGGAAC 180 TGTAATAGCC CTCATAAAAG TGCGAGACAA GGATTCTGGG CAAAATGGCA TGGTGACATG 240 CTATACTCAG GAAGAAGTTC CTTTCAAATT AGAATCCACC TCGAAGAATT ATTACAAGCT 300 GGTGATTGCT GGAGCCCTAA ACCGGGAGCA GACAGCAGAC TACAACGTCA CAATCATAGC 360 CACCGACAAG GGCAAACCAG CCCTTTCCTC CAGGACAAGC ATCACCCTGC ACATCTCCGA 420 CATCAACGAT AATGCCCCCG T 441 (2) INFORMATION FOR SEQ ID NO:91: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 146 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91: Lys Ala Phe Asp Phe Glu Glu Thr Ser Arg Tyr Val Leu Ser Val Glu 1 5 10 15 Ala Lys Asp Gly Gly Val His Thr Ala His Cys Asn Val Gin He Glu 20 25 30 He Val Asp Glu Asn Asp Asn Ala Pro Glu Val Thr Phe Met Ser Phe 35 40 45 Ser Asn Gin He Pro Glu Asp Ser Asp Leu Gly Thr Val He Ala Leu 50 55 60 He Lys Val Arg Asp Lys Asp Ser Gly Gin Asn Gly Met Val Thr Cys 65 70 75 80 Tyr Thr Gin Glu Glu Val Pro Phe Lys Leu Glu Ser Thr Ser Lys Asn 85 90 95 Tyr Tyr Lys Leu Val He Ala Gly Ala Leu Asn Arg Glu Gin Thr Ala 100 105 110 Asp Tyr Asn Val Thr He He Ala Thr Asp Lys Gly Lys Pro Ala Leu 115 120 125 Ser Ser Arg Thr Ser He Thr Leu His He Ser Asp He Asn Asp Asn 130 135 140 Ala Pro 145 (2) INFORMATION FOR SEQ ID NO:92: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 131 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92: AAGCGAGTGG ATTACGAGGC CACTCGGAAT TATAAGCTGA GAGTTAAGGC TACTGATCTT 60 GGGATTCCAC CGAGATCTTC TAACATGACA CTGTTCATTC ATGTCCTTGA TGTTAACGAC 120 AACGCTCCCT T 131 (2) INFORMATION FOR SEQ ID NO:93: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93: Lys Arg Val Asp Tyr Glu Ala Thr Arg Asn Tyr Lys Leu Arg Val Lys 1 5 10 15 Ala Thr Asp Leu Gly He Pro Pro Arg Ser Ser Asn Met Thr Leu Phe 20 25 30 He His Val Leu Asp Val Asn Asp Asn Ala Pro 35 40 (2) INFORMATION FOR SEQ ID NO:94: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4104 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 495.-3572 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94: CCTCTATTCG ACATTCTCTT TGGATTGTTT TGCTATAACT TGAAATTTGG GATGTCACAA 60 ACGAAACTGT CATCTGTTTC CGCCAAACTG TGGTTCTGCT AATCTCCCAG GCTGGCAGCA 120 TTGGAGACTT GCTGACTTCT TTCATCCCCC ACTCTTTTCA CCTGAAATTC CTTTCCTTGG 180 TTTTGCTCTA AGTCCTATGC TTCAGTCAGG GGCCAACCAA ATCTCACTGC CTCCTTTTTA 240 TCATGAAGCC TTTGATCACT GATAGTTCTT TTTATATCTT GAAAAATCAC CCTTCCCAGT 300 ACAGTTAATA TTTAGTATCT CTACTCATCT TGGCACTTAC TCACAGCTCC ATAATTCAGT 360 CGTTTTCGTA CCTCTTCATG GTGATGGGGA GCCCTTTGGA GGTGGTGACT GTGCTTTATA 420 CTCCTCATGA TGCTTCACAT GTGGCAGGCG TGGAGTGCCC GGAGGCGGCC CTCCTGATTC 480 TGGGGCCTCC CAGG ATG GAG CCC CTG AGG CAC AGC CCA GGC CCT GGG GGG 530 Met Glu Pro Leu Arg His Ser Pro Gly Pro Gly Gly 1 5 10 CAA CGG CTA CTG CTG CCC TCC ATG CTG CTA GCA CTG CTG CTC CTG CTG 578 Gin Arg Leu Leu Leu Pro Ser Met Leu Leu Ala Leu Leu Leu Leu Leu 15 20 25 GCT CCA TCC CCA GGC CAC GCC ACT CGG GTA GTG TAC AAG GTG CCG GAG 626 Ala Pro Ser Pro Gly His Ala Thr Arg Val Val Tyr Lys Val Pro Glu 30 35 40 GAA CAG CCA CCC AAC ACC CTC ATT GGG AGC CTC GCA GCC GAC TAT GGT 674 Glu Gin Pro Pro Asn Thr Leu He Gly Ser Leu Ala Ala Asp Tyr Gly 45 50 55 60 TTT CCA GAT GTG GGG CAC CTG TAC AAG CTA GAG GTG GGT GCC CCG TAC 722 Phe Pro Asp Val Gly His Leu Tyr Lys Leu Glu Val Gly Ala Pro Tyr 65 70 75 CTT CGC GTG GAT GGC AAG ACA GGT GAC ATT TTC ACC ACC GAG ACC TCC 770 Leu Arg Val Asp Gly Lys Thr Gly Asp He Phe Thr Thr Glu Thr Ser 80 85 90 ATC GAC CGT GAG GGG CTC CGT GAA TGC CAG AAC CAG CTC CCT GGT GAT 818 He Asp Arg Glu Gly Leu Arg Glu Cys Gin Asn Gin Leu Pro Gly Asp 95 100 105 CCC TGC ATC CTG GAG TTT GAG GTA TCT ATC ACA GAC CTC GTG CAG AAT 866 Pro Cys He Leu Glu Phe Glu Val Ser He Thr Asp Leu Val Gin Asn 110 115 120 GCG AGC CCC CGG CTG CTA GAG GGC CAG ATA GAA GTA CAA GAC ATC AAT 914 Ala Ser Pro Arg Leu Leu Glu Gly Gin He Glu Val Gin Asp He Asn 125 130 135 140 GAC AAC ACA CCC AAC TTC GCC TCA CCA GTC ATC ACT CTG GCC ATC CCT 962 Asp Asn Thr Pro Asn Phe Ala Ser Pro Val He Thr Leu Ala He Pro 145 150 155 GAG AAC ACC AAC ATC GGC TCA CTC TTC CCC ATC CCG CTG GCT TCA GAC 1010 Glu Asn Thr Asn He Gly Ser Leu Phe Pro He Pro Leu Ala Ser Asp 160 165 170 CGT GAT GCT GGT CCC AAC GGT GTG GCA TCC TAT GAG CTG CAG GTG GCA 1058 Arg Asp Ala Gly Pro Asn Gly Val Ala Ser Tyr Glu Leu Gin Val Ala 175 180 185 GAG GAC CAG GAG GAG AAG CAA CCA CAG CTC ATT GTG ATG GGC AAC CTG 1106 Glu Asp Gin Glu Glu Lys Gin Pro Gin Leu He Val Met Gly Asn Leu 190 195 200 GAC CGT GAG CGC TGG GAC TCC TAT GAC CTC ACC ATC AAG GTG CAG GAT 1154 Asp Arg Glu Arg Trp Asp Ser Tyr Asp Leu Thr He Lys Val Gin Asp 205 210 215 220 GGC GGC AGC CCC CCA CGC GCC ACG AGT GCC CTG CTG CGT GTC ACC GTG 1202 Gly Gly Ser Pro Pro Arg Ala Thr Ser Ala Leu Leu Arg Val Thr Val 225 230 235 CTT GAC ACC AAT GAC AAC GCC CCC AAG TTT GAG CGG CCC TCC TAT GAG 1250 Leu Asp Thr Asn Asp Asn Ala Pro Lys Phe Glu Arg Pro Ser Tyr Glu 240 245 250 GCC GAA CTA TCT GAG AAT AGC CCC ATA GGC CAC TCG GTC ATC CAG GTG 1298 Ala Glu Leu Ser Glu Asn Ser Pro He Gly His Ser Val He Gin Val 255 260 265 AAG GCC AAT GAC TCA GAC CAA GGT GCC AAT GCA GAA ATC GAA TAC ACA 1346 Lys Ala Asn Asp Ser Asp Gin Gly Ala Asn Ala Glu He Glu Tyr Thr 270 275 280 TTC CAC CAG GCG CCC GAA GTT GTG AGG CGT CTT CTT CGA CTG GAC AGG 1394 Phe His Gin Ala Pro Glu Val Val Arg Arg Leu Leu Arg Leu Asp Arg 285 290 295 300 AAC ACT GGA CTT ATC ACT GTT CAG GGC CCG GTG GAC CGT GAG GAC CTA 1442 Asn Thr Gly Leu He Thr Val Gin Gly Pro Val Asp Arg Glu Asp Leu 305 310 315 AGC ACC CTG CGC TTC TCA GTG CTT GCT AAG GAC CGA GGC ACC AAC CCC 1490 Ser Thr Leu Arg Phe Ser Val Leu Ala Lys Asp Arg Gly Thr Asn Pro 320 325 330 AAG AGT GCC CGT GCC CAG GTG GTT GTG ACC GTG AAG GAC ATG AAT GAC 1538 Lys Ser Ala Arg Ala Gin Val Val Val Thr Val Lys Asp Met Asn Asp 335 340 345 AAT GCC CCC ACC ATT GAG ATC CGG GGC ATA GGG CTA GTG ACT CAT CAA 1586 Asn Ala Pro Thr He Glu He Arg Gly He Gly Leu Val Thr His Gin 350 355 360 GAT GGG ATG GCT AAC ATC TCA GAG GAT GTG GCA GAG GAG ACA GCT GTG 1634 Asp Gly Met Ala Asn He Ser Glu Asp Val Ala Glu Glu Thr Ala Val 365 370 375 380 GCC CTG GTG CAG GTG TCT GAC CGA GAT GAG GGA GAG AAT GCA GCT GTC 1682 Ala Leu Val Gin Val Ser Asp Arg Asp Glu Gly Glu Asn Ala Ala Val 385 390 395 ACC TGT GTG GTG GCA GGT GAT GTG CCC TTC CAG CTG CGC CAG GCC AGT 1730 Thr Cys Val Val Ala Gly Asp Val Pro Phe Gin Leu Arg Gin Ala Ser 400 405 410 GAG ACA GGC AGT GAC AGC AAG AAG AAG TAT TTC CTG CAG ACT ACC ACC 1778 Glu Thr Gly Ser Asp Ser Lys Lys Lys Tyr Phe Leu Gin Thr Thr Thr 415 420 425 CCG CTA GAC TAC GAG AAG GTC AAA GAC TAC ACC ATT GAG ATT GTG GCT 1826 Pro Leu Asp Tyr Glu Lys Val Lye Asp Tyr Thr He Glu He Val Ala 430 435 440 GTG GAC TCT GGC AAC CCC CCA CTC TCC AGC ACT AAC TCC CTC AAG GTG 1874 Val Asp Ser Gly Asn Pro Pro Leu Ser Ser Thr Asn Ser Leu Lys Val 445 450 455 460 CAG GTG GTG GAC GTC AAT GAC AAC GCA CCT GTC TTC ACT CAG AGT GTC 1922 Gin Val Val Asp Val Asn Asp Asn Ala Pro Val Phe Thr Gin Ser Val 465 470 475 ACT GAG GTC GCC TTC CCG GAA AAC AAC AAG CCT GGT GAA GTG ATT GCT 1970 Thr Glu Val Ala Phe Pro Glu Asn Asn Lys Pro Gly Glu Val He Ala 480 485 490 GAG ATC ACT GCC AGT GAT GCT GAC TCT GGC TCT AAT GCT GAG CTG GTT 2018 Glu He Thr Ala Ser Asp Ala Asp Ser Gly Ser Aβn Ala Glu Leu Val 495 500 505 TAC TCT CTG GAG CCT GAG CCG GCT GCT AAG GGC CTC TTC ACC ATC TCA 2066 Tyr Ser Leu Glu Pro Glu Pro Ala Ala Lys Gly Leu Phe Thr He Ser 510 515 520 CCC GAG ACT GGA GAG ATC CAG GTG AAG ACA TCT CTG GAT CGG GAA CAG 2114 Pro Glu Thr Gly Glu He Gin Val Lys Thr Ser Leu Asp Arg Glu Gin 525 530 535 540 CGG GAG AGC TAT GAG TTG AAG GTG GTG GCA GCT GAC CGG GGC AGT CCT 2162 Arg Glu Ser Tyr Glu Leu Lys Val Val Ala Ala Asp Arg Gly Ser Pro 545 550 555 AGC CTC CAG GGC ACA GCC ACT GTC CTT GTC AAT GTG CTG GAC TGC AAT 2210 Ser Leu Gin Gly Thr Ala Thr Val Leu Val Asn Val Leu Asp Cys Asn 560 565 570 GAC AAT GAC CCC AAA TTT ATG CTG AGT GGC TAC AAC TTC TCA GTG ATG 2258 Asp Asn Asp Pro Lys Phe Met Leu Ser Gly Tyr Asn Phe Ser Val Met 575 580 585 GAG AAC ATG CCA GCA CTG AGT CCA GTG GGC ATG GTG ACT GTC ATT GAT 2306 Glu Asn Met Pro Ala Leu Ser Pro Val Gly Met Val Thr Val He Asp 590 595 600 GGA GAC AAG GGG GAG AAT GCC CAG GTG CAG CTC TCA GTG GAG CAG GAC 2354 Gly Asp Lys Gly Glu Asn Ala Gin Val Gin Leu Ser Val Glu Gin Asp 605 610 615 620 AAC GGT GAC TTT GTT ATC CAG AAT GGC ACA GGC ACC ATC CTA TCC AGC 2402 Asn Gly Asp Phe Val He Gin Asn Gly Thr Gly Thr He Leu Ser Ser 625 630 635 CTG AGC TTT GAT CGA GAG CAA CAA AGC ACC TAC ACC TTC CAG CTG AAG 2450 Leu Ser Phe Asp Arg Glu Gin Gin Ser Thr Tyr Thr Phe Gin Leu Lys 640 645 650 GCA GTG GAT GGT GGC GTC CCA CCT CGC TCA GCT TAC GTT GGT GTC ACC 2498 Ala Val Asp Gly Gly Val Pro Pro Arg Ser Ala Tyr Val Gly Val Thr 655 660 665 ATC AAT GTG CTG GAC GAG AAT GAC AAC GCA CCC TAT ATC ACT GCC CCT 2546 He Asn Val Leu Asp Glu Asn Asp Asn Ala Pro Tyr He Thr Ala Pro 670 675 680 TCT AAC ACC TCT CAC AAG CTG CTG ACC CCC CAG ACA CGT CTT GGT GAG 2594 Ser Asn Thr Ser His Lys Leu Leu Thr Pro Gin Thr Arg Leu Gly Glu 685 690 695 700 ACG GTC AGC CAG GTG GCA GCC GAG GAC TTT GAC TCT GGT GTC AAT GCC 2642 Thr Val Ser Gin Val Ala Ala Glu Asp Phe Asp Ser Gly Val Asn Ala 705 710 715 GAG CTG ATC TAC AGC ATT GCA GGT GGC AAC CCT TAT GGA CTC TTC CAG 2690 Glu Leu He Tyr Ser He Ala Gly Gly Asn Pro Tyr Gly Leu Phe Gin 720 725 730 ATT GGG TCA CAT TCA GGT GCC ATC ACC CTG GAG AAG GAG ATT GAG CGG 2738 He Gly Ser His Ser Gly Ala He Thr Leu Glu Lys Glu He Glu Arg 735 740 745 CGC CAC CAT GGG CTA CAC CGC CTG GTG GTG AAG GTC AGT GAC CGC GGC 2786 Arg His His Gly Leu His Arg Leu Val Val Lys Val Ser Asp Arg Gly 750 755 760 AAG CCC CCA CGC TAT GGC ACA GCC TTG GTC CAT CTT TAT GTC AAT GAG 2834 Lys Pro Pro Arg Tyr Gly Thr Ala Leu Val His Leu Tyr Val Asn Glu 765 770 775 780 ACT CTG GCC AAC CGC ACG CTG CTG GAG ACC CTC CTG GGC CAC AGC CTG 2882 Thr Leu Ala Asn Arg Thr Leu Leu Glu Thr Leu Leu Gly His Ser Leu 785 790 795 GAC ACG CCG CTG GAT ATT GAC ATT GCT GGG GAT CCA GAA TAT GAG CGC 2930 Asp Thr Pro Leu Asp He Asp He Ala Gly Asp Pro Glu Tyr Glu Arg 800 805 810 TCC AAG CAG CGT GGC AAC ATT CTC TTT GGT GTG GTG GCT GGT GTG GTG 2978 Ser Lys Gin Arg Gly Asn He Leu Phe Gly Val Val Ala Gly Val Val 815 820 825 GCC GTG GCC TTG CTC ATC GCC CTG GCG GTT CTT GTG CGC TAC TGC AGA 3026 Ala Val Ala Leu Leu He Ala Leu Ala Val Leu Val Arg Tyr Cys Arg 830 835 840 CAG CGG GAG GCC AAA AGT GGT TAC CAG GCT GGT AAG AAG GAG ACC AAG 3074 Gin Arg Glu Ala Lys Ser Gly Tyr Gin Ala Gly Lys Lys Glu Thr Lys 845 850 855 860 GAC CTG TAT GCC CCC AAG CCC AGT GGC AAG GCC TCC AAG GGA AAC AAA 3122 Asp Leu Tyr Ala Pro Lys Pro Ser Gly Lys Ala Ser Lys Gly Asn Lys 865 870 875 AGC AAA GGC AAG AAG AGC AAG TCC CCA AAG CCC GTG AAG CCA GTG GAG 3170 Ser Lys Gly Lys Lys Ser Lys Ser Pro Lys Pro Val Lys Pro Val Glu 880 885 890 GAC GAG GAT GAG GCC GGG CTG CAG AAG TCC CTC AAG TTC AAC CTG ATG 3218 Asp Glu Asp Glu Ala Gly Leu Gin Lys Ser Leu Lys Phe Asn Leu Met 895 900 905 AGC GAT GCC CCT GGG GAC AGT CCC CGC ATC CAC CTG CCC CTC AAC TAC 3266 Ser Asp Ala Pro Gly Asp Ser Pro Arg He His Leu Pro Leu Asn Tyr 910 915 920 CCA CCA GGC AGC CCT GAC CTG GGC CGC CAC TAT CGC TCT AAC TCC CCA 3314 Pro Pro Gly Ser Pro Asp Leu Gly Arg His Tyr Arg Ser Asn Ser Pro 925 930 935 940 CTG CCT TCC ATC CAG CTG CAG CCC CAG TCA CCC TCA GCC TCC AAG AAG 3362 Leu Pro Ser He Gin Leu Gin Pro Gin Ser Pro Ser Ala Ser Lys Lys 945 950 955 CAC CAG GTG GTA CAG GAC CTG CCA CCT GCA AAC ACA TTC GTG GGC ACC 3410 His Gin Val Val Gin Asp Leu Pro Pro Ala Asn Thr Phe Val Gly Thr 960 965 970 GGG GAC ACC ACG TCC ACG GGC TCT GAG CAG TAC TCC GAC TAC AGC TAC 3458 Gly Asp Thr Thr Ser Thr Gly Ser Glu Gin Tyr Ser Asp Tyr Ser Tyr 975 980 985 CGC ACC AAC CCC CCC AAA TAC CCC AGC AAG CAG GTA GGC CAG CCC TTT 3506 Arg Thr Asn Pro Pro Lys Tyr Pro Ser Lys Gin Val Gly Gin Pro Phe 990 995 1000 CAG CTC AGC ACA CCC CAG CCC CTA CCC CAC CCC TAC CAC GGA GCC ATC 3554 Gin Leu Ser Thr Pro Gin Pro Leu Pro His Pro Tyr His Gly Ala He 1005 1010 1015 1020 TGG ACC GAG GTG TGG GAG TGATGGAGCA GGTTTACTGT GCCTGCCCGT 3602 Trp Thr Glu Val Trp Glu 1025 GTTGGGGGCC AGCCTGAGCC AGCAGTGGGA GGTGGGGCCT TAGTGCCTCA CCGGGCACAC 3662 GGATTAGGCT GAGTGAAGAT TAAGGGAGGG TGTGCTCTGT GGTCTCCTCC CTGCCCTCTC 3722 CCCACTGGGG AGAGACCTGT GATTTGCCAA GTCCCTGGAC CCTGGACCAG CTACTGGGCC 3782 TTATGGGTTG GGGGTGGTAG GCAGGTGAGC GTAAGTGGGG AGGGAAATGG GTAAGAAGTC 3842 TACTCCAAAC CTAGGTCTCT ATGTCAGACC AGACCTAGGT GCTTCTCTAG GAGGGAAACA 3902 GGGAGACCTG GGGTCCTGTG GATAACTGAG TGGGGAGTCT GCCAGGGGAG GGCACCTTCC 3962 CATTGTGCCT TCTGTGTGTA TTGTGCATTA ACCTCTTCCT CACCACTAGG CTTCTGGGGC 4022 TGGGTCCCAC ATGCCCTTGA CCCTGACAAT AAAGTTCTCT ATTTTTGGAA AAAAAAAAAA 4082 AAAAAAAAAA AAAAAAAAAA AA 4104 (2) INFORMATION FOR SEQ ID NO:95: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1026 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95: Met Glu Pro Leu Arg His Ser Pro Gly Pro Gly Gly Gin Arg Leu Leu 1 5 10 15 Leu Pro Ser Met Leu Leu Ala Leu Leu Leu Leu Leu Ala Pro Ser Pro 20 25 30 Gly His Ala Thr Arg Val Val Tyr Lys Val Pro Glu Glu Gin Pro Pro 35 40 45 Asn Thr Leu He Gly Ser Leu Ala Ala Asp Tyr Gly Phe Pro Asp Val 50 55 60 Gly His Leu Tyr Lys Leu Glu Val Gly Ala Pro Tyr Leu Arg Val Asp 65 70 75 80 Gly Lys Thr Gly Asp He Phe Thr Thr Glu Thr Ser He Asp Arg Glu 85 90 95 Gly Leu Arg Glu Cys Gin Asn Gin Leu Pro Gly Asp Pro Cys He Leu 100 105 110 Glu Phe Glu Val Ser He Thr Asp Leu Val Gin Asn Ala Ser Pro Arg 115 120 125 Leu Leu Glu Gly Gin He Glu Val Gin Asp He Asn Asp Asn Thr Pro 130 135 140 Asn Phe Ala Ser Pro Val He Thr Leu Ala He Pro Glu Asn Thr Asn 145 150 155 160 He Gly Ser Leu Phe Pro He Pro Leu Ala Ser Asp Arg Asp Ala Gly 165 170 175 Pro Asn Gly Val Ala Ser Tyr Glu Leu Gin Val Ala Glu Asp Gin Glu 180 185 190 Glu Lys Gin Pro Gin Leu He Val Met Gly Asn Leu Asp Arg Glu Arg 195 200 205 Trp Asp Ser Tyr Asp Leu Thr He Lys Val Gin Asp Gly Gly Ser Pro 210 215 220 Pro Arg Ala Thr Ser Ala Leu Leu Arg Val Thr Val Leu Asp Thr Asn 225 230 235 240 Asp Asn Ala Pro Lys Phe Glu Arg Pro Ser Tyr Glu Ala Glu Leu Ser 245 250 255 Glu Asn Ser Pro He Gly His Ser Val He Gin Val Lys Ala Asn Asp 260 265 270 Ser Asp Gin Gly Ala Asn Ala Glu He Glu Tyr Thr Phe His Gin Ala 275 280 285 Pro Glu Val Val Arg Arg Leu Leu Arg Leu Asp Arg Asn Thr Gly Leu 290 295 300 He Thr Val Gin Gly Pro Val Asp Arg Glu Asp Leu Ser Thr Leu Arg 305 310 315 320 Phe Ser Val Leu Ala Lys Asp Arg Gly Thr Asn Pro Lys Ser Ala Arg 325 330 335 Ala Gin Val Val Val Thr Val Lys Asp Met Asn Asp Asn Ala Pro Thr 340 345 350 Ile Glu He Arg Gly He Gly Leu Val Thr His Gin Asp Gly Met Ala 355 360 365 Asn He Ser Glu Asp Val Ala Glu Glu Thr Ala Val Ala Leu Val Gin 370 375 380 Val Ser Asp Arg Asp Glu Gly Glu Asn Ala Ala Val Thr Cys Val Val 385 390 395 400 Ala Gly Asp Val Pro Phe Gin Leu Arg Gin Ala Ser Glu Thr Gly Ser 405 410 415 Asp Ser Lys Lys Lys Tyr Phe Leu Gin Thr Thr Thr Pro Leu Asp Tyr 420 425 430 Glu Lys Val Lys Asp Tyr Thr He Glu He Val Ala Val Asp Ser Gly 435 440 445 Asn Pro Pro Leu Ser Ser Thr Asn Ser Leu Lys Val Gin Val Val Asp 450 455 460 Val Asn Asp Asn Ala Pro Val Phe Thr Gin Ser Val Thr Glu Val Ala 465 470 475 480 Phe Pro Glu Asn Asn Lys Pro Gly Glu Val He Ala Glu He Thr Ala 485 490 495 Ser Asp Ala Asp Ser Gly Ser Asn Ala Glu Leu Val Tyr Ser Leu Glu 500 505 510 Pro Glu Pro Ala Ala Lys Gly Leu Phe Thr He Ser Pro Glu Thr Gly 515 520 525 Glu He Gin Val Lys Thr Ser Leu Asp Arg Glu Gin Arg Glu Ser Tyr 530 535 540 Glu Leu Lys Val Val Ala Ala Asp Arg Gly Ser Pro Ser Leu Gin Gly 545 550 555 560 Thr Ala Thr Val Leu Val Asn Val Leu Asp Cys Asn Asp Asn Asp Pro 565 570 575 Lys Phe Met Leu Ser Gly Tyr Asn Phe Ser Val Met Glu Asn Met Pro 580 585 590 Ala Leu Ser Pro Val Gly Met Val Thr Val He Asp Gly Asp Lys Gly 595 600 605 Glu Asn Ala Gin Val Gin Leu Ser Val Glu Gin Asp Asn Gly Asp Phe 610 615 620 Val He Gin Asn Gly Thr Gly Thr He Leu Ser Ser Leu Ser Phe Asp 625 630 635 640 Arg Glu Gin Gin Ser Thr Tyr Thr Phe Gin Leu Lys Ala Val Asp Gly 645 650 655 Gly Val Pro Pro Arg Ser Ala Tyr Val Gly Val Thr He Asn Val Leu 660 665 670 Asp Glu Asn Asp Asn Ala Pro Tyr He Thr Ala Pro Ser Asn Thr Ser 675 680 685 His Lys Leu Leu Thr Pro Gin Thr Arg Leu Gly Glu Thr Val Ser Gin 690 695 700 Val Ala Ala Glu Asp Phe Asp Ser Gly Val Asn Ala Glu Leu He Tyr 705 710 715 720 Ser He Ala Gly Gly Asn Pro Tyr Gly Leu Phe Gin He Gly Ser His 725 730 735 Ser Gly Ala He Thr Leu Glu Lys Glu He Glu Arg Arg His His Gly 740 745 750 Leu His Arg Leu Val Val Lys Val Ser Asp Arg Gly Lys Pro Pro Arg 755 760 765 Tyr Gly Thr Ala Leu Val His Leu Tyr Val Asn Glu Thr Leu Ala Asn 770 775 780 Arg Thr Leu Leu Glu Thr Leu Leu Gly His Ser Leu Asp Thr Pro Leu 785 790 795 800 Asp He Asp He Ala Gly Asp Pro Glu Tyr Glu Arg Ser Lys Gin Arg 805 810 815 Gly Asn He Leu Phe Gly Val Val Ala Gly Val Val Ala Val Ala Leu 820 825 830 Leu He Ala Leu Ala Val Leu Val Arg Tyr Cys Arg Gin Arg Glu Ala 835 840 845 Lys Ser Gly Tyr Gin Ala Gly Lys Lys Glu Thr Lys Asp Leu Tyr Ala 850 855 860 Pro Lys Pro Ser Gly Lys Ala Ser Lys Gly Asn Lys Ser Lys Gly Lys 865 870 875 880 Lys Ser Lys Ser Pro Lys Pro Val Lys Pro Val Glu Asp Glu Asp Glu 885 890 895 Ala Gly Leu Gin Lys Ser Leu Lys Phe Asn Leu Met Ser Asp Ala Pro 900 905 910 Gly Asp Ser Pro Arg He His Leu Pro Leu Asn Tyr Pro Pro Gly Ser 915 920 925 Pro Asp Leu Gly Arg His Tyr Arg Ser Asn Ser Pro Leu Pro Ser He 930 935 940 Gin Leu Gin Pro Gin Ser Pro Ser Ala Ser Lys Lys His Gin Val Val 945 950 955 960 Gin Asp Leu Pro Pro Ala Asn Thr Phe Val Gly Thr Gly Asp Thr Thr 965 970 975 Ser Thr Gly Ser Glu Gin Tyr Ser Asp Tyr Ser Tyr Arg Thr Asn Pro 980 985 990 Pro Lys Tyr Pro Ser Lys Gin Val Gly Gin Pro Phe Gin Leu Ser Thr 995 1000 1005 Pro Gin Pro Leu Pro His Pro Tyr His Gly Ala He Trp Thr Glu Val 1010 1015 1020 Trp Glu 1025 (2) INFORMATION FOR SEQ ID NO:96: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4705 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 115..2827 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96: CGAAAGCCAT GTCGGACTCG TCGCCCAGCG CCCAAGCGCT AACCCGCTGA AAGTTTCTCA 60 GCGAAATCTC AGGGACGATC TGGACCCCGC TGAGAGGAAC TGCTTTTGAG TGAG ATG 117 Met 1 GTC CCA GAG GCC TGG AGG AGC GGA CTG GTA AGC ACC GGG AGG GTA GTG 165 Val Pro Glu Ala Trp Arg Ser Gly Leu Val Ser Thr Gly Arg Val Val 5 10 15 GGA GTT TTG CTT CTG CTT GGT GCC TTG AAC AAG GCT TCC ACG GTC ATT 213 Gly Val Leu Leu Leu Leu Gly Ala Leu Asn Lys Ala Ser Thr Val He 20 25 30 CAC TAT GAG ATC CCG GAG GAA AGA GAG AAG GGT TTC GCT GTG GGC AAC 261 His Tyr Glu He Pro Glu Glu Arg Glu Lys Gly Phe Ala Val Gly Asn 35 40 45 GTG GTC GCG AAC CTT GGT TTG GAT CTC GGT AGC CTC TCA GCC CGC AGG 309 Val Val Ala ABΠ Leu Gly Leu Asp Leu Gly Ser Leu Ser Ala Arg Arg 50 55 60 65 TTC CCG GTG GTG TCT GGA GCT AGC CGA AGA TTC TTT GAG GTG AAC CGG 357 Phe Pro Val Val Ser Gly Ala Ser Arg Arg Phe Phe Glu Val Asn Arg 70 75 80 GAG ACC GGA GAG ATG TTT GTG AAC GAC CGT CTG GAT CGA GAG GAG CTG 405 Glu Thr Gly Glu Met Phe Val Asn Asp Arg Leu Asp Arg Glu Glu Leu 85 90 95 TGT GGG ACA CTG CCC TCT TGC ACT GTA ACT CTG GAG TTG GTA GTG GAG 453 Cys Gly Thr Leu Pro Ser Cys Thr Val Thr Leu Glu Leu Val Val Glu 100 105 110 AAC CCG CTG GAG CTG TTC AGC GTG GAA GTG GTG ATC CAG GAC ATC AAC 501 Asn Pro Leu Glu Leu Phe Ser Val Glu Val Val He Gin Asp He Asn 115 120 125 GAC AAC AAT CCT GCT TTC CCT ACC CAG GAA ATG AAA TTG GAG ATT AGC 549 Asp Asn Asn Pro Ala Phe Pro Thr Gin Glu Met Lys Leu Glu He Ser 130 135 140 145 GAG GCC GTG GCT CCG GGG ACG CGC TTT CCG CTC GAG AGC GCG CAC GAT 597 Glu Ala Val Ala Pro Gly Thr Arg Phe Pro Leu Glu Ser Ala His Asp 150 155 160 CCC GAT CTG GGA AGC AAC TCT TTA CAA ACC TAT GAG CTG AGC CGA AAT 645 Pro Asp Leu Gly Ser Asn Ser Leu Gin Thr Tyr Glu Leu Ser Arg Asn 165 170 175 GAA TAC TTT GCG CTT CGC GTG CAG ACG CGG GAG GAC AGC ACC AAG TAC 693 Glu Tyr Phe Ala Leu Arg Val Gin Thr Arg Glu Asp Ser Thr Lys Tyr 180 185 190 GCG GAG CTG GTG TTG GAG CGC GCC CTG GAC CGA GAA CGG GAG CCT AGT 741 Ala Glu Leu Val Leu Glu Arg Ala Leu Asp Arg Glu Arg Glu Pro Ser 195 200 205 CTC CAG TTA GTG CTG ACG GCG TTG GAC GGA GGG ACC CCA GCT CTC TCC 789 Leu Gin Leu Val Leu Thr Ala Leu Asp Gly Gly Thr Pro Ala Leu Ser 210 215 220 225 GCC AGC CTG CCT ATT CAC ATC AAG GTG CTG GAC GCG AAT GAC AAT GCG 837 Ala Ser Leu Pro He His He Lys Val Leu Asp Ala Asn Asp Asn Ala 230 235 240 CCT GTC TTC AAC CAG TCC TTG TAC CGG GCG CGC GTT CCT GGA GGA TGC 885 Pro Val Phe Asn Gin Ser Leu Tyr Arg Ala Arg Val Pro Gly Gly Cys 245 250 255 ACC TCC GGC ACG CGC GTG GTA CAA GTC CTT GCA ACG GAT CTG GAT GAA 933 Thr Ser Gly Thr Arg Val Val Gin Val Leu Ala Thr Asp Leu Asp Glu 260 265 270 GGC CCC AAC GGT GAA ATT ATT TAC TCC TTC GGC AGC CAC AAC CGC GCC 981 Gly Pro Asn Gly Glu He He Tyr Ser Phe Gly Ser His Asn Arg Ala 275 280 285 GGC GTG CGG CAA CTA TTC GCC TTA GAC CTT GTA ACC GGG ATG CTG ACA 1029 Gly Val Arg Gin Leu Phe Ala Leu Asp Leu Val Thr Gly Met Leu Thr 290 295 300 305 ATC AAG GGT CGG CTG GAC TTC GAG GAC ACC AAA CTC CAT GAG ATT TAC 1077 He Lys Gly Arg Leu Asp Phe Glu Asp Thr Lys Leu His Glu He Tyr 310 315 320 ATC CAG GCC AAA GAC AAG GGC GCC AAT CCC GAA GGA GCA CAT TGC AAA 1125 He Gin Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys Lys 325 330 335 GTG TTG GTG GAG GTT GTG GAT GTG AAT GAC AAC GCC CCG GAG ATC ACA 1173 Val Leu Val Glu Val Val Asp Val Asn Asp Asn Ala Pro Glu He Thr 340 345 350 GTC ACC TCC GTG TAC AGC CCA GTA CCC GAG GAT GCC TCT GGG ACT GTC 1221 Val Thr Ser Val Tyr Ser Pro Val Pro Glu Asp Ala Ser Gly Thr Val 355 360 365 ATC GCT TTG CTC AGT GTG ACT GAC CTG GAT GCT GGC GAG AAC GGG CTG 1269 He Ala Leu Leu Ser Val Thr Asp Leu Asp Ala Gly Glu Asn Gly Leu 370 375 380 385 GTG ACC TGC GAA GTT CCA CCG GGT CTC CCT TTC AGC CTT ACT TCT TCC 1317 Val Thr Cys Glu Val Pro Pro Gly Leu Pro Phe Ser Leu Thr Ser Ser 390 395 400 CTC AAG AAT TAC TTC ACT TTG AAA ACC AGT GCA GAC CTG GAT CGG GAG 1365 Leu Lys Asn Tyr Phe Thr Leu Lys Thr Ser Ala Asp Leu Asp Arg Glu 405 410 415 ACT GTG CCA GAA TAC AAC CTC AGC ATC ACC GCC CGA GAC GCC GGA ACC 1413 Thr Val Pro Glu Tyr Asn Leu Ser He Thr Ala Arg Asp Ala Gly Thr 420 425 430 CCT TCC CTC TCA GCC CTT ACA ATA GTG CGT GTT CAA GTG TCC GAC ATC 1461 Pro Ser Leu Ser Ala Leu Thr He Val Arg Val Gin Val Ser Asp He 435 440 445 AAT GAC AAC CCT CCA CAA TCT TCT CAA TCT TCC TAC GAC GTT TAC ATT 1509 Asn Asp Asn Pro Pro Gin Ser Ser Gin Ser Ser Tyr Asp Val Tyr He 450 455 460 465 GAA GAA AAC AAC CTC CCC GGG GCT CCA ATA CTA AAC CTA AGT GTC TGG 1557 Glu Glu Asn Asn Leu Pro Gly Ala Pro He Leu Asn Leu Ser Val Trp 470 475 480 GAC CCC GAC GCC CCG CAG AAT GCT CGG CTT TCT TTC TTT CTC TTG GAG 1605 Asp Pro Asp Ala Pro Gin Asn Ala Arg Leu Ser Phe Phe Leu Leu Glu 485 490 495 CAA GGA GCT GAA ACC GGG CTA GTG GGT CGC TAT TTC ACA ATA AAT CGT 1653 Gin Gly Ala Glu Thr Gly Leu Val Gly Arg Tyr Phe Thr He Asn Arg 500 505 510 GAC AAT GGC ATA GTG TCA TCC TTA GTG CCC CTA GAC TAT GAG GAT CGG 1701 Asp Asn Gly He Val Ser Ser Leu Val Pro Leu Asp Tyr Glu Asp Arg 515 520 525 CGG GAA TTT GAA TTA ACA GCT CAT ATC AGC GAT GGG GGC ACC CCG GTC 1749 Arg Glu Phe Glu Leu Thr Ala His He Ser Asp Gly Gly Thr Pro Val 530 535 540 545 CTA GCC ACC AAC ATC AGC GTG AAC ATA TTT GTC ACT GAT CGC AAT GAC 1797 Leu Ala Thr Asn He Ser Val Aβn He Phe Val Thr Asp Arg Asn Asp 550 555 560 AAT GCC CCC CAG GTC CTA TAT CCT CGG CCA GGT GGG AGC TCG GTG GAG 1845 Asn Ala Pro Gin Val Leu Tyr Pro Arg Pro Gly Gly Ser Ser Val Glu 565 570 575 ATG CTG CCT CGA GGT ACC TCA GCT GGC CAC CTA GTG TCA CGG GTG GTA 1893 Met Leu Pro Arg Gly Thr Ser Ala Gly His Leu Val Ser Arg Val Val 580 585 590 GGC TGG GAC GCG GAT GCA GGG CAC AAT GCC TGG CTC TCC TAC AGT CTC 1941 Gly Trp Asp Ala Asp Ala Gly His Asn Ala Trp Leu Ser Tyr Ser Leu 595 600 605 TTT GGA TCC CCT AAC CAG AGC CTT TTT GCC ATA GGG CTG CAC ACT GGT 1989 Phe Gly Ser Pro Asn Gin Ser Leu Phe Ala He Gly Leu His Thr Gly 610 615 620 625 CAA ATC AGT ACT GCC CGT CCA GTC CAA GAC ACA GAT TCA CCC AGG CAG 2037 Gin He Ser Thr Ala Arg Pro Val Gin Asp Thr Asp Ser Pro Arg Gin 630 635 640 ACT CTC ACT GTC TTG ATC AAA GAC AAT GGG GAG CCT TCG CTC TCC ACC 2085 Thr Leu Thr Val Leu He Lys Asp Asn Gly Glu Pro Ser Leu Ser Thr 645 650 655 ACT GCT ACC CTC ACT GTG TCA GTA ACC GAG GAC TCT CCT GAA GCC CGA 2133 Thr Ala Thr Leu Thr Val Ser Val Thr Glu Asp Ser Pro Glu Ala Arg 660 665 670 GCC GAG TTC CCC TCT GGC TCT GCC CCC CGG GAG CAG AAA AAA AAT CTC 2181 Ala Glu Phe Pro Ser Gly Ser Ala Pro Arg Glu Gin Lys Lys Asn Leu 675 680 685 ACC TTT TAT CTA CTT CTT TCT CTA ATC CTG GTT TCT GTG GGC TTC GTG 2229 Thr Phe Tyr Leu Leu Leu Ser Leu He Leu Val Ser Val Gly Phe Val 690 695 700 705 GTC ACA GTG TTC GGA GTA ATC ATA TTC AAA GTT TAC AAG TGG AAG CAG 2277 Val Thr Val Phe Gly Val He He Phe Lys Val Tyr Lys Trp Lys Gin 710 715 720 TCT AGA GAC CTA TAC CGA GCC CCG GTG AGC TCA CTG TAC CGA ACA CCA 2325 Ser Arg Asp Leu Tyr Arg Ala Pro Val Ser Ser Leu Tyr Arg Thr Pro 725 730 735 GGG CCC TCC TTG CAC GCG GAC GCC GTG CGG GGA GGC CTG ATG TCG CCG 2373 Gly Pro Ser Leu His Ala Asp Ala Val Arg Gly Gly Leu Met Ser Pro 740 745 750 CAC CTT TAC CAT CAG GTG TAT CTC ACC ACG GAC TCC CGC CGC AGC GAC 2421 His Leu Tyr His Gin Val Tyr Leu Thr Thr Asp Ser Arg Arg Ser Asp 755 760 765 CCG CTG CTG AAG AAA CCT GGT GCA GCC AGT CCA CTG GCC AGC CGC CAG 2469 Pro Leu Leu Lys Lys Pro Gly Ala Ala Ser Pro Leu Ala Ser Arg Gin 770 775 780 785 AAC ACG CTG CGG AGC TGT GAT CCG GTG TTC TAT AGG CAG GTG TTG GGT 2517 Asn Thr Leu Arg Ser Cys Asp Pro Val Phe Tyr Arg Gin Val Leu Gly 790 795 800 GCA GAG AGC GCC CCT CCC GGA CAG CAA GCC CCG CCC AAC ACG GAC TGG 2565 Ala Glu Ser Ala Pro Pro Gly Gin Gin Ala Pro Pro Asn Thr Asp Trp 805 810 815 CGT TTC TCT CAG GCC CAG AGA CCC GGC ACC AGC GGC TCC CAA AAT GGC 2613 Arg Phe Ser Gin Ala Gin Arg Pro Gly Thr Ser Gly Ser Gin Asn Gly 820 825 830 GAT GAC ACC GGC ACC TGG CCC AAC AAC CAG TTT GAC ACA GAG ATG CTG 2661 Asp Asp Thr Gly Thr Trp Pro Asn Asn Gin Phe Asp Thr Glu Met Leu 835 840 845 CAA GCC ATG ATC TTG GCG TCC GCC AGT GAA GCT GCT GAT GGG AGC TCC 2709 Gin Ala Met He Leu Ala Ser Ala Ser Glu Ala Ala Asp Gly Ser Ser 850 855 860 865 ACC CTG GGA GGG GGT GCC GGC ACC ATG GGA TTG AGC GCC CGC TAC GGA 2757 Thr Leu Gly Gly Gly Ala Gly Thr Met Gly Leu Ser Ala Arg Tyr Gly 870 875 880 CCC CAG TTC ACC CTG CAG CAC GTG CCC GAC TAC CGC CAG AAT GTC TAC 2805 Pro Gin Phe Thr Leu Gin His Val Pro Asp Tyr Arg Gin Asn Val Tyr 885 890 895 ATC CCA GGC AGC AAT GCA CAC T GACCAACGCA GCTGGCAAGC GGATGGCAAG 2857 He Pro Gly Ser Asn Ala His 900 GCCCAGCAGG TGGCAATGGC AACAAGAAGA AGTCGGCAAG AAGGAGAAGA AGTAACATGG 2917 AGGCCAGGCC AAGAGCCACA GGGCAGCCTC TCCCCGAACC AGCCCAGCTT CTCCTTACCT 2977 GCACCCAGGC CTCAGAGTTT CAGGGCTAAC CCCCAGAATA CTGGTAGGGG CCAAGGCATC 3037 TCCCTTGGAA ACAGAAACAA GTGCCATCAC ACCATCCCTT CCCCAGGTGT AATATCCAAA 3097 GCAGTTCCGC TGGGAACCCC ATCCAATCAG TGGCTGTACC CATTTGGGTA GTGGGGTTCA 3157 TGTAGACACC AAGAACCATT TGCCACACCC CGTTTAGTTA CAGCTGAACC CTCCATCTTC 3217 CAAATCAATC AGGCCCATCC ATCCCATGCC TCCCTCCTCC CCACCCCACT CCAACAGTTC 3277 CTCTTTCCCG AGTAAGGTGG TTGGGGTGTT GAAGTACCAA GTAACCTACA AGCCTCCTAG 3337 TTCTGAAAAG TTGGAAGGGC ATCATGACCT CTTGGCCTCT CCTTTGATTC TCAATCTTCC 3397 CCCAAAGCAT GGTTTGGTGC CAGCCCCTTC ACCTCCTTCC AGAGCCCAAG ATCAATGCTC 3457 AAGTTTTGGA GGACATGATC ACCATCCCCA TGGTACTGAT GCTTGCTGGA TTTAGGGAGG 3517 GCATTTTGCT ACCAAGCCTC TTCCCAACGC CCTGGGACCA GTCTTCTGTT TTGTTTTTCA 3577 TTGTTTGAGC TTTCCACTGC ATGCCTTGAC TTCCCCCACC TCCTCCTCAA ACAAGAGACT 3637 CCACTGCATG TTCCAAGACA GTATGGGGTG GTAAGATAAG GAAGGGAAGT GTGTGGATGT 3697 GGATGGTGGG GGCATGGACA AAGCTTGACA CATCAAGTTA TCAAGGCCTT GGAGGAGGCT 3757 CTGTATGTCC TCAGGGGACT GACAACATCC TCCAGATTCC AGCCATAAAC CAATAACTAG 3817 GCTGGACCCT TCCCACTACA TAATAGGGCT CAGCCAGGCA GCCAGCTTTG GGCTGAGCTA 3877 ACAGGACCAA TGGATTAACT GGCATTTCAG TCCAAGGAAG CTCGAAGCAG GTTTAGGACC 3937 AGGTCCCCTT GAGAGGTCAG AGGGGCCTCT GTGGGTGCTG GGTACTCCAG AGGTGCCACT 3997 GGTGGAAGGG TCAGCGGAGC CCCAGCAGGA AGGGTGGGCC AGCCAGGCCA TTCTTAGTCC 4057 CTGGGTTGGG GAGGCAGGGA GCTAGGGCAG GGACCAAATG AACAGAAAGT CTCAGCCCAG 4117 GATGGGGCTT CTTCAACAGG CCCCTGCCCT CCTGAAGCCT CAGTCCTTCA CCTTGCCAGG 4177 TGCCGTTTCT CTTCCGTGAA GGCCACTGCC CAGGTCCCCA GTGCGCCCCC TAGTGGCCAT 4237 AGCCTGGTTA AAGTTCCCCA GTGCCTCCTT GTGATAGACC TTCTTCTCCC ACCCCCTTCT 4297 GCCCCTGGGT CCCCGGCCAT CCAGCGGGGC TGCCAGAGAA CCCCAGACCT GCCCTTACAG 4357 TAGTGTAGCG CCCCCTCCCT CTTTCGGCTG GTGTAGAATA GCCAGTAGTG TAGTGCGGTG 4417 TGCTTTTACG TGATGGCGGG TGGGCAGCGG GCGGCGGCGT CCGCGCAGCC GTCTGTCCTT 4477 GATCTGCCCG CGGCGGCCCG TGTTGTGTTT TGTGCTGTGT CCAGCGCTAA GGCGACCCCC 4537 TCCCCCGTAC TGACTTCTCC TATAAGCGCT TCTCTTCGCA TAGTCACGTA GCTCCCACCC 4597 CACCCTCTTC CTGTGTCTCA CGCAAGTTTT ATACTCTAAT ATTTATATGG CTTTTTTTCT 4657 TCGACAAAAA AATAATAAAA CGTTTCTTCT GAAAAAAAAA AAAAAAAA 4705 (2) INFORMATION FOR SEQ ID NO:97: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 904 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97: Met Val Pro Glu Ala Trp Arg Ser Gly Leu Val Ser Thr Gly Arg Val 1 5 10 15 Val Gly Val Leu Leu Leu Leu Gly Ala Leu Asn Lys Ala Ser Thr Val 20 25 30 He His Tyr Glu He Pro Glu Glu Arg Glu Lys Gly Phe Ala Val Gly 35 40 45 Asn Val Val Ala Asn Leu Gly Leu Asp Leu Gly Ser Leu Ser Ala Arg 50 55 60 Arg Phe Pro Val Val Ser Gly Ala Ser Arg Arg Phe Phe Glu Val Asn 65 70 75 80 Arg Glu Thr Gly Glu Met Phe Val Asn Asp Arg Leu Asp Arg Glu Glu 85 90 95 Leu Cys Gly Thr Leu Pro Ser Cys Thr Val Thr Leu Glu Leu Val Val 100 105 110 Glu Asn Pro Leu Glu Leu Phe Ser Val Glu Val Val He Gin Asp He 115 120 125 Asn Asp Asn Asn Pro Ala Phe Pro Thr Gin Glu Met Lys Leu Glu He 130 135 140 Ser Glu Ala Val Ala Pro Gly Thr Arg Phe Pro Leu Glu Ser Ala His 145 150 155 160 Asp Pro Asp Leu Gly Ser Asn Ser Leu Gin Thr Tyr Glu Leu Ser Arg 165 170 175 Asn Glu Tyr Phe Ala Leu Arg Val Gin Thr Arg Glu Asp Ser Thr Lys 180 185 190 Tyr Ala Glu Leu Val Leu Glu Arg Ala Leu Asp Arg Glu Arg Glu Pro 195 200 205 Ser Leu Gin Leu Val Leu Thr Ala Leu Asp Gly Gly Thr Pro Ala Leu 210 215 220 Ser Ala Ser Leu Pro He His He Lys Val Leu Asp Ala Asn Asp Asn 225 230 235 240 Ala Pro Val Phe Asn Gin Ser Leu Tyr Arg Ala Arg Val Pro Gly Gly 245 250 255 Cys Thr Ser Gly Thr Arg Val Val Gin Val Leu Ala Thr Asp Leu Asp 260 265 270 Glu Gly Pro Asn Gly Glu He He Tyr Ser Phe Gly Ser His Asn Arg 275 280 285 Ala Gly Val Arg Gin Leu Phe Ala Leu Asp Leu Val Thr Gly Met Leu 290 295 300 Thr He Lys Gly Arg Leu Asp Phe Glu Asp Thr Lys Leu His Glu He 305 310 315 320 Tyr He Gin Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys 325 330 335 Lys Val Leu Val Glu Val Val Asp Val Asn Asp Asn Ala Pro Glu He 340 345 350 Thr Val Thr Ser Val Tyr Ser Pro Val Pro Glu Asp Ala Ser Gly Thr 355 360 365 Val He Ala Leu Leu Ser Val Thr Asp Leu Asp Ala Gly Glu Asn Gly 370 375 380 Leu Val Thr Cys Glu Val Pro Pro Gly Leu Pro Phe Ser Leu Thr Ser 385 390 395 400 Ser Leu Lys Asn Tyr Phe Thr Leu Lys Thr Ser Ala Asp Leu Asp Arg 405 410 415 Glu Thr Val Pro Glu Tyr Asn Leu Ser He Thr Ala Arg Asp Ala Gly 420 425 430 Thr Pro Ser Leu Ser Ala Leu Thr He Val Arg Val Gin Val Ser Asp 435 440 445 He Asn Asp Asn Pro Pro Gin Ser Ser Gin Ser Ser Tyr Asp Val Tyr 450 455 460 He Glu Glu Asn Asn Leu Pro Gly Ala Pro He Leu Asn Leu Ser Val 465 470 475 480 Trp Asp Pro Asp Ala Pro Gin Asn Ala Arg Leu Ser Phe Phe Leu Leu 485 490 495 Glu Gin Gly Ala Glu Thr Gly Leu Val Gly Arg Tyr Phe Thr He Asn 500 505 510 Arg Asp Asn Gly He Val Ser Ser Leu Val Pro Leu Asp Tyr Glu Asp 515 520 525 Arg Arg Glu Phe Glu Leu Thr Ala His He Ser Asp Gly Gly Thr Pro 530 535 540 Val Leu Ala Thr Asn He Ser Val Asn He Phe Val Thr Asp Arg Asn 545 550 555 560 Asp Asn Ala Pro Gin Val Leu Tyr Pro Arg Pro Gly Gly Ser Ser Val 565 570 575 Glu Met Leu Pro Arg Gly Thr Ser Ala Gly His Leu Val Ser Arg Val 580 585 590 Val Gly Trp Asp Ala Asp Ala Gly His Asn Ala Trp Leu Ser Tyr Ser 595 600 605 Leu Phe Gly Ser Pro Asn Gin Ser Leu Phe Ala He Gly Leu His Thr 610 615 620 Gly Gin He Ser Thr Ala Arg Pro Val Gin Asp Thr Asp Ser Pro Arg 625 630 635 640 Gin Thr Leu Thr Val Leu He Lys Asp Asn Gly Glu Pro Ser Leu Ser 645 650 655 Thr Thr Ala Thr Leu Thr Val Ser Val Thr Glu Asp Ser Pro Glu Ala 660 665 670 Arg Ala Glu Phe Pro Ser Gly Ser Ala Pro Arg Glu Gin Lys Lys Asn 675 680 685 Leu Thr Phe Tyr Leu Leu Leu Ser Leu He Leu Val Ser Val Gly Phe 690 695 700 Val Val Thr Val Phe Gly Val He He Phe Lys Val Tyr Lys Trp Lys 705 710 715 720 Gin Ser Arg Asp Leu Tyr Arg Ala Pro Val Ser Ser Leu Tyr Arg Thr 725 730 735 Pro Gly Pro Ser Leu His Ala Asp Ala Val Arg Gly Gly Leu Met Ser 740 745 750 Pro His Leu Tyr His Gin Val Tyr Leu Thr Thr Asp Ser Arg Arg Ser 755 760 765 Asp Pro Leu Leu Lys Lys Pro Gly Ala Ala Ser Pro Leu Ala Ser Arg 770 775 780 Gin Asn Thr Leu Arg Ser Cys Asp Pro Val Phe Tyr Arg Gin Val Leu 785 790 795 800 Gly Ala Glu Ser Ala Pro Pro Gly Gin Gin Ala Pro Pro Asn Thr Asp 805 810 815 Trp Arg Phe Ser Gin Ala Gin Arg Pro Gly Thr Ser Gly Ser Gin Asn 820 825 830 Gly Asp Asp Thr Gly Thr Trp Pro Asn Asn Gin Phe Asp Thr Glu Met 835 840 845 Leu Gin Ala Met He Leu Ala Ser Ala Ser Glu Ala Ala Asp Gly Ser 850 855 860 Ser Thr Leu Gly Gly Gly Ala Gly Thr Met Gly Leu Ser Ala Arg Tyr 865 870 875 880 Gly Pro Gin Phe Thr Leu Gin His Val Pro Asp Tyr Arg Gin Asn Val 885 890 895 Tyr He Pro Gly Ser Asn Ala His 900 (2) INFORMATION FOR SEQ ID NO:98: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 441 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98: Asp Trp Val He Pro Pro He Asn Leu Pro Glu Asn Ser Arg Gly Pro 1 5 10 15 Phe Pro Gin Glu Leu Val Arg He Arg Ser Asp Arg Asp Lys Asn Leu 20 25 30 Ser Leu Arg Tyr Thr Val Thr Gly Pro Gly Ala Asp Gin Pro Pro Thr 35 40 45 Gly He Phe He He Asn Pro He Ser Gly Gin Leu Ser Val Thr Lys 50 55 60 Pro Leu Asp Arg Glu Gin He Ala Arg Phe His Leu Arg Ala His Ala 65 70 75 80 Val Asp He Asn Gly Asn Gin Val Glu Asn Pro He Asp He Val He 85 90 95 Asn Val He Asp Met Asn Asp Asn Arg Pro Glu Phe Thr Ala Met Thr 100 105 110 Phe Tyr Gly Glu Val Pro Glu Asn Arg Val Asp He He Val Ala Asn 115 120 125 Leu Thr Val Thr Asp Lys Asp Gin Pro His Thr Pro Ala Trp Asn Ala 130 135 140 Val Thr Arg He Ser Gly Gly Asp Pro Thr Gly Arg Phe Ala He Gin 145 150 155 160 Thr Asp Pro Asn Ser Asn Asp Gly Leu Val Thr Val Val Lys Pro He 165 170 175 Asp Phe Glu Thr Asn Arg Met Phe Val Leu Thr Val Ala Ala Glu Asn 180 185 190 Gin Val Pro Leu Ala Lys Gly He Gin His Pro Pro Gin Ser Thr Ala 195 200 205 Thr Val Ser Val Thr Val He Asp Val Asn Glu Asn Pro Tyr Phe Ala 210 215 220 Pro Asn Pro Lys He He Arg Gin Glu Glu Gly Leu His Ala Gly Thr 225 230 235 240 Met Leu Thr Thr Phe Thr Ala Gly Asp Pro Asp Arg Tyr Met Gin Gin 245 250 255 Asn He Arg Tyr Thr Lys Leu Ser Asp Pro Ala Asn Trp Leu Lys He 260 265 270 Asp Pro Val Asn Gly Gin He Thr Thr He Ala Val Leu Asp Arg Glu 275 280 285 Ser Pro Asn Val Lys Asn Asn He Tyr Asn Ala Thr Phe Leu Ala Ser 290 295 300 Asp Asn Gly He Pro Pro Met Ser Gly Thr Gly Thr Leu Gin He Tyr 305 310 315 320 Leu Leu Asp He Asn Asp Asn Ala Pro Gin Val Leu Pro Gin Glu Ala 325 330 335 Glu Thr Cys Glu Thr Pro Asp Pro Asn Ser He Asn He Thr Thr Ala 340 345 350 Leu Asp Tyr Asp He Asp Pro Asn Ala Gly Pro Phe Ala Tyr Asp Leu 355 360 365 Pro Leu Ser Pro Val Thr He Lys Arg Asn Trp Thr He Thr Arg Leu 370 375 380 Asn Gly Asp Phe Ala Gin Leu Asn Leu Lys He Lys Phe Leu Glu Ala 385 390 395 400 Gly He Tyr Glu Val Pro He He He Thr Asp Ser Gly Asn Pro Pro 405 410 415 Lys Ser Asn Lys Ser He Leu Arg Val Arg Val Cys Gin Cys Asp Phe 420 425 430 Asn Gly Asp Cys Thr Asp Val Asp Arg 435 440 (2) INFORMATION FOR SEQ ID NO:99: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 105 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99: Glu Asp Thr Val Tyr Ser Phe Asp He Pro Glu Asn Ala Gin Arg Gly 1 5 10 15 Tyr Gin Val Gly Gin He Val Ala Arg Asp Ala Asp Leu Gly Gin Asn 20 25 30 Ala Gin Leu Ser Tyr Gly Val Val Ser Asp Trp Ala Asn Asp Val Phe 35 40 45 Ser Leu Asn Pro Gin Thr Gly Met Leu Thr Leu Thr Ala Arg Leu Asp 50 55 60 Tyr Glu Glu Val Gin His Tyr He Leu He Val Gin Ala Gin Asp Asn 65 70 75 80 Gly Gin Pro Ser Leu Ser Thr Thr He Thr Val Tyr Cys Asn Val Leu 85 90 95 Asp Leu Asn Asp Asn Ala Pro He Phe 100 105 (2) INFORMATION FOR SEQ ID NO:100: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid .(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100: Asp Xaa Asp Xaa Gly Xaa Asn 1 5 (2) INFORMATION FOR SEQ ID NO:101: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101: Ala Xaa Asp Xaa Gly Xaa Pro 1 5 (2) INFORMATION FOR SEQ ID NO:102: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4650 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 495..4103 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102: CCTCTATTCG ACATTCTCTT TGGATTGTTT TGCTATAACT TGAAATTTGG GATGTCACAA 60 ACGAAACTGT CATCTGTTTC CGCCAAACTG TGGTTCTGCT AATCTCCCAG GCTGGCAGCA 120 TTGGAGACTT GCTGACTTCT TTCATCCCCC ACTCTTTTCA CCTGAAATTC CTTTCCTTGG 180 TTTTGCTCTA AGTCCTATGC TTCAGTCAGG GGCCAACCAA ATCTCACTGC CTCCTTTTTA 240 TCATGAAGCC TTTGATCACT GATAGTTCTT TTTATATCTT GAAAAATCAC CCTTCCCAGT 300 ACAGTTAATA TTTAGTATCT CTACTCATCT TGGCACTTAC TCACAGCTCC ATAATTCAGT 360 CGTTTTCGTA CCTCTTCATG GTGATGGGGA GCCCTTTGGA GGTGGTGACT GTGCTTTATA 420 CTCCTCATGA TGCTTCACAT GTGGCAGGCG TGGAGTGCCC GGAGGCGGCC CTCCTGATTC 480 TGGGGCCTCC CAGG ATG GAG CCC CTG AGG CAC AGC CCA GGC CCT GGG GGG 530 Met Glu Pro Leu Arg His Ser Pro Gly Pro Gly Gly 1 5 10 CAA CGG CTA CTG CTG CCC TCC ATG CTG CTA GCA CTG CTG CTC CTG CTG 578 Gin Arg Leu Leu Leu Pro Ser Met Leu Leu Ala Leu Leu Leu Leu Leu 15 20 25 GCT CCA TCC CCA GGC CAC GCC ACT CGG GTA GTG TAC AAG GTG CCG GAG 626 Ala Pro Ser Pro Gly His Ala Thr Arg Val Val Tyr Lys Val Pro Glu 30 35 40 GAA CAG CCA CCC AAC ACC CTC ATT GGG AGC CTC GCA GCC GAC TAT GGT 674 Glu Gin Pro Pro Asn Thr Leu He Gly Ser Leu Ala Ala Asp Tyr Gly 45 50 55 60 TTT CCA GAT GTG GGG CAC CTG TAC AAG CTA GAG GTG GGT GCC CCG TAC 722 Phe Pro Asp Val Gly His Leu Tyr Lys Leu Glu Val Gly Ala Pro Tyr 65 70 75 CTT CGC GTG GAT GGC AAG ACA GGT GAC ATT TTC ACC ACC GAG ACC TCC 770 Leu Arg Val Asp Gly Lys Thr Gly Asp He Phe Thr Thr Glu Thr Ser 80 85 90 ATC GAC CGT GAG GGG CTC CGT GAA TGC CAG AAC CAG CTC CCT GGT GAT 818 He Asp Arg Glu Gly Leu Arg Glu Cys Gin Asn Gin Leu Pro Gly Asp 95 100 105 CCC TGC ATC CTG GAG TTT GAG GTA TCT ATC ACA GAC CTC GTG CAG AAT 866 Pro Cys He Leu Glu Phe Glu Val Ser He Thr Asp Leu Val Gin Asn 110 115 120 GCG AGC CCC CGG CTG CTA GAG GGC CAG ATA GAA GTA CAA GAC ATC AAT 914 Ala Ser Pro Arg Leu Leu Glu Gly Gin He Glu Val Gin Asp He Asn 125 130 135 140 GAC AAC ACA CCC AAC TTC GCC TCA CCA GTC ATC ACT CTG GCC ATC CCT 962 Asp Asn Thr Pro Asn Phe Ala Ser Pro Val He Thr Leu Ala He Pro 145 150 155 GAG AAC ACC AAC ATC GGC TCA CTC TTC CCC ATC CCG CTG GCT TCA GAC 1010 Glu Asn Thr Asn He Gly Ser Leu Phe Pro He Pro Leu Ala Ser Asp 160 165 170 CGT GAT GCT GGT CCC AAC GGT GTG GCA TCC TAT GAG CTG CAG GTG GCA 1058 Arg Asp Ala Gly Pro Asn Gly Val Ala Ser Tyr Glu Leu Gin Val Ala 175 180 185 GAG GAC CAG GAG GAG AAG CAA CCA CAG CTC ATT GTG ATG GGC AAC CTG 1106 Glu Asp Gin Glu Glu Lys Gin Pro Gin Leu He Val Met Gly Asn Leu 190 195 200 GAC CGT GAG CGC TGG GAC TCC TAT GAC CTC ACC ATC AAG GTG CAG GAT 1154 Asp Arg Glu Arg Trp Asp Ser Tyr Asp Leu Thr He Lys Val Gin Asp 205 210 215 220 GGC GGC AGC CCC CCA CGC GCC ACG AGT GCC CTG CTG CGT GTC ACC GTG 1202 Gly Gly Ser Pro Pro Arg Ala Thr Ser Ala Leu Leu Arg Val Thr Val 225 230 235 CTT GAC ACC AAT GAC AAC GCC CCC AAG TTT GAG CGG CCC TCC TAT GAG 1250 Leu Asp Thr Asn Asp Asn Ala Pro Lys Phe Glu Arg Pro Ser Tyr Glu 240 245 250 GCC GAA CTA TCT GAG AAT AGC CCC ATA GGC CAC TCG GTC ATC CAG GTG 1298 Ala Glu Leu Ser Glu Asn Ser Pro He Gly His Ser Val He Gin Val 255 260 265 AAG GCC AAT GAC TCA GAC CAA GGT GCC AAT GCA GAA ATC GAA TAC ACA 1346 Lys Ala Asn Asp Ser Asp Gin Gly Ala Asn Ala Glu He Glu Tyr Thr 270 275 280 TTC CAC CAG GCG CCC GAA GTT GTG AGG CGT CTT CTT CGA CTG GAC AGG 1394 Phe His Gin Ala Pro Glu Val Val Arg Arg Leu Leu Arg Leu Asp Arg 285 290 295 300 AAC ACT GGA CTT ATC ACT GTT CAG GGC CCG GTG GAC CGT GAG GAC CTA 1442 Asn Thr Gly Leu He Thr Val Gin Gly Pro Val Asp Arg Glu Asp Leu 305 310 315 AGC ACC CTG CGC TTC TCA GTG CTT GCT AAG GAC CGA GGC ACC AAC CCC 1490 Ser Thr Leu Arg Phe Ser Val Leu Ala Lys Asp Arg Gly Thr Asn Pro 320 325 330 AAG AGT GCC CGT GCC CAG GTG GTT GTG ACC GTG AAG GAC ATG AAT GAC 1538 Lys Ser Ala Arg Ala Gin Val Val Val Thr Val Lys Asp Met Asn Asp 335 340 345 AAT GCC CCC ACC ATT GAG ATC CGG GGC ATA GGG CTA GTG ACT CAT CAA 1586 Asn Ala Pro Thr He Glu He Arg Gly He Gly Leu Val Thr His Gin 350 355 360 GAT GGG ATG GCT AAC ATC TCA GAG GAT GTG GCA GAG GAG ACA GCT GTG 1634 Asp Gly Met Ala Asn He Ser Glu Asp Val Ala Glu Glu Thr Ala Val 365 370 375 380 GCC CTG GTG CAG GTG TCT GAC CGA GAT GAG GGA GAG AAT GCA GCT GTC 1682 Ala Leu Val Gin Val Ser Asp Arg Asp Glu Gly Glu Asn Ala Ala Val 385 390 395 ACC TGT GTG GTG GCA GGT GAT GTG CCC TTC CAG CTG CGC CAG GCC AGT 1730 Thr Cys Val Val Ala Gly Asp Val Pro Phe Gin Leu Arg Gin Ala Ser 400 405 410 GAG ACA GGC AGT GAC AGC AAG AAG AAG TAT TTC CTG CAG ACT ACC ACC 1778 Glu Thr Gly Ser Asp Ser Lys Lys Lys Tyr Phe Leu Gin Thr Thr Thr 415 420 425 CCG CTA GAC TAC GAG AAG GTC AAA GAC TAC ACC ATT GAG ATT GTG GCT 1826 Pro Leu Asp Tyr Glu Lys Val Lys Asp Tyr Thr He Glu He Val Ala 430 435 440 GTG GAC TCT GGC AAC CCC CCA CTC TCC AGC ACT AAC TCC CTC AAG GTG 1874 Val Asp Ser Gly Asn Pro Pro Leu Ser Ser Thr Asn Ser Leu Lys Val 445 450 455 460 CAG GTG GTG GAC GTC AAT GAC AAC GCA CCT GTC TTC ACT CAG AGT GTC 1922 Gin Val Val Asp Val Asn Asp Asn Ala Pro Val Phe Thr Gin Ser Val 465 470 475 ACT GAG GTC GCC TTC CCG GAA AAC AAC AAG CCT GGT GAA GTG ATT GCT 1970 Thr Glu Val Ala Phe Pro Glu Asn Asn Lys Pro Gly Glu Val He Ala 480 485 490 GAG ATC ACT GCC AGT GAT GCT GAC TCT GGC TCT AAT GCT GAG CTG GTT 2018 Glu He Thr Ala Ser Asp Ala Asp Ser Gly Ser Asn Ala Glu Leu Val 495 500 505 TAC TCT CTG GAG CCT GAG CCG GCT GCT AAG GGC CTC TTC ACC ATC TCA 2066 Tyr Ser Leu Glu Pro Glu Pro Ala Ala Lys Gly Leu Phe Thr He Ser 510 515 520 CCC GAG ACT GGA GAG ATC CAG GTG AAG ACA TCT CTG GAT CGG GAA CAG 2114 Pro Glu Thr Gly Glu He Gin Val Lys Thr Ser Leu Asp Arg Glu Gin 525 530 535 540 CGG GAG AGC TAT GAG TTG AAG GTG GTG GCA GCT GAC CGG GGC AGT CCT 2162 Arg Glu Ser Tyr Glu Leu Lys Val Val Ala Ala Asp Arg Gly Ser Pro 545 550 555 AGC CTC CAG GGC ACA GCC ACT GTC CTT GTC AAT GTG CTG GAC TGC AAT 2210 Ser Leu Gin Gly Thr Ala Thr Val Leu Val Asn Val Leu Asp Cys Asn 560 565 570 GAC AAT GAC CCC AAA TTT ATG CTG AGT GGC TAC AAC TTC TCA GTG ATG 2258 Asp Asn Asp Pro Lys Phe Met Leu Ser Gly Tyr Asn Phe Ser Val Met 575 580 585 GAG AAC ATG CCA GCA CTG AGT CCA GTG GGC ATG GTG ACT GTC ATT GAT 2306 Glu Asn Met Pro Ala Leu Ser Pro Val Gly Met Val Thr Val He Asp 590 595 600 GGA GAC AAG GGG GAG AAT GCC CAG GTG CAG CTC TCA GTG GAG CAG GAC 2354 Gly Asp Lys Gly Glu Asn Ala Gin Val Gin Leu Ser Val Glu Gin Asp 605 610 615 620 AAC GGT GAC TTT GTT ATC CAG AAT GGC ACA GGC ACC ATC CTA TCC AGC 2402 Asn Gly Asp Phe Val He Gin Asn Gly Thr Gly Thr He Leu Ser Ser 625 630 635 CTG AGC TTT GAT CGA GAG CAA CAA AGC ACC TAC ACC TTC CAG CTG AAG 2450 Leu Ser Phe Asp Arg Glu Gin Gin Ser Thr Tyr Thr Phe Gin Leu Lys 640 645 650 GCA GTG GAT GGT GGC GTC CCA CCT CGC TCA GCT TAC GTT GGT GTC ACC 2498 Ala Val Asp Gly Gly Val Pro Pro Arg Ser Ala Tyr Val Gly Val Thr 655 660 665 ATC AAT GTG CTG GAC GAG AAT GAC AAC GCA CCC TAT ATC ACT GCC CCT 2546 He Asn Val Leu Asp Glu Asn Asp Asn Ala Pro Tyr He Thr Ala Pro 670 675 680 TCT AAC ACC TCT CAC AAG CTG CTG ACC CCC CAG ACA CGT CTT GGT GAG 2594 Ser Asn Thr Ser His Lys Leu Leu Thr Pro Gin Thr Arg Leu Gly Glu 685 690 695 700 ACG GTC AGC CAG GTG GCA GCC GAG GAC TTT GAC TCT GGT GTC AAT GCC 2642 Thr Val Ser Gin Val Ala Ala Glu Asp Phe Asp Ser Gly Val Asn Ala 705 710 715 GAG CTG ATC TAC AGC ATT GCA GGT GGC AAC CCT TAT GGA CTC TTC CAG 2690 Glu Leu He Tyr Ser He Ala Gly Gly Asn Pro Tyr Gly Leu Phe Gin 720 725 730 ATT GGG TCA CAT TCA GGT GCC ATC ACC CTG GAG AAG GAG ATT GAG CGG 2738 He Gly Ser His Ser Gly Ala He Thr Leu Glu Lys Glu He Glu Arg 735 740 745 CGC CAC CAT GGG CTA CAC CGC CTG GTG GTG AAG GTC AGT GAC CGC GGC 2786 Arg His His Gly Leu His Arg Leu Val Val Lys Val Ser Asp Arg Gly 750 755 760 AAG CCC CCA CGC TAT GGC ACA GCC TTG GTC CAT CTT TAT GTC AAT GAG 2834 Lys Pro Pro Arg Tyr Gly Thr Ala Leu Val His Leu Tyr Val Asn Glu 765 770 775 780 ACT CTG GCC AAC CGC ACG CTG CTG GAG ACC CTC CTG GGC CAC AGC CTG 2882 Thr Leu Ala Asn Arg Thr Leu Leu Glu Thr Leu Leu Gly His Ser Leu 785 790 795 GAC ACG CCG CTG GAT ATT GAC ATT GCT GGG GAT CCA GAA TAT GAG CGC 2930 Asp Thr Pro Leu Asp He Asp He Ala Gly Asp Pro Glu Tyr Glu Arg 800 805 810 TCC AAG CAG CGT GGC AAC ATT CTC TTT GGT GTG GTG GCT GGT GTG GTG 2978 Ser Lys Gin Arg Gly Asn He Leu Phe Gly Val Val Ala Gly Val Val 815 820 825 GCC GTG GCC TTG CTC ATC GCC CTG GCG GTT CTT GTG CGC TAC TGC AGA 3026 Ala Val Ala Leu Leu He Ala Leu Ala Val Leu Val Arg Tyr Cys Arg 830 835 840 CAG CGG GAG GCC AAA AGT GGT TAC CAG GCT GGT AAG AAG GAG ACC AAG 3074 Gin Arg Glu Ala Lys Ser Gly Tyr Gin Ala Gly Lys Lys Glu Thr Lys 845 850 855 860 GAC CTG TAT GCC CCC AAG CCC AGT GGC AAG GCC TCC AAG GGA AAC AAA 3122 Asp Leu Tyr Ala Pro Lys Pro Ser Gly Lys Ala Ser Lys Gly Asn Lys 865 870 875 AGC AAA GGC AAG AAG AGC AAG TCC CCA AAG CCC GTG AAG CCA GTG GAG 3170 Ser Lys Gly Lys Lys Ser Lys Ser Pro Lys Pro Val Lys Pro Val Glu 880 885 890 GAC GAG GAT GAG GCC GGG CTG CAG AAG TCC CTC AAG TTC AAC CTG ATG 3218 Asp Glu Asp Glu Ala Gly Leu Gin Lys Ser Leu Lys Phe Asn Leu Met 895 900 905 AGC GAT GCC CCT GGG GAC AGT CCC CGC ATC CAC CTG CCC CTC AAC TAC 3266 Ser Asp Ala Pro Gly Asp Ser Pro Arg He His Leu Pro Leu Asn Tyr 910 915 920 CCA CCA GGC AGC CCT GAC CTG GGC CGC CAC TAT CGC TCT AAC TCC CCA 3314 Pro Pro Gly Ser Pro Asp Leu Gly Arg His Tyr Arg Ser Asn Ser Pro 925 930 935 940 CTG CCT TCC ATC CAG CTG CAG CCC CAG TCA CCC TCA GCC TCC AAG AAG 3362 Leu Pro Ser He Gin Leu Gin Pro Gin Ser Pro Ser Ala Ser Lys Lys 945 950 955 CAC CAG GTG GTA CAG GAC CTG CCA CCT GCA AAC ACA TTC GTG GGC ACC 3410 His Gin Val Val Gin Asp Leu Pro Pro Ala Asn Thr Phe Val Gly Thr 960 965 970 GGG GAC ACC ACG TCC ACG GGC TCT GAG CAG TAC TCC GAC TAC AGC TAC 3458 Gly Asp Thr Thr Ser Thr Gly Ser Glu Gin Tyr Ser Asp Tyr Ser Tyr 975 980 985 CGC ACC AAC CCC CCC AAA TAC CCC AGC AAG CAG TTA CCT CAC CGC CGC 3506 Arg Thr Asn Pro Pro Lys Tyr Pro Ser Lys Gin Leu Pro His Arg Arg 990 995 1000 GTC ACC TTC TCG GCC ACC AGC CAG GCC CAG GAG CTG CAG GAC CCA TCC 3554 Val Thr Phe Ser Ala Thr Ser Gin Ala Gin Glu Leu Gin Asp Pro Ser 1005 1010 1015 1020 CAG CAC AGT TAC TAT GAC AGT GGC CTG GAG GAG TCT GAG ACG CCG TCC 3602 Gin His Ser Tyr Tyr Asp Ser Gly Leu Glu Glu Ser Glu Thr Pro Ser 1025 1030 1035 AGC AAG TCA TCC TCA GGG CCT CGA CTC GGT CCC CTG GCC CTG CCT GAG 3650 Ser Lys Ser Ser Ser Gly Pro Arg Leu Gly Pro Leu Ala Leu Pro Glu 1040 1045 1050 GAT CAC TAT GAG CGC ACC ACC CCT GAT GGC AGC ATA GGA GAG ATG GAG 3698 Asp His Tyr Glu Arg Thr Thr Pro Asp Gly Ser He Gly Glu Met Glu 1055 1060 1065 CAC CCC GAG AAT GAC CTT CGC CCT TTG CCT GAT GTC GCC ATG ACA GGC 3746 His Pro Glu Asn Asp Leu Arg Pro Leu Pro Asp Val Ala Met Thr Gly 1070 1075 1080 ACA TGT ACC CGG GAG TGC AGT GAG TTT GGC CAC TCT GAC ACA TGC TGG 3794 Thr Cys Thr Arg Glu Cys Ser Glu Phe Gly His Ser Asp Thr Cys Trp 1085 1090 1095 1100 ATG CCT GGC CAG TCA TCT CCC AGC CGC CGG ACC AAG AGC AGC GCC CTC 3842 Met Pro Gly Gin Ser Ser Pro Ser Arg Arg Thr Lys Ser Ser Ala Leu 1105 1110 1115 AAA CTC TCC ACC TTC ATG CCT TAC CAG GAC CGA GGA GGG CAG GAG CCT 3890 Lys Leu Ser Thr Phe Met Pro Tyr Gin Asp Arg Gly Gly Gin Glu Pro 1120 1125 1130 GCG GGC GCC GGC AGC CCC AGC CCC CCG GAA GAC CGG AAC ACC AAA ACG 3938 Ala Gly Ala Gly Ser Pro Ser Pro Pro Glu Asp Arg Asn Thr Lys Thr 1135 1140 1145 GCC CCC GTG CGC CTC CTG CCC TCC TAC AGT GCC TTC TCC CAC AGT AGC 3986 Ala Pro Val Arg Leu Leu Pro Ser Tyr Ser Ala Phe Ser His Ser Ser 1150 1155 1160 CAT GAT TCC TGC AAG GAC TCG GCC ACC TTG GAG GAA ATC CCC CTG ACC 4034 His Asp Ser Cys Lys Asp Ser Ala Thr Leu Glu Glu He Pro Leu Thr 1165 1170 1175 1180 CAG ACC TCG GAC TTC CCA CCC GCA GCC ACA CCG GCA TCT GCC CAG ACG 4082 Gin Thr Ser Asp Phe Pro Pro Ala Ala Thr Pro Ala Ser Ala Gin Thr 1185 1190 1195 GCC AAG CGC GAG ATC TAC CTG TGAGCCCCCT ACTGGCCGGC CCCCCTCCCC 4133 Ala Lys Arg Glu He Tyr Leu 1200 CAGCGCCGGC CAGCTCCCAA ATGCCCATTC CAGGGCCTCA CTCTCCACCC CTTCAGCGTG 4193 GACTTCCTGC CAGGGCCCAA GTGGGGGTAT CACTGACCTC ATGACCACGC TGGCCCTTCT 4253 CCCATGCAGG GTCCAGGTCC TCTCCCCTCA TTTCCATCTC CCAGCCCAGG GGCCCCTTCC 4313 CCTTTATGGG GCTTCCCCCA GCTGATGCCC AAGAGGGCTC CTCTGCAATG ACTGGGCTCC 4373 TTCCCTTGAC TTCCAGGGAG CACCCCCTCG ATTTGGGCAG ATGGTGGAGT CAAGGGTGGG 4433 CAGCGTACTT CTAACTCATT GTTTCCCTCA TGGCCGACCA GGGCGGGGAT AGCATGCCCA 4493 ATTTTAGCCC TGAAGCAGGG CTGAACTGGG GAGCCCCTTT CCCTGGGAGC TCCCAGAGGA 4553 AACTCTTGAC CACCAGTGGC TCCCTGAAGG GCTTTTGTTA CCAAAGGTGG GGTAGGGACG 4613 GGGGTGGGAG TGGAGCGGAG GCCTTGTTTT CCCGTGG 4650 (2) INFORMATION FOR SEQ ID NO:103: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1203 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103: Met Glu Pro Leu Arg His Ser Pro Gly Pro Gly Gly Gin Arg Leu Leu 1 5 10 15 Leu Pro Ser Met Leu Leu Ala Leu Leu Leu Leu Leu Ala Pro Ser Pro 20 25 30 Gly His Ala Thr Arg Val Val Tyr Lys Val Pro Glu. Glu Gin Pro Pro 35 40 45 Asn Thr Leu He Gly Ser Leu Ala Ala Asp Tyr Gly Phe Pro Asp Val 50 55 60 Gly His Leu Tyr Lys Leu Glu Val Gly Ala Pro Tyr Leu Arg Val Asp 65 70 75 80 Gly Lys Thr Gly Asp He Phe Thr Thr Glu Thr Ser He Asp Arg Glu 85 90 95 Gly Leu Arg Glu Cys Gin Asn Gin Leu Pro Gly Asp Pro Cys He Leu 100 105 110 Glu Phe Glu Val Ser He Thr Asp Leu Val Gin Asn Ala Ser Pro Arg 115 120 125 Leu Leu Glu Gly Gin He Glu Val Gin Asp He Asn Asp Asn Thr Pro 130 135 140 Asn Phe Ala Ser Pro Val He Thr Leu Ala He Pro Glu Asn Thr Asn 145 150 155 160 Ile Gly Ser Leu Phe Pro He Pro Leu Ala Ser Asp Arg Asp Ala Gly 165 170 175 Pro Asn Gly Val Ala Ser Tyr Glu Leu Gin Val Ala Glu Asp Gin Glu 180 185 190 Glu Lys Gin Pro Gin Leu He Val Met Gly Asn Leu Asp Arg Glu Arg 195 200 205 Trp Asp Ser Tyr Asp Leu Thr He Lys Val Gin Asp Gly Gly Ser Pro 210 215 220 Pro Arg Ala Thr Ser Ala Leu Leu Arg Val Thr Val Leu Asp Thr Asn 225 230 235 240 Asp Asn Ala Pro Lys Phe Glu Arg Pro Ser Tyr Glu Ala Glu Leu Ser 245 250 255 Glu Asn Ser Pro He Gly His Ser Val He Gin Val Lys Ala Asn Asp 260 265 270 Ser Asp Gin Gly Ala Asn Ala Glu He Glu Tyr Thr Phe His Gin Ala 275 280 285 Pro Glu Val Val Arg Arg Leu Leu Arg Leu Asp Arg Asn Thr Gly Leu 290 295 300 He Thr Val Gin Gly Pro Val Asp Arg Glu Asp Leu Ser Thr Leu Arg 305 310 315 320 Phe Ser Val Leu Ala Lys Asp Arg Gly Thr Asn Pro Lys Ser Ala Arg 325 330 335 Ala Gin Val Val Val Thr Val Lys Asp Met Asn Asp Asn Ala Pro Thr 340 345 350 He Glu He Arg Gly He Gly Leu Val Thr His Gin Asp Gly Met Ala 355 360 365 Asn He Ser Glu Asp Val Ala Glu Glu Thr Ala Val Ala Leu Val Gin 370 375 380 Val Ser Asp Arg Asp Glu Gly Glu Asn Ala Ala Val Thr Cys Val Val 385 390 395 400 Ala Gly Asp Val Pro Phe Gin Leu Arg Gin Ala Ser Glu Thr Gly Ser 405 410 415 Asp Ser Lys Lys Lys Tyr Phe Leu Gin Thr Thr Thr Pro Leu Asp Tyr 420 425 430 Glu Lys Val Lys Asp Tyr Thr He Glu He Val Ala Val Asp Ser Gly 435 440 445 Asn Pro Pro Leu Ser Ser Thr Asn Ser Leu Lys Val Gin Val Val Asp 450 455 460 Val Asn Asp Asn Ala Pro Val Phe Thr Gin Ser Val Thr Glu Val Ala 465 470 475 480 Phe Pro Glu Asn Asn Lys Pro Gly Glu Val He Ala Glu He Thr Ala 485 490 495 Ser Asp Ala Asp Ser Gly Ser Asn Ala Glu Leu Val Tyr Ser Leu Glu 500 505 510 Pro Glu Pro Ala Ala Lys Gly Leu Phe Thr He Ser Pro Glu Thr Gly 515 520 525 Glu He Gin Val Lys Thr Ser Leu Asp Arg Glu Gin Arg Glu Ser Tyr 530 535 540 Glu Leu Lys Val Val Ala Ala Asp Arg Gly Ser Pro Ser Leu Gin Gly 545 550 555 560 Thr Ala Thr Val Leu Val Asn Val Leu Asp Cys Asn Asp Asn Asp Pro 565 570 575 Lys Phe Met Leu Ser Gly Tyr Asn Phe Ser Val Met Glu Asn Met Pro 580 585 590 Ala Leu Ser Pro Val Gly Met Val Thr Val He Asp Gly Asp Lye Gly 595 600 605 Glu Asn Ala Gin Val Gin Leu Ser Val Glu Gin Asp Asn Gly Asp Phe 610 615 620 Val He Gin Asn Gly Thr Gly Thr He Leu Ser Ser Leu Ser Phe Asp 625 630 635 640 Arg Glu Gin Gin Ser Thr Tyr Thr Phe Gin Leu Lys Ala Val Asp Gly 645 650 655 Gly Val Pro Pro Arg Ser Ala Tyr Val Gly Val Thr He Asn Val Leu 660 665 670 Asp Glu Asn Asp Asn Ala Pro Tyr He Thr Ala Pro Ser Asn Thr Ser 675 680 685 His Lys Leu Leu Thr Pro Gin Thr Arg Leu Gly Glu Thr Val Ser Gin 690 695 700 Val Ala Ala Glu Asp Phe Asp Ser Gly Val Asn Ala Glu Leu He Tyr 705 710 715 720 Ser He Ala Gly Gly Asn Pro Tyr Gly Leu Phe Gin He Gly Ser His 725 730 735 Ser Gly Ala He Thr Leu Glu Lys Glu He Glu Arg Arg His His Gly 740 745 750 Leu His Arg Leu Val Val Lys Val Ser Asp Arg Gly Lys Pro Pro Arg 755 760 765 Tyr Gly Thr Ala Leu Val His Leu Tyr Val Asn Glu Thr Leu Ala Asn 770 775 780 Arg Thr Leu Leu Glu Thr Leu Leu Gly His Ser Leu Asp Thr Pro Leu 785 790 795 800 Asp He Asp He Ala Gly Asp Pro Glu Tyr Glu Arg Ser Lys Gin Arg 805 810 815 Gly Asn He Leu Phe Gly Val Val Ala Gly Val Val Ala Val Ala Leu 820 825 830 Leu He Ala Leu Ala Val Leu Val Arg Tyr Cys Arg Gin Arg Glu Ala 835 840 845 Lys Ser Gly Tyr Gin Ala Gly Lys Lys Glu Thr Lys Asp Leu Tyr Ala 850 855 860 Pro Lys Pro Ser Gly Lys Ala Ser Lys Gly Asn Lys Ser Lys Gly Lys 865 870 875 880 Lys Ser Lys Ser Pro Lys Pro Val Lys Pro Val Glu Asp Glu Asp Glu 885 890 895 Ala Gly Leu Gin Lys Ser Leu Lys Phe Asn Leu Met Ser Asp Ala Pro 900 905 910 Gly Asp Ser Pro Arg He His Leu Pro Leu Asn Tyr Pro Pro Gly Ser 915 920 925 Pro Asp Leu Gly Arg His Tyr Arg Ser Asn Ser Pro Leu Pro Ser He 930 935 940 Gin Leu Gin Pro Gin Ser Pro Ser Ala Ser Lys Lys His Gin Val Val 945 950 955 960 Gin Asp Leu Pro Pro Ala Asn Thr Phe Val Gly Thr Gly Asp Thr Thr 965 970 975 Ser Thr Gly Ser Glu Gin Tyr Ser Asp Tyr Ser Tyr Arg Thr Asn Pro 980 985 990 Pro Lys Tyr Pro Ser Lys Gin Leu Pro His Arg Arg Val Thr Phe Ser 995 1000 1005 Ala Thr Ser Gin Ala Gin Glu Leu Gin Asp Pro Ser Gin His Ser Tyr 1010 1015 1020 Tyr Asp Ser Gly Leu Glu Glu Ser Glu Thr Pro Ser Ser Lys Ser Ser 1025 1030 1035 1040 Ser Gly Pro Arg Leu Gly Pro Leu Ala Leu Pro Glu Asp His Tyr Glu 1045 1050 1055 Arg Thr Thr Pro Asp Gly Ser He Gly Glu Met Glu His Pro Glu Asn 1060 1065 1070 Asp Leu Arg Pro Leu Pro Asp Val Ala Met Thr Gly Thr Cys Thr Arg 1075 1080 1085 Glu Cys Ser Glu Phe Gly His Ser Asp Thr Cys Trp Met Pro Gly Gin 1090 1095 1100 Ser Ser Pro Ser Arg Arg Thr Lys Ser Ser Ala Leu Lys Leu Ser Thr 1105 1110 1115 1120 Phe Met Pro Tyr Gin Asp Arg Gly Gly Gin Glu Pro Ala Gly Ala Gly 1125 1130 1135 Ser Pro Ser Pro Pro Glu Asp Arg Asn Thr Lys Thr Ala Pro Val Arg 1140 1145 1150 Leu Leu Pro Ser Tyr Ser Ala Phe Ser His Ser Ser His Asp Ser Cys 1155 1160 1165 Lys Asp Ser Ala Thr Leu Glu Glu He Pro Leu Thr Gin Thr Ser Asp 1170 1175 1180 Phe Pro Pro Ala Ala Thr Pro Ala Ser Ala Gin Thr Ala Lys Arg Glu 1185 1190 1195 1200 He Tyr Leu (2) INFORMATION FOR SEQ ID NO:104: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2789 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 115..2622 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104: CGAAAGCCAT GTCGGACTCG TCGCCCAGCG CCCAAGCGCT AACCCGCTGA AAGTTTCTCA 60 GCGAAATCTC AGGGACGATC TGGACCCCGC TGAGAGGAAC TGCTTTTGAG TGAG ATG 117 Met 1 GTC CCA GAG GCC TGG AGG AGC GGA CTG GTA AGC ACC GGG AGG GTA GTG 165 Val Pro Glu Ala Trp Arg Ser Gly Leu Val Ser Thr Gly Arg Val Val 5 10 15 GGA GTT TTG CTT CTG CTT GGT GCC TTG AAC AAG GCT TCC ACG GTC ATT 213 Gly Val Leu Leu Leu Leu Gly Ala Leu Asn Lys Ala Ser Thr Val He 20 25 30 CAC TAT GAG ATC CCG GAG GAA AGA GAG AAG GGT TTC GCT GTG GGC AAC 261 His Tyr Glu He Pro Glu Glu Arg Glu Lys Gly Phe Ala Val Gly Asn 35 40 45 GTG GTC GCG AAC CTT GGT TTG GAT CTC GGT AGC CTC TCA GCC CGC AGG 309 Val Val Ala Asn Leu Gly Leu Asp Leu Gly Ser Leu Ser Ala Arg Arg 50 55 60 65 TTC CCG GTG GTG TCT GGA GCT AGC CGA AGA TTC TTT GAG GTG AAC CGG 357 Phe Pro Val Val Ser Gly Ala Ser Arg Arg Phe Phe Glu Val Asn Arg 70 75 80 GAG ACC GGA GAG ATG TTT GTG AAC GAC CGT CTG GAT CGA GAG GAG CTG 405 Glu Thr Gly Glu Met Phe Val Asn Asp Arg Leu Asp Arg Glu Glu Leu 85 90 95 TGT GGG ACA CTG CCC TCT TGC ACT GTA ACT CTG GAG TTG GTA GTG GAG 453 Cys Gly Thr Leu Pro Ser Cys Thr Val Thr Leu Glu Leu Val Val Glu 100 105 110 AAC CCG CTG GAG CTG TTC AGC GTG GAA GTG GTG ATC CAG GAC ATC AAC 501 Asn Pro Leu Glu Leu Phe Ser Val Glu Val Val He Gin Asp He Asn 115 120 125 GAC AAC AAT CCT GCT TTC CCT ACC CAG GAA ATG AAA TTG GAG ATT AGC 549 Asp Asn Asn Pro Ala Phe Pro Thr Gin Glu Met Lys Leu Glu He Ser 130 135 140 145 GAG GCC GTG GCT CCG GGG ACG CGC TTT CCG CTC GAG AGC GCG CAC GAT 597 Glu Ala Val Ala Pro Gly Thr Arg Phe Pro Leu Glu Ser Ala His Asp 150 155 160 CCC GAT CTG GGA AGC AAC TCT TTA CAA ACC TAT GAG CTG AGC CGA AAT 645 Pro Asp Leu Gly Ser Asn Ser Leu Gin Thr Tyr Glu Leu Ser Arg Asn 165 170 175 GAA TAC TTT GCG CTT CGC GTG CAG ACG CGG GAG GAC AGC ACC AAG TAC 693 Glu Tyr Phe Ala Leu Arg Val Gin Thr Arg Glu Asp Ser Thr Lys Tyr 180 185 190 GCG GAG CTG GTG TTG GAG CGC GCC CTG GAC CGA GAA CGG GAG CCT AGT 741 Ala Glu Leu Val Leu Glu Arg Ala Leu Asp Arg Glu Arg Glu Pro Ser 195 200 205 CTC CAG TTA GTG CTG ACG GCG TTG GAC GGA GGG ACC CCA GCT CTC TCC 789 Leu Gin Leu Val Leu Thr Ala Leu Asp Gly Gly Thr Pro Ala Leu Ser 210 215 220 225 GCC AGC CTG CCT ATT CAC ATC AAG GTG CTG GAC GCG AAT GAC AAT GCG 837 Ala Ser Leu Pro He His He Lys Val Leu Asp Ala Asn Asp Asn Ala 230 235 240 CCT GTC TTC AAC CAG TCC TTG TAC CGG GCG CGC GTT CCT GGA GGA TGC 885 Pro Val Phe Asn Gin Ser Leu Tyr Arg Ala Arg Val Pro Gly Gly Cys 245 250 255 ACC TCC GGC ACG CGC GTG GTA CAA GTC CTT GCA ACG GAT CTG GAT GAA 933 Thr Ser Gly Thr Arg Val Val Gin Val Leu Ala Thr Asp Leu Asp Glu 260 265 270 GGC CCC AAC GGT GAA ATT ATT TAC TCC TTC GGC AGC CAC AAC CGC GCC 981 Gly Pro Asn Gly Glu He He Tyr Ser Phe Gly Ser His Asn Arg Ala 275 280 285 GGC GTG CGG CAA CTA TTC GCC TTA GAC CTT GTA ACC GGG ATG CTG ACA 1029 Gly Val Arg Gin Leu Phe Ala Leu Asp Leu Val Thr Gly Met Leu Thr 290 295 300 305 ATC AAG GGT CGG CTG GAC TTC GAG GAC ACC AAA CTC CAT GAG ATT TAC 1077 He Lys Gly Arg Leu Asp Phe Glu Asp Thr Lys Leu His Glu He Tyr 310 315 320 ATC CAG GCC AAA GAC AAG GGC GCC AAT CCC GAA GGA GCA CAT TGC AAA 1125 He Gin Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys Lys 325 330 335 GTG TTG GTG GAG GTT GTG GAT GTG AAT GAC AAC GCC CCG GAG ATC ACA 1173 Val Leu Val Glu Val Val Asp Val Asn Asp Asn Ala Pro Glu He Thr 340 345 350 GTC ACC TCC GTG TAC AGC CCA GTA CCC GAG GAT GCC TCT GGG ACT GTC 1221 Val Thr Ser Val Tyr Ser Pro Val Pro Glu Asp Ala Ser Gly Thr Val 355 360 365 ATC GCT TTG CTC AGT GTG ACT GAC CTG GAT GCT GGC GAG AAC GGG CTG 1269 He Ala Leu Leu Ser Val Thr Asp Leu Asp Ala Gly Glu Asn Gly Leu 370 375 380 385 GTG ACC TGC GAA GTT CCA CCG GGT CTC CCT TTC AGC CTT ACT TCT TCC 1317 Val Thr Cys Glu Val Pro Pro Gly Leu Pro Phe Ser Leu Thr Ser Ser 390 395 400 CTC AAG AAT TAC TTC ACT TTG AAA ACC AGT GCA GAC CTG GAT CGG GAG 1365 Leu Lys Asn Tyr Phe Thr Leu Lys Thr Ser Ala Asp Leu Asp Arg Glu 405 410 415 ACT GTG CCA GAA TAC AAC CTC AGC ATC ACC GCC CGA GAC GCC GGA ACC 1413 Thr Val Pro Glu Tyr Asn Leu Ser He Thr Ala Arg Asp Ala Gly Thr 420 425 430 CCT TCC CTC TCA GCC CTT ACA ATA GTG CGT GTT CAA GTG TCC GAC ATC 1461 Pro Ser Leu Ser Ala Leu Thr He Val Arg Val Gin Val Ser Asp He 435 440 445 AAT GAC AAC CCT CCA CAA TCT TCT CAA TCT TCC TAC GAC GTT TAC ATT 1509 Asn Asp Asn Pro Pro Gin Ser Ser Gin Ser Ser Tyr Asp Val Tyr He 450 455 460 465 GAA GAA AAC AAC CTC CCC GGG GCT CCA ATA CTA AAC CTA AGT GTC TGG 1557 Glu Glu Asn Asn Leu Pro Gly Ala Pro He Leu Asn Leu Ser Val Trp 470 475 480 GAC CCC GAC GCC CCG CAG AAT GCT CGG CTT TCT TTC TTT CTC TTG GAG 1605 Asp Pro Asp Ala Pro Gin Asn Ala Arg Leu Ser Phe Phe Leu Leu Glu 485 490 495 CAA GGA GCT GAA ACC GGG CTA GTG GGT CGC TAT TTC ACA ATA AAT CGT 1653 Gin Gly Ala Glu Thr Gly Leu Val Gly Arg Tyr Phe Thr He Asn Arg 500 505 510 GAC AAT GGC ATA GTG TCA TCC TTA GTG CCC CTA GAC TAT GAG GAT CGG 1701 Asp Asn Gly He Val Ser Ser Leu Val Pro Leu Asp Tyr Glu Asp Arg 515 520 525 CGG GAA TTT GAA TTA ACA GCT CAT ATC AGC GAT GGG GGC ACC CCG GTC 1749 Arg Glu Phe Glu Leu Thr Ala His He Ser Asp Gly Gly Thr Pro Val 530 535 540 545 CTA GCC ACC AAC ATC AGC GTG AAC ATA TTT GTC ACT GAT CGC AAT GAC 1797 Leu Ala Thr Asn He Ser Val Asn He Phe Val Thr Asp Arg Asn Asp 550 555 560 AAT GCC CCC CAG GTC CTA TAT CCT CGG CCA GGT GGG AGC TCG GTG GAG 1845 Asn Ala Pro Gin Val Leu Tyr Pro Arg Pro Gly Gly Ser Ser Val Glu 565 570 575 ATG CTG CCT CGA GGT ACC TCA GCT GGC CAC CTA GTG TCA CGG GTG GTA 1893 Met Leu Pro Arg Gly Thr Ser Ala Gly His Leu Val Ser Arg Val Val 580 585 590 GGC TGG GAC GCG GAT GCA GGG CAC AAT GCC TGG CTC TCC TAC AGT CTC 1941 Gly Trp Asp Ala Asp Ala Gly His Asn Ala Trp Leu Ser Tyr Ser Leu 595 600 605 TTT GGA TCC CCT AAC CAG AGC CTT TTT GCC ATA GGG CTG CAC ACT GGT 1989 Phe Gly Ser Pro Asn Gin Ser Leu Phe Ala He Gly Leu His Thr Gly 610 615 620 625 CAA ATC AGT ACT GCC CGT CCA GTC CAA GAC ACA GAT TCA CCC AGG CAG 2037 Gin He Ser Thr Ala Arg Pro Val Gin Asp Thr Asp Ser Pro Arg Gin 630 635 640 ACT CTC ACT GTC TTG ATC AAA GAC AAT GGG GAG CCT TCG CTC TCC ACC 2085 Thr Leu Thr Val Leu He Lys Asp Asn Gly Glu Pro Ser Leu Ser Thr 645 650 655 ACT GCT ACC CTC ACT GTG TCA GTA ACC GAG GAC TCT CCT GAA GCC CGA 2133 Thr Ala Thr Leu Thr Val Ser Val Thr Glu Asp Ser Pro Glu Ala Arg 660 665 670 GCC GAG TTC CCC TCT GGC TCT GCC CCC CGG GAG CAG AAA AAA AAT CTC 2181 Ala Glu Phe Pro Ser Gly Ser Ala Pro Arg Glu Gin Lys Lys Asn Leu 675 680 685 ACC TTT TAT CTA CTT CTT TCT CTA ATC CTG GTT TCT GTG GGC TTC GTG 2229 Thr Phe Tyr Leu Leu Leu Ser Leu He Leu Val Ser Val Gly Phe Val 690 695 700 705 GTC ACA GTG TTC GGA GTA ATC ATA TTC AAA GTT TAC AAG TGG AAG CAG 2277 Val Thr Val Phe Gly Val He He Phe Lys Val Tyr Lys Trp Lys Gin 710 715 720 TCT AGA GAC CTA TAC CGA GCC CCG GTG AGC TCA CTG TAC CGA ACA CCA 2325 Ser Arg Asp Leu Tyr Arg Ala Pro Val Ser Ser Leu Tyr Arg Thr Pro 725 730 735 GGG CCC TCC TTG CAC GCG GAC GCC GTG CGG GGA GGC CTG ATG TCG CCG 2373 Gly Pro Ser Leu His Ala Asp Ala Val Arg Gly Gly Leu Met Ser Pro 740 745 750 CAC CTT TAC CAT CAG GTG TAT CTC ACC ACG GAC TCC CGC CGC AGC GAC 2421 His Leu Tyr His Gin Val Tyr Leu Thr Thr Asp Ser Arg Arg Ser Asp 755 760 765 CCG CTG CTG AAG AAA CCT GGT GCA GCC AGT CCA CTG GCC AGC CGC CAG 2469 Pro Leu Leu Lys Lys Pro Gly Ala Ala Ser Pro Leu Ala Ser Arg Gin 770 775 780 785 AAC ACG CTG CGG AGC TGT GAT CCG GTG TTC TAT AGG CAG GTG TTG GGT 2517 Asn Thr Leu Arg Ser Cys Asp Pro Val Phe Tyr Arg Gin Val Leu Gly 790 795 800 GCA GAG AGC GCC CCT CCC GGA CAG GTA AGG TTT AGC AAG TCA TGC TTG 2565 Ala Glu Ser Ala Pro Pro Gly Gin Val Arg Phe Ser Lys Ser Cys Leu 805 810 815 ACC CTG TTA GTG CCT TTT TAT TCC TAC ATC ATA TTG AGA AGG CTG GAG 2613 Thr Leu Leu Val Pro Phe Tyr Ser Tyr He He Leu Arg Arg Leu Glu 820 825 830 CTG TTT TTT TAGTGATGAA GATGTTTTCC TGGTGATGCA TTCACACTTT 2662 Leu Phe Phe 835 CAACTGGCTC TTCCTAGATC AAAGTTAGTG CCTTTGTGAG ATGGTGGCCT GCCAGAGTGT 2722 GGTTTGTGGT CCCATTTCAG GGGGAAGATA CTTGACTCAT CTGTGGACCT AATTCACATC 2782 CTCAGCG 2789 (2) INFORMATION FOR SEQ ID NO:105: (i) " SEQUENCE CHARACTERISTICS: (A) LENGTH: 836 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105: Met Val Pro Glu Ala Trp Arg Ser Gly Leu Val Ser Thr Gly Arg Val 1 5 10 15 Val Gly Val Leu Leu Leu Leu Gly Ala Leu Asn Lys Ala Ser Thr Val 20 25 30 He His Tyr Glu He Pro Glu Glu Arg Glu Lys Gly Phe Ala Val Gly 35 40 45 Asn Val Val Ala Asn Leu Gly Leu Asp Leu Gly Ser Leu Ser Ala Arg 50 55 60 Arg Phe Pro Val Val Ser Gly Ala Ser Arg Arg Phe Phe Glu Val Asn 65 70 75 80 Arg Glu Thr Gly Glu Met Phe Val Asn Asp Arg Leu Asp Arg Glu Glu 85 90 95 Leu Cys Gly Thr Leu Pro Ser Cys Thr Val Thr Leu Glu Leu Val Val 100 105 110 Glu Asn Pro Leu Glu Leu Phe Ser Val Glu Val Val He Gin Asp He 115 120 125 Asn Asp Asn Asn Pro Ala Phe Pro Thr Gin Glu Met Lys Leu Glu He 130 135 140 Ser Glu Ala Val Ala Pro Gly Thr Arg Phe Pro Leu Glu Ser Ala His 145 150 155 160 Asp Pro Asp Leu Gly Ser Asn Ser Leu Gin Thr Tyr Glu Leu Ser Arg 165 170 175 Asn Glu Tyr Phe Ala Leu Arg Val Gin Thr Arg Glu Asp Ser Thr Lys 180 185 190 Tyr Ala Glu Leu Val Leu Glu Arg Ala Leu Asp Arg Glu Arg Glu Pro 195 200 205 Ser Leu Gin Leu Val Leu Thr Ala Leu Asp Gly Gly Thr Pro Ala Leu 210 215 220 Ser Ala Ser Leu Pro He His He Lys Val Leu Asp Ala Asn Asp Asn 225 230 235 240 Ala Pro Val Phe Asn Gin Ser Leu Tyr Arg Ala Arg Val Pro Gly Gly 245 250 255 Cys Thr Ser Gly Thr Arg Val Val Gin Val Leu Ala Thr Asp Leu Asp 260 265 270 Glu Gly Pro Asn Gly Glu He He Tyr Ser Phe Gly Ser His Asn Arg 275 280 285 Ala Gly Val Arg Gin Leu Phe Ala Leu Asp Leu Val Thr Gly Met Leu 290 295 300 Thr He Lys Gly Arg Leu Asp Phe Glu Asp Thr Lys Leu His Glu He 305 310 315 320 Tyr He Gin Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys 325 330 335 Lys Val Leu Val Glu Val Val Asp Val Asn Asp Asn Ala Pro Glu He 340 345 350 Thr Val Thr Ser Val Tyr Ser Pro Val Pro Glu Asp Ala Ser Gly Thr 355 360 365 Val He Ala Leu Leu Ser Val Thr Asp Leu Asp Ala Gly Glu Asn Gly 370 375 380 Leu Val Thr Cys Glu Val Pro Pro Gly Leu Pro Phe Ser Leu Thr Ser 385 390 395 400 Ser Leu Lys Asn Tyr Phe Thr Leu Lys Thr Ser Ala Asp Leu Asp Arg 405 410 415 Glu Thr Val Pro Glu Tyr Asn Leu Ser He Thr Ala Arg Asp Ala Gly 420 425 430 Thr Pro Ser Leu Ser Ala Leu Thr He Val Arg Val Gin Val Ser Asp 435 440 445 Ile Asn Asp Asn Pro Pro Gin Ser Ser Gin Ser Ser Tyr Asp Val Tyr 450 455 460 He Glu Glu Asn Asn Leu Pro Gly Ala Pro He Leu Asn Leu Ser Val 465 470 475 480 Trp Asp Pro Asp Ala Pro Gin Asn Ala Arg Leu Ser Phe Phe Leu Leu 485 490 495 Glu Gin Gly Ala Glu Thr Gly Leu Val Gly Arg Tyr Phe Thr He Asn 500 505 510 Arg Asp Asn Gly He Val Ser Ser Leu Val Pro Leu Asp Tyr Glu Asp 515 520 525 Arg Arg Glu Phe Glu Leu Thr Ala His He Ser Asp Gly Gly Thr Pro 530 535 540 Val Leu Ala Thr Asn He Ser Val Asn He Phe Val Thr Asp Arg Asn 545 550 555 560 Asp Asn Ala Pro Gin Val Leu Tyr Pro Arg Pro Gly Gly Ser Ser Val 565 570 575 Glu Met Leu Pro Arg Gly Thr Ser Ala Gly His Leu Val Ser Arg Val 580 585 590 Val Gly Trp Asp Ala Asp Ala Gly His Asn Ala Trp Leu Ser Tyr Ser 595 600 605 Leu Phe Gly Ser Pro Asn Gin Ser Leu Phe Ala He Gly Leu His Thr 610 615 620 Gly Gin He Ser Thr Ala Arg Pro Val Gin Asp Thr Asp Ser Pro Arg 625 630 635 640 Gin Thr Leu Thr Val Leu He Lys Asp Asn Gly Glu Pro Ser Leu Ser 645 650 655 Thr Thr Ala Thr Leu Thr Val Ser Val Thr Glu Asp Ser Pro Glu Ala 660 665 670 Arg Ala Glu Phe Pro Ser Gly Ser Ala Pro Arg Glu Gin Lys Lys Asn 675 680 685 Leu Thr Phe Tyr Leu Leu Leu Ser Leu He Leu Val Ser Val Gly Phe 690 695 700 Val Val Thr Val Phe Gly Val He He Phe Lys Val Tyr Lys Trp Lys 705 710 715 720 Gin Ser Arg Asp Leu Tyr Arg Ala Pro Val Ser Ser Leu Tyr Arg Thr 725 730 735 Pro Gly Pro Ser Leu His Ala Asp Ala Val Arg Gly Gly Leu Met Ser 740 745 750 Pro His Leu Tyr His Gin Val Tyr Leu Thr Thr Asp Ser Arg Arg Ser 755 760 765 Asp Pro Leu Leu Lys Lys Pro Gly Ala Ala Ser Pro Leu Ala Ser Arg 770 775 780 Gin Asn Thr Leu Arg Ser Cys Asp Pro Val Phe Tyr Arg Gin Val Leu 785 790 795 800 Gly Ala Glu Ser Ala Pro Pro Gly Gin Val Arg Phe Ser Lys Ser Cys 805 810 815 Leu Thr Leu Leu Val Pro Phe Tyr Ser Tyr He He Leu Arg Arg Leu 820 825 830 Glu Leu Phe Phe 835 (2) INFORMATION FOR SEQ ID NO:106: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2751 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 115..2160 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106: CGAAAGCCAT GTCGGACTCG TCGCCCAGCG CCCAAGCGCT AACCCGCTGA AAGTTTCTCA 60 GCGAAATCTC AGGGACGATC TGGACCCCGC TGAGAGGAAC TGCTTTTGAG TGAG ATG 117 Met 1 GTC CCA GAG GCC TGG AGG AGC GGA CTG GTA AGC ACC GGG AGG GTA GTG 165 Val Pro Glu Ala Trp Arg Ser Gly Leu Val Ser Thr Gly Arg Val Val 5 10 15 GGA GTT TTG CTT CTG CTT GGT GCC TTG AAC AAG GCT TCC ACG GTC ATT 213 Gly Val Leu Leu Leu Leu Gly Ala Leu Asn Lys Ala Ser Thr Val He 20 25 30 CAC TAT GAG ATC CCG GAG GAA AGA GAG AAG GGT TTC GCT GTG GGC AAC 261 His Tyr Glu He Pro Glu Glu Arg Glu Lys Gly Phe Ala Val Gly Asn 35 40 45 GTG GTC GCG AAC CTT GGT TTG GAT CTC GGT AGC CTC TCA GCC CGC AGG 309 Val Val Ala Asn Leu Gly Leu Asp Leu Gly Ser Leu Ser Ala Arg Arg 50 55 60 65 TTC CCG GTG GTG TCT GGA GCT AGC CGA AGA TTC TTT GAG GTG AAC CGG 357 Phe Pro Val Val Ser Gly Ala Ser Arg Arg Phe Phe Glu Val Asn Arg 70 75 80 GAG ACC GGA GAG ATG TTT GTG AAC GAC CGT CTG GAT CGA GAG GAG CTG 405 Glu Thr Gly Glu Met Phe Val Asn Asp Arg Leu Asp Arg Glu Glu Leu 85 90 95 TGT GGG ACA CTG CCC TCT TGC ACT GTA ACT CTG GAG TTG GTA GTG GAG 453 Cys Gly Thr Leu Pro Ser Cys Thr Val Thr Leu Glu Leu Val Val Glu 100 105 110 AAC CCG CTG GAG CTG TTC AGC GTG GAA GTG GTG ATC CAG GAC ATC AAC 501 Asn Pro Leu Glu Leu Phe Ser Val Glu Val Val He Gin Asp He Asn 115 120 125 GAC AAC AAT CCT GCT TTC CCT ACC CAG GAA ATG AAA TTG GAG ATT AGC 549 Asp Asn Asn Pro Ala Phe Pro Thr Gin Glu Met Lys Leu Glu lie Ser 130 135 140 145 GAG GCC GTG GCT CCG GGG ACG CGC TTT CCG CTC GAG AGC GCG CAC GAT 597 Glu Ala Val Ala Pro Gly Thr Arg Phe Pro Leu Glu Ser Ala His Asp 150 155 160 CCC GAT CTG GGA AGC AAC TCT TTA CAA ACC TAT GAG CTG AGC CGA AAT 645 Pro Asp Leu Gly Ser Asn Ser Leu Gin Thr Tyr Glu Leu Ser Arg Asn 165 170 175 GAA TAC TTT GCG CTT CGC GTG CAG ACG CGG GAG GAC AGC ACC AAG TAC 693 Glu Tyr Phe Ala Leu Arg Val Gin Thr Arg Glu Asp Ser Thr Lys Tyr 180 185 190 GCG GAG CTG GTG TTG GAG CGC GCC CTG GAC CGA GAA CGG GAG CCT AGT 741 Ala Glu Leu Val Leu Glu Arg Ala Leu Asp Arg Glu Arg Glu Pro Ser 195 200 205 CTC CAG TTA GTG CTG ACG GCG TTG GAC GGA GGG ACC CCA GCT CTC TCC 789 Leu Gin Leu Val Leu Thr Ala Leu Asp Gly Gly Thr Pro Ala Leu Ser 210 215 220 225 GCC AGC CTG CCT ATT CAC ATC AAG GTG CTG GAC GCG AAT GAC AAT GCG 837 Ala Ser Leu Pro He His He Lys Val Leu Asp Ala Asn Asp Asn Ala 230 235 240 CCT GTC TTC AAC CAG TCC TTG TAC CGG GCG CGC GTT CCT GGA GGA TGC 885 Pro Val Phe Asn Gin Ser Leu Tyr Arg Ala Arg Val Pro Gly Gly Cys 245 250 255 ACC TCC GGC ACG CGC GTG GTA CAA GTC CTT GCA ACG GAT CTG GAT GAA 933 Thr Ser Gly Thr Arg Val Val Gin Val Leu Ala Thr Asp Leu Asp Glu 260 265 270 GGC CCC AAC GGT GAA ATT ATT TAC TCC TTC GGC AGC CAC AAC CGC GCC 981 Gly Pro Asn Gly Glu He He Tyr Ser Phe Gly Ser His Asn Arg Ala 275 280 285 GGC GTG CGG CAA CTA TTC GCC TTA GAC CTT GTA ACC GGG ATG CTG ACA 1029 Gly Val Arg Gin Leu Phe Ala Leu Asp Leu Val Thr Gly Met Leu Thr 290 295 300 305 ATC AAG GGT CGG CTG GAC TTC GAG GAC ACC AAA CTC CAT GAG ATT TAC 1077 He Lys Gly Arg Leu Asp Phe Glu Asp Thr Lys Leu His Glu He Tyr 310 315 320 ATC CAG GCC AAA GAC AAG GGC GCC AAT CCC GAA GGA GCA CAT TGC AAA 1125 He Gin Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys Lys 325 330 335 GTG TTG GTG GAG GTT GTG GAT GTG AAT GAC AAC GCC CCG GAG ATC ACA 1173 Val Leu Val Glu Val Val Asp Val Asn Asp Asn Ala Pro Glu He Thr 340 345 350 GTC ACC TCC GTG TAC AGC CCA GTA CCC GAG GAT GCC TCT GGG ACT GTC 1221 Val Thr Ser Val Tyr Ser Pro Val Pro Glu Asp Ala Ser Gly Thr Val 355 360 365 ATC GCT TTG CTC AGT GTG ACT GAC CTG GAT GCT GGC GAG AAC GGG CTG 1269 He Ala Leu Leu Ser Val Thr Asp Leu Asp Ala Gly Glu Asn Gly Leu 370 375 380 385 GTG ACC TGC GAA GTT CCA CCG GGT CTC CCT TTC AGC CTT ACT TCT TCC 1317 Val Thr Cys Glu Val Pro Pro Gly Leu Pro Phe Ser Leu Thr Ser Ser 390 395 400 CTC AAG AAT TAC TTC ACT TTG AAA ACC AGT GCA GAC CTG GAT CGG GAG 1365 Leu Lys Asn Tyr Phe Thr Leu Lys Thr Ser Ala Asp Leu Asp Arg Glu 405 410 415 ACT GTG CCA GAA TAC AAC CTC AGC ATC ACC GCC CGA GAC GCC GGA ACC 1413 Thr Val Pro Glu Tyr Asn Leu Ser He Thr Ala Arg Asp Ala Gly Thr 420 425 430 CCT TCC CTC TCA GCC CTT ACA ATA GTG CGT GTT CAA GTG TCC GAC ATC 1461 Pro Ser Leu Ser Ala Leu Thr He Val Arg Val Gin Val Ser Asp He 435 440 445 AAT GAC AAC CCT CCA CAA TCT TCT CAA TCT TCC TAC GAC GTT TAC ATT 1509 Asn Asp Asn Pro Pro Gin Ser Ser Gin Ser Ser Tyr Asp Val Tyr He 450 455 460 465 GAA GAA AAC AAC CTC CCC GGG GCT CCA ATA CTA AAC CTA AGT GTC TGG 1557 Glu Glu Asn Asn Leu Pro Gly Ala Pro He Leu Asn Leu Ser Val Trp 470 475 480 GAC CCC GAC GCC CCG CAG AAT GCT CGG CTT TCT TTC TTT CTC TTG GAG 1605 Asp Pro Asp Ala Pro Gin Asn Ala Arg Leu Ser Phe Phe Leu Leu Glu 485 490 495 CAA GGA GCT GAA ACC GGG CTA GTG GGT CGC TAT TTC ACA ATA AAT CGT 1653 Gin Gly Ala Glu Thr Gly Leu Val Gly Arg Tyr Phe Thr He Asn Arg 500 505 510 GAC AAT GGC ATA GTG TCA TCC TTA GTG CCC CTA GAC TAT GAG GAT CGG 1701 Asp Asn Gly He Val Ser Ser Leu Val Pro Leu Asp Tyr Glu Asp Arg 515 520 525 CGG GAA TTT Α TTA ACA GCT CAT ATC AGC GAT GGG GGC ACC CCG GTC 1749 Arg Glu Phe .lu Leu Thr Ala His He Ser Asp Gly Gly Thr Pro Val 530 535 540 545 CTA GCC ACC AAC ATC AGC GTG AAC ATA TTT GTC ACT GAT CGC AAT GAC 1797 Leu Ala Thr Asn He Ser Val Asn He Phe Val Thr Asp Arg Asn Asp 550 555 560 AAT GCC CCC CAG GTC CTA TAT CCT CGG CCA GGT GGG AGC TCG GTG GAG 1845 Asn Ala Pro Gin Val Leu Tyr Pro Arg Pro Gly Gly Ser Ser Val Glu 565 570 575 ATG CTG CCT CGA GGT ACC TCA GCT GGC CAC CTA GTG TCA CGG GTG GTA 1893 Met Leu Pro Arg Gly Thr Ser Ala Gly His Leu Val Ser Arg Val Val 580 585 590 GGC TGG GAC GCG GAT GCA GGG CAC AAT GCC TGG CTC TCC TAC AGT CTC 1941 Gly Trp Asp Ala Asp Ala Gly His Asn Ala Trp Leu Ser Tyr Ser Leu 595 600 605 TTT GGA TCC CCT AAC CAG AGC CTT TTT GCC ATA GGG CTG CAC ACT GGT 1989 Phe Gly Ser Pro Asn Gin Ser Leu Phe Ala He Gly Leu His Thr Gly 610 615 620 625 CAA ATC AGT ACT GCC CGT CCA GTC CAA GAC ACA GAT TCA CCC AGG CAG 2037 Gin He Ser Thr Ala Arg Pro Val Gin Asp Thr Asp Ser Pro Arg Gin 630 635 640 ACT CTC ACT GTC TTG ATC AAA GAC AAT GGG GAG CCT TCG CTC TCC ACC 2085 Thr Leu Thr Val Leu He Lys Asp Asn Gly Glu Pro Ser Leu Ser Thr 645 650 655 ACT GCT ACC CTC ACT GTG TCA GTA ACC GAG GAC TCT CCT GAA GCC CGA 2133 Thr Ala Thr Leu Thr Val Ser Val Thr Glu Asp Ser Pro Glu Ala Arg 660 665 670 GCC GAG TTC CCC TCT GGC TCT GCC AGT TAAACCTTCT TTAATTATGG 2180 Ala Glu Phe Pro Ser Gly Ser Ala Ser 675 680 ATTAGCCATT AACATTTTTG AAACGTGGAC CATTTAACCT CGGCCTACCC CCTCCAACTG 2240 TCCTGGTGAT GAGTTCATTA GCTAAGTTAA ATTAATTGAA CTTTGATCTA AACCAAAACA 2300 AATCAGGAAA ATAAAGCTGT AAAGGAACTT ATCAAGCATT CCAAAACCAA CTAGAAATTA 2360 CTTGAAGTTT CGAGTGAGCA TTGCCTGTGC CAGTATTCTT CATTATAGGA TTATAAACTC 2420 GTTTTTTTCC CAAAGCGCAT GTCTACGCCA GGCAGAGGAG TAATTATTCA GCCAATTTCA 2480 TGGATGTAAC GATGGATATA AATAATTGAT AGCACCTAGA GGCTTCCAGT TTGGGTGGAA 2540 GGCTAAAAGT AGAGGGGAAC TCACTCACTT GAGAAATGAT ATTTAAGTGA ATAAATAGTT 2600 CTCTTCTATG AAACTATTAC TATTTAGTTC TCTGGAAAAC TTAAGTGTAT TAATGATTAG 2660 AACATCAAAT CCTAAGTAAA GAAATGACAT TTTAAATATA AAAAGCCAAA CTTTAAATAA 2720 ATCATAGAGA CCTCAGACAT AATATAGGAA A 2751 (2) INFORMATION FOR SEQ ID NO:107: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 682 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107: Met Val Pro Glu Ala Trp Arg Ser Gly Leu Val Ser Thr Gly Arg Val 1 5 10 15 Val Gly Val Leu Leu Leu Leu Gly Ala Leu Asn Lys Ala Ser Thr Val 20 25 30 He His Tyr Glu He Pro Glu Glu Arg Glu Lys Gly Phe Ala Val Gly 35 40 45 Asn Val Val Ala Asn Leu Gly Leu Asp Leu Gly Ser Leu Ser Ala Arg 50 55 60 Arg Phe Pro Val Val Ser Gly Ala Ser Arg Arg Phe Phe Glu Val Asn 65 70 75 80 Arg Glu Thr Gly Glu Met Phe Val Asn Asp Arg Leu Asp Arg Glu Glu 85 90 95 Leu Cys Gly Thr Leu Pro Ser Cys Thr Val Thr Leu Glu Leu Val Val 100 105 110 Glu Asn Pro Leu Glu Leu Phe Ser Val Glu Val Val He Gin Asp He 115 120 125 Asn Asp Asn Asn Pro Ala Phe Pro Thr Gin Glu Met Lys Leu Glu He 130 135 140 Ser Glu Ala Val Ala Pro Gly Thr Arg Phe Pro Leu Glu Ser Ala His 145 150 155 160 Asp Pro Asp Leu Gly Ser Asn Ser Leu Gin Thr Tyr Glu Leu Ser Arg 165 170 175 Asn Glu Tyr Phe Ala Leu Arg Val Gin Thr Arg Glu Asp Ser Thr Lys 180 185 190 Tyr Ala Glu Leu Val Leu Glu Arg Ala Leu Asp Arg Glu Arg Glu Pro 195 200 205 Ser Leu Gin Leu Val Leu Thr Ala Leu Asp Gly Gly Thr Pro Ala Leu 210 215 220 Ser Ala Ser Leu Pro He His He Lys Val Leu Asp Ala Asn Asp Asn 225 230 235 240 Ala Pro Val Phe Asn Gin Ser Leu Tyr Arg Ala Arg Val Pro Gly Gly 245 250 255 Cys Thr Ser Gly Thr Arg Val Val Gin Val Leu Ala Thr Asp Leu Asp 260 265 270 Glu Gly Pro Asn Gly Glu He He Tyr Ser Phe Gly Ser His Asn Arg 275 280 285 Ala Gly Val Arg Gin Leu Phe Ala Leu Asp Leu Val Thr Gly Met Leu 290 295 300 Thr He Lys Gly Arg Leu Asp Phe Glu Asp Thr Lys Leu His Glu He 305 310 315 320 Tyr He Gin Ala Lys Asp Lys Gly Ala Asn Pro Glu Gly Ala His Cys 325 330 335 Lys Val Leu Val Glu Val Val Asp Val Asn Asp Asn Ala Pro Glu He 340 345 350 Thr Val Thr Ser Val Tyr Ser Pro Val Pro Glu Asp Ala Ser Gly Thr 355 360 365 Val He Ala Leu Leu Ser Val Thr Asp Leu Asp Ala Gly Glu Asn Gly 370 375 380 Leu Val Thr Cys Glu Val Pro Pro Gly Leu Pro Phe Ser Leu Thr Ser 385 390 395 400 Ser Leu Lys Asn Tyr Phe Thr Leu Lys Thr Ser Ala Asp Leu Asp Arg 405 410 415 Glu Thr Val Pro Glu Tyr Asn Leu Ser He Thr Ala Arg Asp Ala Gly 420 425 430 Thr Pro Ser Leu Ser Ala Leu Thr He Val Arg Val Gin Val Ser Asp 435 440 445 He Asn Asp Asn Pro Pro Gin Ser Ser Gin Ser Ser Tyr Asp Val Tyr 450 455 460 He Glu Glu Asn Asn Leu Pro Gly Ala Pro He Leu Asn Leu Ser Val 465 470 475 480 Trp Asp Pro Asp Ala Pro Gin Asn Ala Arg Leu Ser Phe Phe Leu Leu 485 490 495 Glu Gin Gly Ala Glu Thr Gly Leu Val Gly Arg Tyr Phe Thr He Asn 500 505 510 Arg Asp Asn Gly lie Val Ser Ser Leu Val Pro Leu Asp Tyr Glu Asp 515 520 525 Arg Arg Glu Phe Glu Leu Thr Ala His He Ser Asp Gly Gly Thr Pro 530 535 540 Val Leu Ala Thr Asn He Ser Val Asn He Phe Val Thr Asp Arg Asn 545 550 555 560 Asp Asn Ala Pro Gin Val Leu Tyr Pro Arg Pro Gly Gly Ser Ser Val 565 570 575 Glu Met Leu Pro Arg Gly Thr Ser Ala Gly His Leu Val Ser Arg Val 580 585 590 Val Gly Trp Asp Ala Asp Ala Gly His Asn Ala Trp Leu Ser Tyr Ser 595 600 605 Leu Phe Gly Ser Pro Asn Gin Ser Leu Phe Ala He Gly Leu His Thr 610 615 620 Gly Gin He Ser Thr Ala Arg Pro Val Gin Asp Thr Asp Ser Pro Arg 625 630 635 640 Gin Thr Leu Thr Val Leu He Lys Asp Asn Gly Glu Pro Ser Leu Ser 645 650 655 Thr Thr Ala Thr Leu Thr Val Ser Val Thr Glu Asp Ser Pro Glu Ala 660 665 670 Arg Ala Glu Phe Pro Ser Gly Ser Ala Ser 675 680

Claims: What is claimed is: 1. A purified and isolated polynucleotide sequence encoding protocadherin-42. 2. A purified and isolated polynucleotide sequence encoding protocadherin-43. 3. The polynucleotide sequence of claim 1 or 2 which is a DNA sequence. 4. The DNA sequence of claim 1 or 2 which is a cDNA sequence. 5. The DNA sequence of claim 1 or 2 which is a genomic DNA sequence. 6. The DNA sequence of claim 1 or 2 which is a wholly or partially chemically synthesized DNA sequence. 7. A polynucleotide sequence according to claim 1 comprising the protocadherin-42 encoding sequence of SEQ ID NO: 94. 8. A polynucleotide sequence according to claim 2 comprising the protocadherin-43 encoding sequence of SEQ ID NO: 96. 9. A biologically functional DNA vector comprising a DNA sequence according to claim 3. 10. The vector of claim 11 wherein said DNA sequence is operatively linked to an expression control DNA sequence. 11. A host cell stably transformed or transfected with a DNA sequence according to claim 3 in a manner allowing the expression in said host cell of a protocadherin polypeptide. 12. A method for producing a protocadherin polypeptide comprising the steps of growing a host cell according to claim 11 in a suitable nutrient medium and isolating protocadherin polypeptide from said cell or from the medium of its growth. 13. Purified and isolated protocadherin-42 polypeptide. 14. Purified and isolated protocadherin-43 polypeptide. 15. An antibody substance specific for protocadherin-42. 16. An antibody substance specific for protocadherin-43. 17. The antibody substance of claim 15 or 16 which is a monoclonal antibody. 18. A hybridoma cell line producing a monoclonal antibody according to claim 16 and having ATCC Accession No. HB 11207. 19. A method for modulating the binding activity of protocadheri- 42 comprising contacting said protocadherin with an antibody substance according to claim 15 specific for said protocadherin. 20. A method for modulating the binding activity of protocadherin- 42 comprising contacting said protocadherin with a peptide ligand of said protocadherin. 21. A method for modulating the binding activity of protocadheri- 43 comprising contacting said protocadherin with an antibody substance according to claim 15 specific for said protocadherin. 22. A method for modulating the binding activity of protocadherin- 43 comprising contacting said protocadherin with a peptide ligand of said protocadherin.

Inventors: SUZUKI SHINTARO, SUZUKI, SHINTARO
Applicants: DOHENY EYE INST, SUZUKI SHINTARO, DOHENY EYE INSTITUTE, SUZUKI, SHINTARO
Application year: 1993
Main classification: C12N15
IPC codes: A61K38, C07K14, C07K16, C07K19, C12N5, C12N15, C12P21